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Abstract
An Abstract of a Dissertation Submitted to Nova Southeastern University in
Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy
PROTECTIVE ACTIONS OF OXYTOCIN ON AORTIC WISTAR AND SHR VSMCS
By
VARUN KUMAR SOTI
AUGUST 2019
Background. Oxytocin, known as a female reproductive hormone, has emerged as a
cardiovascular hormone showing cardioprotective effects, for instance, negative
chronotropic and inotropic effects and ANP release in cardiomyocytes and endothelium.
However, oxytocin’s effect in VSMCs remains to be explored. Objectives. This study had
three goals: characterizing oxytocin’s effect on proliferation, inflammation, oxidative
stress, and vasocontraction pathway in Wistar VSMCs; determining oxytocin’s effect on
Ang II; describing oxytocin’s effect and its interaction with Ang II in SHR VSMCs.
Methods: Aortic VSMCs were isolated from Wistar rats and SHRs. Hemocytometer, MTT
and 3H-Thymidine incorporation assays, and flow cytometry were employed for cell
proliferation studies. Two key proliferation pathways — ERK1/2 and PI3K/Akt pathways,
and vasocontraction (ROCK) pathway were investigated for mechanistic studies utilizing
Western blotting. IL-6 and ROS were measured to assess inflammation and oxidative
stress, respectively. Results. Cell proliferation studies and Western blotting outcomes in
Wistar and SHR VSMCs, demonstrated that oxytocin (100 nM) significantly decreased
cell proliferation and reduced phosphorylation of ERK1/2, PI3Kp110α, Akt, ROCK-1, and
ROCK-2, respectively. OXTA antagonized these effects of oxytocin. Flow cytometric
measurements indicated that oxytocin-induced apoptosis and necrosis. IL-6 assay and ROS
assay results displayed that oxytocin increased IL-6 and ROS, respectively. Oxytocin’s
pre-treatment with Ang II in Wistar and SHR VSMCs caused: decreased cell proliferation;
reduced phospho-ERK1/2, phospho-PI3Kp110α, phospho-Akt, ROCK-1, and ROCK-2;
decreased IL-6; increased ROS. Comparison between Wistar and SHR VSMCs illustrated
that oxytocin greatly reduced PI3Kp110α phosphorylation in Wistar VSMCs than SHR
VSMCs (P < 0.01). Oxytocin caused higher IL-6 secretion in SHR VSMCs (P < 0.01) and
higher ROS production in Wistar VSMCs (P < 0.001). Oxytocin’s pre-treatment with Ang
II showed: higher reduction in ERK1/2 phosphorylation in SHR VSMCs (P < 0.001);
higher reduction in PI3Kp110α phosphorylation (P < 0.05) and higher increase in ROS in
Wistar VSMCs (P < 0.001). Conclusion. Oxytocin showed an anti-proliferative effect on
aortic VSMCs, likely through inhibition of ERK1/2 and PI3K/Akt phosphorylation.
Oxytocin-mediated decreased phosphorylation of ROCK-1 and ROCK-2 suggest
oxytocin’s anti-vasoconstrictive action in VSMCs. Oxytocin’s antagonistic actions against
Ang II indicate that oxytocin may exert beneficial vascular effects in conditions associated
with high levels of Ang II.
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Chapter 1: Introduction
1.1.

Background
At the dawn of the 19th century, Sir Henry Dale achieved a breakthrough
that would herald a new era in endocrinology. He discovered that a chemical
extracted from the human posterior pituitary gland caused uterine contractions in
pregnant cats, dogs and guinea pigs. He called this chemical ‘oxytocin,’ derived
from the Greek words ‘ωχνξ,’ ‘τoχoxξ,’ meaning ‘swift birth.’ Over the next 100
years, oxytocin became a subject for extensive research.1
It is now established that oxytocin is a neurohypophysial nonapeptide
secreted by magnocellular cells in the paraventricular and supraoptic nuclei of the
hypothalamus. It is stored in the posterior lobe of the pituitary gland. A wide range
of stimuli including sucking (milk ejection reflex), pre- (labor induction) and postparturition, and stress trigger oxytocin release from the posterior pituitary into the
blood circulation. There is an extensive projection of oxytocinergic neurons in the
central nervous system (CNS) — brain and spinal cord including amygdala,
ventromedial hypothalamus, nucleus acumben, septum, and brainstem.2 Besides,
oxytocin is also synthesized peripherally in tissues such as placenta, uterus, testis,
kidney, heart, and blood vessels in both vascular endothelial cells (ECs) and
vascular smooth muscle cells (VSMCs).3
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The oxytocin receptor gene (OXTRG) has been mapped in the human
chromosome at the locus 3p25-3p26.2 alongside a gene that encodes the
vasopressin receptor. The distance between the two genes is 500-kilo bases (kb).
The human OXTRG spreading over 17 kb consists of three introns and four exons.
The third intron, being the largest spanning 12 kb, separates the transmembrane
domain 6 from the coding region. Exons 1 and 2 frame the 5’ prime non-coding
domain, while the exons 3 and 4 code for the amino acids sequence for oxytocin
receptors. Exon 4, in particular, codes for the seven transmembrane domain,
carboxyl terminal and the 3’ non-coding region.3
Both oxytocin and vasopressin are the neurohypophysial peptides, with
each having a sequence of nine amino acids, and are stored in the posterior lobe of
the pituitary gland. The point of difference between the structure of oxytocin and
vasopressin is the amino acid at position 8. In oxytocin, leucine is present at number
8. Whereas, in vasopressin, either lysine or arginine is present at this position. The
sequence of amino acid in oxytocin is as follows: Cysteine (1) – Tyrosine (2) –
Phenylalanine (3) – Glutamine (4) – Asparagine (5) – Cysteine (6) – Proline (7) –
Leucine (8) – Glycine (9). Importantly, the presence of isoleucine at position 3 in
the oxytocin family is required for the activation of oxytocin receptors.4
Oxytocin receptors belong to the class I G-protein coupled receptors
(GPCRs) that predominantly bind to Gq/α11 class of guanosine triphosphate (GTP)
binding proteins that activate phospholipase C (PLC). This brings about the
formation of the two important secondary messengers: inositol-3-phosphate (IP3)
and 1, 2-diacylglycerol (DAG). IP3 sparks the release of intracellular calcium
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(Ca2+); DAG activates protein kinase C (PKC) that triggers the phosphorylation of
targets leading to a further downstream signaling. The activation of these second
messengers result in oxytocin-mediated physiological effects at different locations.
When bound with Gi protein, oxytocin receptors inhibit the adenylyl cyclase (AC),
leading to inhibition of the production of cyclic adenosine monophosphate (cAMP)
from adenosine triphosphate (ATP). This inhibits cAMP pathway-dependent
phosphorylation of targets and attenuates further downstream signaling. The effects
of oxytocin varies widely and depends upon the target tissue(s), gland(s), organ(s)
or system(s). 3,5,6
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1.2.

Traditional roles of oxytocin
Oxytocin is often referred to as a ‘female reproductive hormone.’ It is
known to contract pregnant uterus assisting parturition1. It also affects lactating
breasts by initiating milk ejection reflex7, promotes maternal-fetal bonding8 and
plays a role in reproduction and in reaching an orgasm.9
Oxytocin became commercially available in 1980. Its agonist and
antagonists have found applications in both clinical research and pre-clinical
studies.10,11,12
It has become common in medical practice to employ pharmacological
interventions such as intravenous administration of Pitocin (a commercial brand
name oxytocin), along with other mechanical methods (for example extra-amniotic
Foley catheter) to induce labor.13,14
Oxytocin has emerged as a versatile hormone affecting social bonding,
trust, memory, learning, empathy, and depression.15,16,17,18
From as recent as the year 2012, the intranasal administration of oxytocin
has found an application in clinical behavioral studies.19,20,21
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1.3.

Emerging role of oxytocin in the cardiovascular system (CVS)
In the last decade, the dynamics in oxytocin research have been completely
shifted. A new role for oxytocin has now evolved in cardiovascular regulation.22,23
Oxytocin being considered initially as a female hormone is now gaining consensus
as a ‘cardiovascular hormone.’24 The present study is an endeavor to develop a
deeper understanding of the role that oxytocin plays in cardiovascular physiology
and pathophysiological conditions.
1.3.1. Effect of oxytocin on heart
Several studies in rats and humans have reported that oxytocin is
synthesized locally in the heart. The studies demonstrating competition binding
curves have revealed only one receptor subtype for oxytocin in the heart. All the
chambers of the heart and the large blood vessels have oxytocin and its
receptors.25,26
The equilibrium dissociation constant (KD) values are slightly different in
rat heart (KD ~ 1.00 nM), hypothalamus (KD ~ 0.02 nM), and uterus (KD ~ 0.76
nM). However, in the blood vessels there are no significant difference between the
KD values of rat vena cava (KD ~ 0.78 nM) and aorta (KD ~ 0.59 nM). The right
atrium and the left ventricle have the highest and lowest concentrations of oxytocin,
respectively. The right atrium’s oxytocin levels are equivalent to hypothalamic
oxytocin levels.25
Studies have shown that oxytocin can reduce the rate of cardiac blood flow
and induce bradycardia. In isolated dog atriums, oxytocin produced negative
inotropic and chronotropic effects via its receptors in the heart.27,28
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1.3.2. Effect of oxytocin on cardiomyocytes
Oxytocin plays a role in the regulation of atrial natriuretic peptide
(ANP).29,30 The ANP is a peptide hormone consisting of 28-amino acids. It is
synthesized, stored and released locally in cardiomyocytes. The factors that cause
the secretion of ANP include atrial wall distension, increased blood volume (in
pathological conditions such as congestive heart failure), angiotensin II (Ang II),
endothelin, and sympathetic activation (norepinephrine). The ANP elicits a
cardioprotective effect by decreasing the central venous pressure, thereby reducing
blood volume and decreasing ventricular pre-load, and thus decreasing cardiac
output. Besides, ANP also inhibits renin release and aldosterone synthesis.31
One previous study has demonstrated the functional relevance of oxytocin
and its receptors in rat heart and cultured cardiomyocytes. The study has evidenced
that oxytocin (10-6 M, a physiologically relevant concentration) stimulates ANP
release from isolated perfused female rat hearts and cultured cardiomyocytes. In
this study, not only had the oxytocin antagonist (10-6 M and 10-7 M) , in a
concentration-dependent manner, inhibited the oxytocin-stimulated ANP release in
the heart perfusion medium, but also inhibited the basal release.29
The research findings of these studies indicate that oxytocin, via ANP
release, reduces cardiac contraction - force and rate, and decreases circulating blood
volume.

This illustrates the protective effect of oxytocin in cardiovascular

physiology, and its benefits can be further explored in cardiovascular
pathophysiological conditions, for instance, congestive heart failure.
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In recent years, oxytocin has also found relevance in stem cell research on
cardiogenesis. A few studies have indicated that oxytocin has the potential to
induce differentiation of embryonic stem cells (P-19ECs) to cardiomyocytes
(CMs). Studies have brought to light that nitric oxide (NO) signaling is involved in
oxytocin-induced differentiation of P-19ECs to CMs.32 There is also an
upregulation of oxytocin receptors and Gata-4 (a protein required for the atriaventricular formation and its functions) that are considered crucial to the oxytocinmediated cardiomyocytes differentiation process.33

8
1.3.3. Effect of oxytocin on blood vessels (endothelial cells and VSMCs)
Several pre-clinical studies have demonstrated that oxytocin has shown
anti-oxidant and anti-inflammatory effects in vascular endothelial cells (derived
from the aorta), THP-1 monocyte, and macrophages. The physiological levels of
oxytocin have shown significant reduction in nicotinamide adenine dinucleotide
phosphate (NADPH) superoxide production, and also decreased the levels of the
interleukin-6 (IL-6) in monocytes, macrophages, and aortic endothelial cells.34
It has been reported that in diabetes, an independent risk factor for many
cardiovascular diseases (CVD),35 neovascularization is significantly impaired after
ischemia.36 The endothelial cells lose the ability to recover significant blood flow
due to endothelial dysfunction. Besides, the progenitor endothelial cells suffer
reduced angiogenic functions.37 Oxytocin has been shown to restore angiogenic
functions in a streptozocin-induced diabetes rat model. The pre-treatment of
cultured bone marrow-mesenchymal stem cells (MSCs) with oxytocin has shown
significant restoration of kruppel-like factor 2 (KLF2) which is a crucial angiogenic
factor.38
Many in vitro studies have shown that oxytocin, in endothelial cells derived
from the human dermal microvasculature, umbilical vein and breast cancer cells,
induces an overexpression of vascular endothelial growth factor (VEGF), matrix
metalloproteinases (MMP-11, MMP-17 and MMP-26), integrin β6 genes, and
cathepsin D.39,40 Thereby, stimulating migration and proliferation (which are the
crucial steps in angiogenesis) of endothelial cells.
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These studies have suggested that oxytocin induces angiogenic effects via
an

oxytocin

receptor

stimulation

of

the

phosphatidylinositol-3-kinases

(PI3K)/Akt/endothelial nitric oxide synthase (eNOS) pathway. It has been
determined that the ability of oxytocin to phosphorylate Akt and eNOS depends on
the PLC activity.39 A subsequent study has revealed that it is through the
stimulation of PLC and calcium mobilization, oxytocin phosphorylates the tyrosine
kinases: proline-rich tyrosine kinase-2 (Pyk-2) and Src. This activates the
PI3K/Akt/eNOS pathway.41
It is interesting to note that most of the cardiovascular effects of oxytocin
have been studied in vascular endothelial cells and cardiomyocytes. However, in
VSMCs, only the presence of oxytocin receptors has been established thus far.
There is very little information regarding oxytocin effects in VSMCs.42,43
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1.3.4. Effect of oxytocin in various pathophysiological cardiovascular
conditions
Inflammation and oxidative stress are the two critical pathophysiological
events in atherosclerosis.44 In a rat model of atherosclerosis, the administration of
oxytocin showed an improvement in the lipid profile and decreased the plasma
levels of IL-6, monocyte chemoattractant protein-1 (MCP-1) and C reactive protein
(CRP). It also improved the plasma levels of reduced glutathione (GSH) and nitric
oxide (NO). Besides, oxytocin treatment significantly improved the histological
structure of the aorta detected by a significantly decreased expression of the nuclear
factor kappa-light-chain-enhancer of activated B cells (NF-κB) in a rat model of
atherosclerosis.45
The ability of oxytocin to counteract oxidative stress and reduce
inflammation underscores the importance of oxytocin in many other cardiovascular
pathophysiological conditions including atherosclerosis.45
In myocardial infarction (MI), oxytocin has displayed a cardioprotective
role. In a rabbit model of MI, oxytocin has been reported to protect against
myocardial injury through the phosphorylation of kinases such as extracellular
signal-regulated kinase (ERK), signal transducer and activator of transcription 3
(STAT3), Akt, MMP and eNOS. Akt, ERK, and STAT3 are all pro-survival signals
that may play an important role in cardiac ischemic preconditioning, thereby
reducing ischemic damage to the heart.46
In a rat model, oxytocin has mediated improvement in myocardial injury
immediately after heart transplant by downregulating the chemotactic agents:
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chemokine (C-X-C motif) ligand 1 (CXCL1), and macrophage inflammatory
protein-2 alpha (MIP-2α)/Chemokine (C-X-C motif) ligand 2 (CXCL2). These
agents are known to recruit neutrophils in the myocardium.47 In ovariectomized
rats, the oxytocin pre-treatment protected from injury after MI by reducing
plasminogen activator inhibitor-1 (PAI-1) concentrations.48
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1.4.

Role of angiotensin II (Ang II) in the CVS and its pathophysiology
The emergence of the different functional aspects of oxytocin in the CVS
continues to fascinate the scientific community. It is noteworthy that a central
component of the CVS is the renin-angiotensin-aldosterone system (RAAS). The
principal effector hormone of the RAAS is Ang II. It is an octapeptide, and an
enzyme known as the angiotensin converting enzyme (ACE) catalyzes the
conversion of angiotensin I (Ang I) into Ang II. Ang II affects all major organs of
the body – heart, kidney, vasculature, and brain. In particular, Ang II has a diverse
range of effects in the CVS.49
Ang II causes vasoconstriction and maintains the blood pressure in the
normal physiological conditions.50 Besides, it is also involved in many CVD such
as atherosclerosis, congestive heart failure, diabetes, hypertension, inflammation
and MI.51 It mainly binds to the angiotensin type 1 receptors (AT-1R) in the CVS
and execute its actions via stimulation of the mitogen-activated protein kinases
(MAPKs) pathways, PI3K/Akt/mammalian target of rapamycin (mTOR) pathways,
and Rho kinase pathways.51,52 These signaling pathways and kinases are involved
in Ang II-mediated contraction of VSMCs, hypertrophy, hyperplasia, endothelial
dysfunction, vascular diseases, and their progression.53,54
In pathological conditions such as hypertension and atherosclerosis, Ang II
significantly impacts the repair and the remodeling of VSMCs in large blood
vessels. It phosphorylates ERK1/2 and p38 MAPKs, thereby inducing expression
of immediate early response genes: c-fos, c-myc and c-jun. Thus, Ang II mediates
cell proliferation, migration, and hypertrophy in VSMCs.55,56 Besides, Ang II
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causes the migration of VSMCs on receiving pathogenic stimuli by inducing
STAT3 phosphorylation, and its subsequent nuclear translocation induces
expression of the genes specific to cell proliferation, hypertrophy, and migration of
VSMCs.57,58
Ang II is also a known pro-oxidant.59 It causes production of reactive
oxygen species (ROS) via the activation of NADPH oxidase, leading to increased
oxidative stress. The Ang II-induced oxidative stress causes endothelial
dysfunction and vascular inflammation by the activation of NF-kB, a redoxsensitive nuclear transcription factor, and upregulation of adhesion molecules:
intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1
(VCAM-1), selectin, integrin, cytokines [IL-6, IL-12, IL-1, tumor necrosis factoralpha (TNF-α)], and chemokines (MCP-1, IL-8, osteopontin).60 It has been reported
that glutathione s-transferase (GST) attenuates Ang II-induced STAT3
phosphorylation and exerts a protective effect in VSMCs. GST conjugates the
reduced form of glutathione (a cellular antioxidant) with reactive oxygen species
(ROS) and detoxifies it.58
Ang II has been shown to influence fibrinolysis activity.51,61 A key regulator
of endogenous fibrinolytic activity and thrombolysis resistance is PAI-1. It
physiologically inhibits plasminogen activation. In response to vascular injury,
PAI inhibits cellular migration and matrix degradation.62,63 Ang II infusion in
normotensive and hypertensive patients showed increased circulating levels of
PAI-1.64 In a rat model, Ang II via interactions with AT1R, increased the expression
of PAI in VSMCs from isolated aorta, thereby influencing endogenous fibrinolytic
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activity.65,66 PAI-1 is an important cardiovascular risk factor in atherosclerosis.
Besides, an increased PAI-1 also manifests amongst the metabolic abnormalities
associated with hypertension.67,68
The antagonizing of Ang II effects by employing ACE inhibitors is a wellestablished therapy commonly used in CVD. The ACE inhibitors are in clinical
practice in the management of hypertension, coronary artery disease, heart failure,
diabetes, and chronic kidney diseases.69 They are one of the few treatment options
that we have currently for these diseases. However, there are many side effects
attributed to ACE inhibitors’ use in CVD.70 Despite the long clinical use of these
agents, treatment of hypertension has not been all that successful. The need of the
present times is to identify alternative targets and unveil better therapeutic
approaches to better treat CVD.
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1.5.

The gap in the literature, research hypotheses, and study aims
As mentioned earlier in the background, oxytocin has demonstrated
cardioprotective effects in various in-vitro and in-vivo studies performed on
vascular endothelial cells and cardiomyocytes.23 However, there is a gap in the
literature. Even though previous researches have established that oxytocin receptors
are found in VSMCs, interestingly, oxytocin effects in VSMCs have not been fully
characterized. On the contrary, the effects of Ang II, another crucial cardiovascular
peptide, have been well established in VSMCs and the CVS to a significant extent.
As stated before, Ang II is known to induce vascular oxidative stress, phosphorylate
ERKs, PI3Ks, and Rho kinases, leading to marked VSMCs proliferation,
hypertrophy, hyper-contraction, inflammation, and increased oxidative stress.51
Therefore, to fill in the gap regarding the lack of research on the effect of oxytocin
on VSMCs and its interaction with Ang II, the present study was conducted.
In the context of the protective effects of oxytocin in the cardiovascular
system and from the results of the preliminary experiments, the following research
hypotheses were proposed:
1.5.1. Hypothesis 1
By its ability to reduce proliferation, inflammation, oxidative stress, and
vasocontraction pathway, oxytocin antagonizes Ang II-induced proliferation,
inflammation,

and

oxidative

stress

and

dysregulates

vasocontraction pathway in primary Wistar aortic VSMCs.

Ang

II-induced
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1.5.2. Hypothesis 2
Oxytocin signaling pathways in aortic VSMCs are altered in hypertensive
conditions.
The hypotheses mentioned above were tested by pursuing the following
specific aims:
1.5.3. Specific Aim 1
To characterize the effect of oxytocin on proliferation, inflammation,
oxidative stress and vasocontraction in primary aortic VSMCs obtained from
normotensive Wistar rats. The VSMCs proliferation was determined by
employing cell proliferation, cell viability, and cell growth assays. To further
understand the mechanism of how oxytocin reduces aortic VSMC proliferation, the
two critical signaling pathways involved in VSMCs proliferation were investigated:
ERK1/2 pathway and PI3K/Akt pathway. The oxidative stress was measured as the
function of the ROS levels, and inflammation was assessed by measuring IL-6
levels. The effect of oxytocin on vasocontraction was assessed indirectly by
investigating oxytocin’s effect on the Rho-kinase pathway [Rho-associated coiledcoil kinase-1 (ROCK-1) and -2 (ROCK-2)] involved in the vasocontraction of
VSMCs.
1.5.4. Specific Aim 2
To determine of the interaction between oxytocin and Ang II in
primary aortic VSMCs obtained from normotensive Wistar rats. The
interaction of oxytocin with Ang II was investigated by studying the effect of
pretreatment of oxytocin on Ang II-induced cell proliferation and proliferation
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pathways (the ERK1/2 pathway and PI3K/Akt pathway), inflammation, oxidative
stress, and the Rho-kinase pathway in aortic VSMCs obtained from normotensive
Wistar rats.
1.5.5. Specific Aim 3
To characterize the effect of oxytocin on proliferation, inflammation,
oxidative stress and vasocontraction in primary aortic VSMCs obtained from
spontaneously hypertensive rats (SHRs). The effects of oxytocin on VSMC
proliferation (ERK1/2, PI3K, Akt), oxidative stress (ROS), inflammation (IL-6)
and vasocontraction (ROCK-1 and ROCK-2) were characterized on VSMCs
isolated from SHRs. The comparison was made, and the analysis was carried out
between the effects of oxytocin on its own and its pre-treatment with Ang II in
aortic VSMCs Wistar rats and SHRs.
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1.6.

Role of VSMCs in the CVS and its pathophysiology
VSMCs constitute tunica media, the middle layer of blood vessels, with
endothelial cells and connective tissues making tunica intima and tunica externa,
respectively (Figure 1). VSMCs are the stromal cells which perform a variety of
functions and play a crucial role in the CVS.71

Figure 1. Histology of a blood vessel. VSMCs form the middle layer (tunica media)
of a blood vessel. Adapted from Muscle cell and Tissue, Intech Open. 2018;230.
VSMCs maintain the contractile tone of the arterial wall via intracellular
calcium release causing the myosin-actin interactions, regulating blood pressure
and flow to meet the metabolic demands of the body. They secrete molecules that
comprise the extracellular matrix (ECM) which enable arteries to withstand the
high pressure of the circulating blood.72
In normal physiological conditions, VSMCs remain quiescent and adhere
to their phenotype essential in regulating contractile tone of arteries. Molecules
such as laminin, perlecan, heparan sulfate proteoglycan (HSPG), and collagen type
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IV, composing the basement of VSMCs are attributed to keeping VSMCs
quiescent.73
However, in the event(s) of pathological or pathophysiological condition(s)
such as arterial injury, an excessive overload of lipids, pressure-related stress,
hyperglycemic conditions, VSMCs undergo a variety of adaptations and
remodeling. They become active and transition into mitogen-responsive
phenotypes in the presence of fibronectin.74 They start interacting with the
intracellular signaling pathways, involving the ERKs, PI3Ks, and Rho kinases.75,76
The activation of these pathways leads to hypercontraction, proliferation
and migration of VSMCs often leading to the thickening of the tunica intima,
hyperplasia, precipitating aneurysm, hemorrhage, and restenosis, and worsening
the other cardiovascular diseases including atherosclerosis, hypertension and
increasing the complications post-vascular surgical procedures. 72,77
The activated phenotype of VSMCs also produce ROS which play a role in
the vascular pathology through its redox potential.78, The principal enzymatic
source of the production of ROS in VSMCs is NOX. In hypertension, vasoactive
agents such as Ang II activate the NOX, leading to the increased production of
ROS, ultimately resulting in increased oxidative stress and increased expression of
inflammatory mediators such as cytokines (example IL-6).79
The functions of VSMCs in physiology and their role in the
pathophysiology of the CVS are crucial and render them a potential target of
therapeutic approaches in cardiovascular research. Anti-proliferative therapies
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such as rapamycin and paclitaxel targeting VSMCs’ hyperplasia in animal models
have failed to show similar effects in patients.80
Therefore, there is a need to develop therapies that are not only targeting
the most notable pathophysiological features of CVD such as proliferation,
migration, hypercontraction, oxidative stress, and inflammation of VSMCs but are
also maintaining contractile phenotype of VSMCs.
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1.7.

Study significance
It was envisioned that this study would be a step towards the long-term goal
of identifying oxytocin as an alternative therapeutic target in the treatment of CVD.
The present study was an attempt to determine the potential role of oxytocin with
regards to its cardioprotective effects against Ang II-induced deleterious effects.
Previous studies have established that at sustained high levels, Ang II acts as the
‘aggressor’ in the cardiovascular system.53 On the contrary, pre-clinical evidence
have, so far, indicated a ‘protective’ role of oxytocin in the cardiovascular system.23
This in vitro study was the first of its kind to investigate and understand the
protective effects of oxytocin against the harmful actions of Ang II, with relation
to VSMCs, on the cardiovascular system. The study findings contributed towards a
better understanding of oxytocin actions on blood vessels (VSMCs), and
identification of secondary messenger pathways involved in this oxytocin effect.
The research findings demonstrated that oxytocin blocked Ang II-mediated
hyperproliferation of VSMCs and proliferation and vasocontraction pathways in
VSMCs from SHRs, thus providing evidence of oxytocin’s vital role in
cardiovascular pathophysiology and it shows the potential therapeutic benefits it
might have in the management of hypertension. The study generated significant
pre-clinical evidence regarding the beneficial effects of oxytocin in a hypertensive
rat model, laying a platform foundation for future mechanistic in vivo studies and
pilot clinical studies.
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1.8.

Barriers, issues, limitations, and delimitations
The present study involved the use of primary rat aortic VSMCs. The
advantage of using laboratory-cultured primary VSMCs is that they retain many
cellular functions and markers quite similar to the ones observed in vivo. Whereas,
commercially available VSMCs cell lines may differ phenotypically and
genetically from their origin. However, there were specific challenges that occurred
during the course of this study.
Firstly, the procurement of significant yield of high purity VSMCs was
challenging. The techniques utilized in this research to harvest primary cells was
the ‘explant method.’81 Although this technique is cost-effective and routinely
applied to obtain a high yield of VSMCs, its major drawback is the purity of
primary cells obtained. That VSMCs are prone to natural contamination with
intimal endothelial or adventitial fibroblasts, the VSMCs isolation protocol was
optimized, and the cells were used from passages between 3-15 for maintaining the
phenotypical uniformity and the purity of cells.81 The endothelial cells and
fibroblast eventually die out by the time VSMCs underwent the third passage.
Secondly, the effect of many cell passages was a challenge. For avoiding
this, care was taken to make sure that all the experiments in both Wistar rats and
SHRs were conducted using the same passage number. For example, if a cell
proliferation experiment was carried out with VSMCs in the passage 4 in Wistar
rats, the VSMCs from the similar passage number was utilized to perform a cell
proliferation experiment in SHRs.
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Lastly, the magnitude of the response of cells to the treatments obtained
from one rat was different from the other rat. Therefore, to reduce the variation in
data and increase the reproducibility of the data, the experiments were repeated
numerous times using multiple rats to increase the number of replicates. However,
the repetition of all the experiments was tough, time-consuming and challenging.
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Chapter 2: Literature Review
2.1.

MAPK/ERK1/2 pathway in the CVS
MAPKs belong to the serine-threonine specific class of kinases. They
constitute a signal transduction pathway known as the MAPK pathway. The
MAPK pathway is a cascade that converts signals from external mechanical
stimuli and growth factors into signal transduction, leading to the regulation of
genes involved primarily in protein synthesis.82 It occurs in sequential
phosphorylation of the three core protein kinases from cytosol: mitogenactivated protein kinase kinase kinase (MAPKKK), mitogen-activated protein
kinase kinase (MAPKK), and mitogen-activated protein kinase (MAPK).83 A
schematic representation of the activation of MAPK signaling pathway is
shown in the Figure 2.1.84
It is the MAPKs which carry out intracellular signal transduction
through three distinct pathways. The first one is through the phosphorylation
and activation of extracellular signal-regulated kinase (ERK), which has two
isoforms: ERK1 and ERK2. The phosphorylated ERK1 and 2 (active form) lead
to the phosphorylation and activation of various regulatory proteins in the
cytosol as well as in the nucleus, which is critical for protein synthesis and cell
survival.83
The second MAPK pathway involves the phosphorylation and
activation of stress-activated protein kinases (SAPK). This cascade of MAPK
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is triggered in response to external stimuli such as ultraviolet rays, stress (heat
shock), altered osmolarity, hypoxia, and exposure to reactive oxygen species.85
The

triggering

of

the

second

MAPK

pathway

causes

the

phosphorylation and activation of c-Jun N-terminal kinases (JNK) which is
critical in proliferation, apoptosis, inflammation, and in response to
deoxyribonucleic acid (DNA) damage.86–88

Figure 2.1. Activation of mitogen-activated protein kinase (MAPK) signaling
pathway

in

the

cardiovascular

system.

Adapted

from Physiol

Rev.

2010;90(4);1508. GPCR indicates G-protein coupled receptor; RTK, receptor
tyrosine kinase; ERK, extracellular signal-regulated kinase; JNK, c-Jun Nterminal kinase; RAF, rapidly accelerated fibrosarcoma ; MLK, mixed-lineage
kinases; ASK-1, apoptosis signal-regulating kinase 1; TAK-1, transforming growth
factor-β-activated kinase 1; MAPKKK/MEKK, mitogen-activated protein kinase
kinase kinase; MAPKK/MEK/MKK, mitogen-activated protein kinase kinase;
MAPK, mitogen-activated protein kinase.
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The third pathway consists of p38 MAPK. Like the JNK pathway, this
pathway can also be triggered in response to stress induced by a change in
cellular osmolarity, exposure to free radicals, heat shock, and inflammation.89
The p38 MAPK signaling is involved in cellular processes such as proliferation,
differentiation, migration and immune response.90–92
The ERK1/2 pathway is one of the first MAPK pathways to be
characterized in mammals. In VSMCs, the stimulation of AT1R by Ang II,
causes the phosphorylation of ERK1/2. The phosphorylated ERK1/2 (active
form) then translocate to the nucleus, and subsequently result in the
phosphorylation of transcription factors including c-Fos, c-Jun, and activator
protein-1 transcription factors, ultimately carrying out cell synthesis,
proliferation, differentiation and migration of VSMCs. In addition, ERK1/2
targets the ribosomal S6 kinase (RSK). Once phosphorylated, the activated
ERK1/2, in turn, phosphorylates RSK via the transfer of ribonucleic acid
(RNA)-binding factor. This is a key step in the initiation of translation, leading
to protein synthesis, regulation, and progression of the cell cycle of VSMCs.93–
95

Phosphorylated ERK1/2 is also known to be involved in the regulation
of vascular tone of VSMCs. It has been established that h-Caldesmon (h-CD)
is a downstream target of the phosphorylated ERK1/2.96 An h-CD is a high
molecular weight contractile regulatory protein involved in the contractile
responses of vascular walls.97
Numerous studies have implicated ERK1/2 signaling in the
pathophysiology of CVDs such as hypertension.98,99 In an in vivo study,
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increased activity of ERK1/2 was reported after transient elevation of blood
pressure with Ang II in femoral arteries and rat aortas.100
The pharmacological inhibition of ERK1/2 signaling was shown to
improve endothelial function, and significantly reduced Ang II-induced
contraction of mesenteric resistance arteries in spontaneously hypertensive rats
(SHRs).100

In transgenic mice models, ERK1/2 signaling was shown to

stimulate hypertrophy in cardiomyocytes via phosphorylation of factors such
as elk-1, necessary for the activation of the c-Fos gene.101
Oxytocin was demonstrated to exert differential effects on the ERK1/2
signaling pathway. For example, oxytocin-induced phosphorylation of ERK1/2
increased the proliferation of cardiomyocytes and vascular endothelial
cells.40,102 In other instances, such as in human embryonic kidney (HEK293)
cells, oxytocin exhibited proliferative as well as anti-proliferative actions. The
dual action of oxytocin on the proliferation of HEK293 cells was determined
by the location of the oxytocin receptors. Oxytocin reduced the phosphorylation
of ERK1/2, and as a result, inhibited cell proliferation when the oxytocin
receptors were present outside the caveolin-1-enriched microdomains. And,
oxytocin augmented phosphorylation of ERK1/2, resulting in stimulated cell
proliferation when the oxytocin receptors were inside caveolin-1-enriched
microdomains.103
It is imperative to understand the role of caveolins. Caveolins are
scaffolding proteins involved in the regulation of GPCR signaling. They
facilitate GPCR regulation via scaffolding and partitioning of different
receptors, G-proteins trafficking, and signaling.104
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As stated earlier, oxytocin’s effect on cell proliferation and ERK1/2
activity has been studied in cardiomyocytes and vascular endothelial cells.
However, little to no information is available on the effects of oxytocin on
ERK1/2 signaling pathway and on its effects on the proliferation of VSMCs.
The present study characterized the effect of oxytocin and its impact on
Ang II (known for stimulating cell proliferation via the ERK1/2 signaling55) on
cell proliferation in aortic VSMCs from normotensive rats (Wistar rats).
Further, oxytocin’s impact on aortic VSMCs proliferation and on ERK1/2
signaling, and oxytocin’s effect on Ang II-mediated cell proliferation and Ang
II-stimulated ERK1/2 signaling were also investigated in aortic VSMCs from
SHRs.
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2.2.

PI3K/Akt signaling in the CVS
The phosphoinositide-3-kinase (PI3K)/Akt pathway is an essential
intracellular signaling transduction pathway involved in the regulation of the
CVS.105 It is crucial in the proliferation of VSMCs,106 control of the vascular
myogenic tone, and inflammation.107,108 Over the last decade, the PI3K/Akt
signaling has been implicated in various pathological conditions of the CVS

109

such as cardiac hypertrophy (a critical risk factor of heart failure),110 and
hypertension. 107
Phosphoinositide-3-kinases (PI3Ks) are intracellular enzymes which
catalyze the phosphorylation of phosphatidylinositol (PI). PI are lipids
(phosphatidyl glycerides).111 PI3Ks phosphorylate PI at the 3-hydroxyl group of the
inositol ring. Based on the products of the catalysis, PI3Ks have been grouped into
three classes: Class I PI3Ks, which form phosphatidylinositol-3,4-biphosphate (PI3,4-P2); Class II PI3Ks, which form phosphatidylinositol-3-phosphate (PI-3-P), PI3,4-P2, and phosphatidylinositol triphosphate (PIP3); and Class III PI3Ks, which
generate PI-3-P. All classes of PI3Ks are present in cardiomyocytes, vascular
endothelial cells, and VSMCs.112
A general structure of a PI3K includes three domains: C-2 domain, helical
domain, and a catalytic domain. The C-2 domain binds to the membranes, the
helical domain serves regulatory functions, and the catalytic domain carries out the
kinase activity of PI3Ks. Based on the regulatory domain, the Class I PI3Ks are
further subdivided into two categories: Class I A PI3Ks which bind to receptor
tyrosine kinases (RTKs), and Class I B PI3Ks which bind to GPCRs. The Class I
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A PI3Ks exist as heterodimers of different isoforms of α, β, and δ of the p110
catalytic domain. Whereas, the Class I B PI3Ks exist as heterodimers of p110𝛾 and
p101 catalytic domains.113 All Class I PI3Ks are significant in the CVS and its
pathophysiology.114 Their actions are antagonized by phosphatase and tensin
homolog deleted on chromosome ten (PTEN).115
Akt is a serine-threonine kinase and also known as protein kinase B (PKB).
Akt is a downstream signaling target of PI3Ks. There are three isoforms of Akt:
Akt 1 (PKBα), Akt 2 (PKBβ), Akt 3 (PKB𝛾). All forms of Akt are present
throughout blood vessels, heart, lungs, and brain.116 The stimulation of GPCRs by
peptides such as Ang II or growth factors results in the activation of PI3Ks. The
activated PI3Ks lead to the formation of PI-3,4-P2 and PIP3, which in turn
phosphorylate Akt (active form).117
The phosphorylated form of Akt triggers downstream signaling via the
phosphorylation of downstream signaling molecules such as mTOR. mTOR is a
serine-threonine kinase. The phosphorylation of mTOR by phosphorylated Akt is
vital to protein synthesis by the PI3K/Akt signaling pathway. mTOR has two
isoforms: mTORC1 and mTORC2. The phosphorylated mTORC1 stimulates cell
proliferation via the phosphorylation of p70S6 kinase, eukaryotic initiation factor
4E (elF4E), and 4E-binding protein 1 (4E-BP1). The activated p70S6 kinase
phosphorylates and activates S6 ribosomal protein. The activated elF4E acts as
translator initiator. It phosphorylates 4E-BP1. A phosphorylated 4E-BP1 is
required for protein translation. The phosphorylated mTORC2 stimulates the

31
phosphorylation of Akt and is involved in the autoregulation of mTOR.118 The
PI3K/Akt signaling pathway is illustrated in the following figure (Figure 2.2):

Figure 2.2. The PI3K/Akt signaling pathway in the cardiovascular system. A
schematic representation of the PI3K/Akt signaling pathway in cardiomyocytes,
vascular endothelial cells, and vascular smooth muscle cells (VSMCs). Adapted
from Curr Pharm Des. 2011;17(18):1819. FKBP indicates FK506-binding protein;
GLUT, glucose transporter; GPCR, G-protein coupled receptor; GSK, glycogen
synthase kinase; IGF, insulin-like growth factor; PDK, phosphoinositidedependent kinase; PI3K, phosphoinositide 3-kinase; PtdIns, phosphatidylinositol;
PTEN, phosphatase and tensin homolog deleted on chromosome ten; p70S6K,
p70S6 kinase; TSC, tuberous sclerosis complex; eIF4, eukaryotic initiation factor
4.
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The implication of PI3K/Akt signaling cascade in many cardiovascular
pathophysiological conditions has been reported by previous studies.119 In
hypertension, it has been shown that the PI3K/Akt pathway alters vascular function
mainly by increasing the myogenic tone of resistance arteries and by enhancing the
constricting activity of VSMCs. A myogenic tone can be described as the functional
behavior of resistance arteries in response to perfusion pressure.107 On the
activation of GPCRs by cardiovascular peptides such as Ang II, the PI3K/Akt
signaling results in an increased intracellular level of calcium via the L-type
voltage-gated calcium channel (L-VGCC).120,121
It is noteworthy that L-VGCC dysfunction is an important characteristic
feature of CVDs such as hypertension and cardiac arrhythmia, and its targeting by
the compounds known as calcium channel blockers has been a long-standing
clinical practice in the management of hypertension and arrhythmia.122,123
Several

studies

have

documented

the

relevance

of

PI3Ks

in

hypertension.107,124,125 A study conducted using a transgenic mice model revealed
that the chronic administration of Ang II did not produce hypertension in mice
lacking PI3K𝛾. The lack of PI3K𝛾 not only reduced the L-VGCC-mediated
intracellular calcium reflux but also decreased VSMCs contractility when
stimulated with Ang II.121
Another relevant aspect of the PI3K/Akt signaling in the physiology and
pathophysiology of the CVS is its role in cardiac hypertrophy.110 It is pertinent to
highlight that cardiac hypertrophy can be both beneficial and harmful. Beneficial
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cardiac hypertrophy is called ‘physiological cardiac hypertrophy,’ whereas the
harmful hypertrophy is known as ‘pathological cardiac hypertrophy.’126
Physiological cardiac hypertrophy is usually seen and is associated with
natural post-natal development, pregnancy, and exercise. Thus, this is an adaptive
growth of cardiomyocytes. The characteristic features of physiological cardiac
hypertrophy are the preservation of contractile functions of the sarcomere (the
contractile unit of cardiomyocytes) and a lack of interstitial fibrosis.127,128 On the
other hand, pathological cardiac hypertrophy is ‘maladaptive hypertrophy.’ It is
characterized by increased cell volume of cardiomyocytes, the new formation of
sarcomeres, interstitial fibrosis and inflammation.129
Several studies have demonstrated PI3K/Akt-mediated cell signaling in
both physiological and pathological cardiac hypertrophy.130,131 In a study
employing a transgenic mice model, mice with dominant negative PI3K showed a
significant reduction in exercise-induced physiological cardiac hypertrophy
compared to wild type mice (control).132 In another study employing a similar
transgenic mice model, mice deficient in PI3K showed protection against
isoproterenol-induced pathological cardiac hypertrophy and thus protection from
heart failure.133
It is thought-provoking that oxytocin is being touted as a ‘cardioprotective’
hormone,23 yet it has not been investigated for its effects on PI3K/Akt signaling in
cardiomyocytes, vascular endothelial cells, and VSMCs. To partially address this
gap in the scientific literature, the present study used an in vitro model to investigate
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the effects of oxytocin alone and its pre-treatment with Ang II on the PI3K/Akt
signaling pathway in VSMCs in both normotensive and hypertensive conditions.
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2.3.

Rho kinases (ROCK-1 and ROCK-2) signaling in the CVS
Rho-associated coiled-coil kinases (ROCK) -1 and -2 belong to the
serine/threonine category of kinases. They are the targets of small GTPases (that
bind and hydrolyze the guanosine triphosphates) : Rho A, Rho B, and Rho C.134
These GTPases are found abundantly in VSMCs and are rapidly activated by
vasoconstricting peptides such as Ang II.135 Both ROCK-1 and ROCK-2 are
involved in the organization and remodeling of actin cytoskeleton, extracellular
matrix, and in the contraction of VSMCs.136,137 They are also critical in cell
adhesion, motility, and proliferation.138,139 Pre-clinical research and clinical
evidence have implicated ROCK signaling in the pathogenesis of various diseases
of the CVS including angina pectoris, hypertension, pulmonary arterial
hypertension, heart failure, and stroke.140–144
The structural features of ROCKs include phosphorylation and cleavage
sites. The structure of both ROCK-1 and ROCK-2 has an N-terminal containing a
kinase domain, coiled-coil region, Rho-binding domain (RBD), and a C-terminal
comprising of a PH-domain containing a cysteine-rich C1 domain. An RBD
possesses three zones known as a ‘switch’: Switch I, Switch II, and Switch III, with
each having a strong binding affinity for Rho A, Rho B, and Rho C, respectively.
The C1-domain of C-terminal is involved in the autoinhibition of ROCKs. The two
isoforms of ROCK have the highest homology in their kinase domain (about 92
percent) and the least homology in their coiled-coil domain (about 55 percent).
145,146
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The activation of ROCKs depends on the catalytic activity of both the Nterminal and C-terminal regions. The ROCKs form homodimers, and dimerization
depends upon kinase domains, an extension of N-terminals, and coiled-coil regions.
Following an interaction of RBD with guanosine-5'-triphosphate (GTP)-loaded
Rho proteins (Rho-A, -B, -C), the phosphorylation of the hydrophobic motif near
the C-terminal region occurs, causing the kinase domain to undergo conformational
changes from a closed (inactive) to an open (active) state.147,148 The active state of
ROCKs is essential in carrying out the downstream cell signaling in the following
three different ways:
First, the activated form of ROCKs directly augments the phosphorylation
of myosin phosphatase target subunit-1 (MYPT-1). Second, it stimulates the
phosphorylation of zipper-interacting protein kinase (ZIPK) which in turn
phosphorylates MYPT-1.149,150 Third, activated ROCKs phosphorylate C-kinases
potentiated protein phosphatase 1 inhibitor -17 (CPI-17). A CPI-17 is a direct
inhibitor of MYPT-1.151,152
The phosphorylation of MYPT-1 prevents the binding of myosin light chain
phosphatases (MLCP) with myosin light chain (MLC), thus boosting myosin light
chain kinase (MLCK)-induced phosphorylation of actin leading to sustained
contraction of VSMCs. The stimulation of the ROCK signaling results in decreased
activation of MLCP, and increased contraction of VSMCs which ultimately leads
to elevated blood pressure.151,152 The ROCK-mediated contraction of VSMCs is
depicted in the Figure 2.3.
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In animal models of hypertension, an increased ROCK signaling has been
observed which is further enhanced by the intake of a high-salt diet.153 An increased
ROCK signaling in hypertension has been attributed to the dysregulation of Rho
guanine nucleotide exchange factors (Rho-GEFs).154,155 In clinical studies, an
elevated phosphorylation level of MYPT-1 has been reported in patients diagnosed
with essential hypertension. Ang II-induced hypertension and cardiac hypertrophy
have also been linked with hyper-ROCKs signaling.156,157
In samples of heart-tissues obtained from patients with heart failure,
truncated ROCKs have been found. A cleavage of C-terminal of ROCKs by the
activation of pro-apoptotic enzymes such as caspases abolishes the autoinhibitory
capability of ROCKs. This leads to constitutive activation of ROCKs, resulting in
a sustained hypercontraction of blood vessels, fibrotic cardiomyopathy, and
diastolic dysfunction.158
These detrimental effects of truncated ROCKs were further supported by
findings from a study carried out on cardiomyocytes from mice. The
cardiomyocytes showed an increased expression of C-terminally nicked ROCK-1,
and the histopathological findings presented the characteristics of fibrotic
cardiomyopathy.159
Over the years many compounds have been developed to target the ROCK
signaling. A wide range of those compounds are often non-selective ROCK
inhibitors (i.e., they are non-specific in their binding to the two ROCK isoforms).
They compete for ATP in the kinase domain of ROCKs, thus acting as competitive
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inhibitors.160 Fasudil is the only ROCK inhibitor that has been approved for clinical
use for the treatment of various CVD including hypertension. 161
Medical interventions employing fasudil in patients with hypertension,
pulmonary arterial hypertension (PAH), angina pectoris, and heart failure have
shown significant improvement in their medical conditions.142,162–164 The
administration of fasudil in patients with congenital heart defects significantly
reduced pulmonary artery pressure and pulmonary vascular resistance.165
Evidence presenting an increased expression of ROCK-2 in the pulmonary
arteries and pulmonary VSMCs in patients with idiopathic PAH has demonstrated
the role of ROCK signaling in PAH.166 This was further strengthened by another
study in which patients with PAH treated with fasudil resulted in acute pulmonary
vasodilation.167 Chronic treatment with fasudil not only resulted in an improvement
in pulmonary hypertension, but also reduced right ventricular hypertrophy, and
prevented further remodeling in the pulmonary vasculature, along with significant
decrease in VSMCs proliferation and hypercontraction, and lower endothelial
dysfunction.168
Previous studies have highlighted enhanced activity of ROCK in patients
with acute and chronic heart failure.169 ROCK activity measured in terms of
phosphorylated levels of total MYPT-1 in circulating leukocytes indicates the
involvement of ROCK signaling in heart failure.170 Also, stimulated ROCK activity
has been found in patients with myocardial infarction. A study in which fasudil was
administered to patients with heart failure showed a significant decrease in vascular
resistance in the forearm and a noticeable increase in forearm vasodilation.171
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Another clinical study showed the beneficial effect of ROCK inhibitors in
patients with angina. The treatment with fasudil resulted in reduced number of
angina attacks per week in patients with stable angina and also increased their
maximum exercise time.162,164
The literature presented above underlines a crucial role of ROCK signaling
pathway in physiological and pathophysiological conditions of CVS. Interestingly,
oxytocin effect on ROCKs’ signaling has not been previously studied. The present
study endeavored to investigate the effect oxytocin, and its impact on Ang IIstimulated ROCK signaling in aortic VSMCs isolated from normotensive and
hypertensive rats.
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Figure 2.3. ROCK signaling pathway in the contraction of VSMCs. Adapted from
Cardiovasc Res. 2018;114(4):534. Ang II indicates angiotensin II; ET-1,
endothelin-1; GPCR, G-protein coupled receptor; RTK, receptor tyrosine kinase;
GDP, guanosine diphosphate; GTP, guanosine triphosphate; GEF; guanine
nucleotide exchange factor; GDI, guanine nucleotide dissociation inhibitor; PI3K,
phosphoinositide-3-kinase; ROCK, rho-associated coiled-coil kinase; CPI-17, Ckinases potentiated protein phosphatase 1 inhibitor-17; MLCP, myosin light chain
phosphatases; ZIPK, zipper-interacting protein kinase; MLCK, myosin light chain
kinase.
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2.4.

Interleukin-6 in the CVS
IL-6 is a cytokine which has pleiotropic effects.172 It is crucial in the CVS
and its diseases.173 IL-6 is involved in the process of inflammation eliciting a
myriad of immunological responses such as activation of thymocytes, stimulation
and activation of T-cells and B-cell differentiation, differentiation and
galvanization of macrophages, activation of natural killer (NK) cells, and
stimulation of hepatocytes for the production of inflammatory proteins such as the
CRP.174–181
IL-6 binds to the IL-6 receptor complex to induce the signal transduction.
The IL-6 receptor complex is comprised of two membrane-bound glycoproteins:
IL-6R and glycoprotein 130 (gp130). The IL-6R is an 80 Kilo dalton (KD)
component which binds to a ligand. The gp130 is the signal transducing part of the
IL-6 receptor complex with an atomic mass of 130 KD.182 Also, there is a soluble
form of IL-6R (termed sIL-6R). The binding of IL-6 to the membrane-bound IL6R has been attributed to normal physiological immune responses of IL-6.183
However, the binding of IL-6 to the soluble form (IL-6/sIL-6R) has been
implicated in various pathological conditions,184,185 and has been clinically targeted
by anti-IL-6 agents such as tocilizumab in severe cases of rheumatoid arthritis
(RA).186,187,188, The IL-6 and its receptors both soluble and membrane-bound are
present ubiquitously in all tissues, and abundantly in endothelial cells, VSMCs, and
cardiomyocytes in particular.189–191
The effects of IL-6 are both protective and detrimental.192 The duration of
pathogenic stimuli or conditions determines these actions whether they would be
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beneficial or deleterious.193,194 Short-term exposure to pathogenic stimuli results in
protective effects of IL-6, whereas, a long-term exposure culminates in IL-6 driven
harmful effects. A classic example of such consequences is the effects of IL-6 on
the heart. IL-6 signaling in cardiomyocytes is cardioprotective in response to a
short-term

pathophysiological

condition.194–196

However,

when

that

pathophysiological condition remains for a long time, then the IL-6 signaling
induces pathological cardiac hypertrophy, reduces cardiac contractility, ultimately
leading to decreased cardiac function.193,197,198 Studies have highlighted IL-6
mediated decreased cardiac contractility is associated with the JAK/STAT pathway
and not the ERK pathway.199
IL-6 has been implicated in the pathogenesis of coronary artery disease such
as atherosclerosis.200 Previous studies have shown the IL-6-mediated upregulation
of MMPs contribute to vascular remodeling and atherosclerotic plaque
disruption.201 Many studies have demonstrated higher serum levels of IL-6 in
patients diagnosed with and hospitalized for unstable angina.202
The increased expression of myocardial IL-6 has been associated with the
progression of heart disease.203,204–206 Studies have established elevated levels of
IL-6 in patients with heart failure. More specifically, the concentrations of IL-6
were directly related to the severity of left ventricular dysfunction and to the extent
of the activation of the sympathetic system and RAAS.207
Ang II, an effector hormone of the RAAS, is known to induce inflammation
in VSMCs via stimulation of IL-6 signaling.208 Oxytocin, on the other hand, has
shown anti-inflammatory actions via decreasing IL-6 signaling in vascular
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endothelial cells.34 The effects of oxytocin on inflammation in VSMCs have not
been studied. Interestingly, its interaction with Ang II with regards to inflammation
has also not been investigated. This study undertook the investigation of oxytocin’s
effect on inflammation, and its interaction with Ang II in aortic VSMCs isolated
from both normotensive rats and hypertensive rats.
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2.5.

Reactive oxygen species (ROS) in the CVS
The ability of a living organism to convert oxygen into water through
aerobic phosphorylation forms the core of the metabolism and production of
energy. This very process of the metabolism of oxygen yields a byproduct known
as ‘ROS.’209 These toxic species are extremely deleterious in nature. They cause
severe damage to cellular DNA, RNA, lipids, and proteins, resulting in cellular
apoptosis, necrosis, and inflammation.210–212 ROS play a significant role in the
development of various pathological condition of the CVS including hypertension,
cardiac hypertrophy, heart failure, diabetes, and atherosclerosis.78,213–216
The primary source of ROS in cells in general, and in vascular endothelial
cells, VSMCs, and cardiomyocytes, in particular, is an enzyme called ‘nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase.’217
The catalytic component of NADPH oxidase is NOX. There are seven
isoforms of NOX that have been identified, and five of them are found in human:
NOX1, NOX2, NOX3, NOX4, and NOX5.79,218
In cardiovascular cells, the generation of ROS is stimulated by
neurohumoral vasoconstrictor peptides such as Ang II and Endothelin -1 (ET-1),
and by norepinephrine (NE). It is well known that activation of AT-1R by Ang II,
triggers the production of superoxide (O2−) by NADPH oxidase. Studies have
demonstrated the production of O2−, by NADPH oxidase, resulting in vasopressor
action in response to Ang II infusion in normotensive conditions (Wistar rats).219,220
The reaction of NADPH oxidase-mediated
superoxide is as follows:

production of highly reactive
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2O2 + NADPH → 2·O2− + NAD(P)+ + H+
ET-1 is also known to induce ROS production via the activation of NADPH
oxidase. ET-1 is a potent vasoconstrictor of the endothelium layer of blood vessels.
There are two isoforms of ET receptors: ETA and ETB. The stimulation of ETA
receptors induces ROS production via NADPH oxidase activation and results in
vasoconstriction of endothelium. The ETB receptors have the opposite effect. They
mediate vasorelaxation of endothelium.221
ROS production in VSMCs and cardiomyocytes is also induced through the
stimulation of alpha-1 adrenergic receptors (⍺1-ADR) by NE.222 The AT-1R, ET1, and ⍺1-ADR activate NADPH oxidase via interaction with G-proteins and thus
generate ROS.223
The other sources of ROS production are mitochondrial transport chain and
eNOS uncoupling. In addition to ROS production by NADPH oxidase, ROS
generated via NOS uncoupling and in mitochondria contribute to pathogenesis of
the CVDs such as hypertension.224–227
Under normal physiological conditions, the production of NO occurs via the
coupling of L-arginine, in the presence of tetrahydrobiopterin (BH4) acting as a cofactor, with eNOS. On stimulation by pathogenic stimuli, the levels of BH4 are
reduced, leading to the uncoupling of eNOS. eNOS uncoupling results in the release
of O2− from the oxygenase domain of eNOS. The increased production of O2−
causes

endothelial

damage.224,228,229

dysfunction

and

eventually

precipitates

vascular
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The dysfunction of the mitochondrial respiratory chain due to vascular
damage under pathophysiological conditions causes the transfer of electrons to
molecular oxygen and bring about the formation of ROS such as O2− and hydrogen
peroxide (H2O2).230–232 Increased mitochondrial ROS production damages
mitochondrial antioxidants such as manganese superoxide dismutase (MnSOD), in
turn, further initiating ROS production.233 The imbalance between ROS and
antioxidants creates oxidative stress which is at the core of the pathogenesis of
many CVD including hypertension.234 Redox signaling in the CVS is elucidated in
the following figure:

Figure 2.4. Redox signaling in the cardiovascular system. Adapted from J Biomed
Sci.2013;20(69):4. AT-1 indicates angiotensin-1 receptors; α-AR, alphaadrenergic receptors; ET-1, endothelin-1; Ang II, angiotensin II; NE,
norepinephrine; ROS, reactive oxygen species; HO-1, heme oxygenase-1; Cat,
catalase; AP-1, activator protein-1; NF-κB, nuclear factor kappa-light-chainenhancer of activated B cells; Nrf2, nuclear factor (erythroid-derived 2)-like 2;
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MAPK, mitogen-activated protein kinase; PI3K, phosphoinositide-3-kinase; eNOS,
endothelial nitric oxide synthase.
Oxidative stress is known to induce activation of MAPKs (ERK1/2, JNK,
and p-38 MAPK).235,236 Many studies have demonstrated that the induction of
oxidative stress under pathophysiological conditions increases ROS production,
which in turn activates various MAPKs, leading to activation of several
transcription factors, for example, activator protein-1 (AP-1), NF-κB, and nuclear
factor (erythroid-derived 2)-like 2 (Nrf2). These transcription factors are involved
in hypertrophy of cardiomyocytes, endothelial cells and VSMCs, necrosis,
apoptosis, and inflammation which are characteristic features of many CVD.237,238
Previous research has shed light on the effect of oxytocin on oxidative stress
in cardiomyocytes and vascular endothelial cells. However, the impact of oxytocin
on oxidative stress in VSMCs has not been investigated thus far. The present study
examined oxytocin’s effect on oxidative stress in VSMCs via ROS measurement.
Also, the interaction of oxytocin with Ang II, a known pro-oxidant, was studied in
aortic VSMCs isolated from normotensive rats and hypertensive rats.
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2.6.

Summary
The present study was conducted to address the gap in the literature regarding
oxytocin’s effect on proliferation, proliferation pathways (ERK1/s and PI3K/Akt
signaling pathways), and vasocontraction pathways (ROCK pathway) in VSMCs.
The study also evaluated the impact of oxytocin on oxidative address (assessed by
measuring ROS levels) and inflammation (analyzed by measuring IL-6 levels). To
characterize these effects of oxytocin on VSMCs, this study employed aortic
VSMCs isolated from Wistar rats (normotensive) and SHRs (hypertensive rats).
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Chapter 3: Methodology
3.1.

Wistar rats and SHRs
The present study employed aortic VSMCs isolated from Wistar rats and
SHRs. Hypertension has been extensively studied pre-clinically in SHRs models,
often using normotensive Wistar rats as control.239,240 The SHR is a wellestablished genetic animal model of primary hypertension. The major advantage of
the SHR model is the lack of inter-individual variation. Similar to the progression
of hypertension in humans, SHRs have pre-hypertensive, developing and sustained
hypertensive phases.241,239

3.2.

Isolation and culture of primary rat aortic VSMCs
The study protocol was approved by the Nova Southeastern University
Institutional Animal Care and Use Committee (NSU-IACUC). Adult male Wistar
rats (300-350g) and spontaneously hypertensive rats [(SHRs) 300-350g] were
euthanized in a carbon dioxide (CO2) chamber as per the established guidelines.
VSMCs were isolated and cultured as per the previously established explant
method. 242
The thoracic cavity was cut-open, the aorta was isolated, and placed in a
sterile 100 mm Petri dish containing sterile phosphate-buffered saline (PBS).
Sterile forceps were utilized to clean the aorta by removing adjacent fat layers and
coagulated blood.
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Once cleaned, the aorta was slit from top to bottom and cut into two pieces
using sterile scissors. Each piece was then cut into a 1 mm strip and each strip was
placed in a sterile 100 mm Petri dish containing Dulbecco’s Modification of Eagle’s
Medium (DMEM) [(Corning Cellgro, NY)], supplemented with 10% (v/v) fetal
bovine serum (FBS) glutamine (2 mM/L), streptomycin (100 1g/mL) and penicillin
(VWR Life Science, GA). Petri dishes containing strips of freshly isolated aortic
VSMCs were incubated at 37°C under standard humidified conditions (95% air and
5% CO2) to allow VSMCs to grow out from strips onto the surface of petri-dish.
Once VSMCs were outgrown, strips were removed, and VSMCs were allowed to
grow in petri-dish. On reaching confluency, VSMCs were passaged in T-75 flasks
so that enough number of cells were obtained to be able to conduct experiments
using 100-mm Petri dishes, 6-well plates, 24-well plates, and 96-well plates.
Before every experiment, VSMCs were subjected to trypsinization
(Corning™ 0.25% Trypsin, Fischer Scientific, FL), counted using the
Hemocytometer method, and were seeded in either 100 mm Petri dishes, 6-, 24-, or
96-well plates depending on the experimental design. They were incubated at 37°C
under previously described standard humidified conditions. After every 48 hours,
the culture medium was replenished until VSMCs were about 90% confluent. Once
confluent, VSMCs were washed with sterile PBS. VSMCs were made quiescent by
replenishing with the serum-free media (SFM) for 24 hours before commencing
with the experimental treatments. Cell passages from 3-15 were used for all
experiments. All experiments were performed using the primary aortic VSMCs
isolated from at least three rats or more. 81
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3.3.

VSMCs proliferation assessment by the Hemocytometer method
3.3.1. The principle of the Hemocytometer method
The Hemocytometer method is the most widely used technique used to
determine the number of cells per unit volume of a suspension.243 It is a valuable
research tool utilized to count cells in cell proliferation studies. It consists of a
microscopic slide which is divided into two chambers. Each chamber has grid lines
which make nine large squares. Each large square has an area of 1mm². The large
squares are demarcated from each other by compact grid lines. The volume of the
entire counting grid lines is 0.9 mm3 in each chamber. A glass cover-slip is placed
over a chamber following which a suspension of cells is introduced into the
chamber, and the cells are counted under the microscope. The cells are excluded
from counting if they are touching the right-side and the bottom (Figure 3.1).

Figure 3.1. Hemocytometer and the grid lines of a chamber in a hemocytometer
microscopic

slide.

Adapted

from

https://www.hemocytometer.org/wp-

content/uploads/2013/06/hemocytometer-squares-to-count.png?w=551.
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The hemocytometer technique employs the staining of cells with dyes such
as trypan blue to identify live and dead cells. The cytoplasm of dead cells readily
absorbs trypan blue and turns the appearance of dead cells to blue, making it easy
to distinguish from live cells which have intact cytoplasm that does not take up
trypan blue.243
3.3.2. The procedure of the cell counting by the hemocytometer method
Aortic VSMCs were seeded at 1×106 cells/well in 6-well plates and cultured
as mentioned before. The cells were made quiescent by replacing serum-media with
SFM, 24 hours prior to treatment. Post-treatment, the cells in each well were
subjected to trypsinization and centrifuged at 1,500 rpm at 21°C for 10 minutes.
The pellet was used to make the cell suspension with 1000 µL SFM, of which 100
µL was pipetted out and transferred in an Eppendorf tube, and stained with 900 µL
0.4% trypan blue. From the trypan blue-stained cell suspension, 10 µL was applied
to the hemocytometer (Bright-Line Hemocytometer Set, Hausser Scientific, VWR
Life Science, GA).
The cover-slip was placed on top to allow the complete and gentle filling of
both chambers of the hemocytometer. The grid lines of the hemocytometer were
focused under a microscope with a 10X objective. The cells were counted in all the
4 sets of large squares in the four corners of a chamber of the hemocytometer. The
cells were excluded from counting when present on the right-hand boundary line or
touching the bottom. The stained cells (dead cells), and unstained cells (live cells)
were calculated and the dilution factor was corrected as per the manufacturer’s
protocol.243,244
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3.4.

VSMCs viability determination by the MTT assay
3.4.1. The principle of the MTT assay
The MTT assay measures cell viability as a function of the mitochondrial
activity. It is a colorimetric assay which relies on the reduction of the yellow
colored 3-(4,5-dimethylthiazo-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) by
mitochondrial enzymes such NADPH oxidase and mitochondrial succinate, into an
insoluble purple colored formazan. Organic solvents such as isopropanol and
dimethyl sulfoxide (DMSO) are employed to solubilize the insoluble formazan, and
the color change is measured as ‘optical density’ by a microplate reader. The optical
density is a function of the mitochondrial activity. The higher optical density is
indicative of higher mitochondrial activity, and the higher mitochondrial activity
relates to the higher number of metabolically active cells.245
3.4.2. The procedure of the MTT assay
Aortic VSMCs were seeded at 1×104 cells/well in 96-well plates. The
serum-media was replaced with SFM 24 hours prior to treatment. After carrying
out the treatments with different groups, the SFM-containing the different
treatments was aspirated, and 50 µL of MTT (ACROS Organics, NJ) was added to
each 96-well. The 96-well plates were incubated at 37°C under standard humidified
conditions for 45 minutes. Following the incubation, 100 µL of DMSO (Merc
KGaA, Germany) was added to each well. The plates were read at 570 nm using a
Biotek microplate reader (Biotek-Synergy H1 Hybrid Reader, VT).244
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3.5.

VSMCs growth measurement by the 3H-Thymidine incorporation assay
3.5.1. The principle of the 3H-Thymidine incorporation assay
The tritiated-Thymidine (3H-Thymidine) incorporation assay is considered
as the gold-standard method to assess cell proliferation. This assay involves the
direct measurement of cell proliferation by determining the synthesis of DNA. It
employs the incorporation of the radioactive nucleoside tritiated (3H)-Thymidine
into strands of chromosomal DNA of the actively dividing cells, during the mitotic
phase of cell division. The radioactivity recovered from the cells is measured using
a liquid scintillation counter as ‘counts per minute.’ The cell growth is assessed as
the function counts per minute (cpm).
A higher radioactivity count reflects higher cell growth. The cells
undergoing active division resulting in higher cell growth will have more
incorporation of 3H-Thymidine into their DNA strands and consequently will have
higher radioactivity count than those that are undergoing lesser cell division. Hence,
a higher reading of cpm reflects a higher cell growth, and a lower reading of cpm
represents a lower cell growth.246
3.5.2. The procedure of 3H-Thymidine incorporation assay
Aortic VSMCs were seeded at 5×104 cells/well in 24-well plates, cultured
and made quiescent, as described previously, 24 hours before starting the
treatments. Quiescent cells were subjected to different treatments. After the first 24
hours of treatment, 5 µL of 3H-thymidine (1 µCi/mL) [Thymidine (Methyl-3H), MP
Biomedicals, LLC, CA], was added to each well. The plates were incubated at 37°C
under standard humidified conditions for another 24 hours. In the end, the SFM
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containing the treatments and 3H-thymidine was aspirated and washed with sterile
cold-PBS (1,000 µL), and 500 µL of cold 10% trichloroacetic acid (TCA) was
added to each well (this was done to precipitate out remnants of any radioactive
material present outside cells). The 24-well plates were incubated overnight at 4°C.
TCA was removed and 500 µL of 0.1 N sodium hydroxide (NaOH) − 2%
sodium dodecyl sulfate [(SDS), NaOH-SDS] solution, previously maintained at
room temperature (25°C), was added to each well and incubated for one hour at
4°C. This step was carried out to cause alkaline lysis of cells resulting in protein
denaturation (breaking of double-stranded DNA into a single-stranded DNA). SDS
solubilizes the cell membrane, and NaOH disrupts the hydrogen bonding between
the DNA bases and thus causing protein denaturation).
The samples were collected in vials (20 mL). To each sample, 6 mL of
liquid scintillation cocktail (Ultima Gold™, PerkinElmer Inc., CA) was added, and
the samples were quantified by a PerkinElmer liquid scintillation counter (TriCarb® 2810TR Liquid Scintillation Analyzer, PerkinElmer Inc., CA) as per the
manufacturer’s protocol.247
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3.6.

VSMCs apoptosis and necrosis assessment by flow cytometery
3.6.1. The principle of flow cytometery
Flow cytometry is a technique commonly used in determining the
characteristics of a single cell in suspension. It involves the measurement of the
optical and fluorescence properties of cells including their nuclei and
chromosomes. The technique relies on the use of fluorescent dyes, for example
Annexin V and propidium iodide, that are specific in their binding to cellular
components such as membrane phospholipids, DNA, and RNA. When cells in a
suspension labeled with fluorescent dyes are passed through a light (laser) source,
they rise to a higher energy state. When cells return to their resting state, they emit
light energy at higher wavelengths. Multiple fluorochromes with similar excitation
and different emission wavelengths enable the simultaneous determination of
several properties of cells.248
This technique is also valuable in cell sorting and is widely utilized in
clinical hematology. When cells continue to move straight in the direction of the
light source, the process is called ‘forward-scatter,’ and when they deviate from the
direction of the light source, it is referred to as ‘side-scatter.’ The larger cells
demonstrate forward-scatter whereas, the smaller cells show side-scatter.249 A flow
diagram of a typical flow cytometer is shown in Figure 3.2.
Flow cytometry has profound applications in cell viability studies. It is used
in the detection of apoptosis and necrosis.250 Apoptosis is defined as ‘programmed
cell death’ whereas necrosis is 'premature cell death' due to external factors
including injury and acute infection.251 Apoptosis is characterized by specific
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morphological changes such as loss of plasma membrane asymmetry, membrane
blebbing, shrinking of cytoplasm and nucleus, and DNA cleavage in the
nucleosome. One of the earliest features of a cell undergoing apoptosis is the loss
of plasma membrane asymmetry. It is characterized by the translocation of
phosphatidylserine (PS), a membrane phospholipid, from the inside to the outside
of the plasma membrane (Figure 3.3).252
A fluorochrome-labeled dye such as Annexin V binds to the PS of plasma
membranes of an apoptotic cell and is detected by flow cytometer. Similarly, a
fluorescent 7-amino actinomycin D dye (7-AAD) binds to broken fragments of
DNA, the hallmark of necrosis, and thus enable the detection of cells undergoing
necrosis by flow cytometer.253

Figure 3.2. Flow cytometer. A flow diagram of a typical flow cytometer analyzing
a single cell suspension. The sample containing a single suspension is projected
with a sheath fluid. The argon-ion laser intersects the cells and causes the forwardscatter and the side-scatter. The signals are detected, amplified, registered, and
digitally analyzed in a computer. Adapted from Clin Chem. 2000;46(8 Pt 2):1222.
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Figure 3.3. Presentation of markers for detection by healthy, apoptotic, lateapoptotic and necrotic cells. Adapted from BD Biosci. 2011; 8:2.
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3.6.2. The procedure of apoptosis and necrosis assessment using flow
cytometer
The present study utilized flow cytometry to study the effect of oxytocin on
cell viability, apoptosis, and necrosis in aortic VSMCs from Wistar rats and SHRs.
Aortic VSMCs were made quiescent 24 hours before the treatments. On the day of
the assay after replenishing with the serum-free media (SFM), the treatment was
performed, and cells were placed under standard incubation conditions for 24 hours.
Post-treatment, the supernatant was removed. The cells were washed with 1,000
µL of sterilized PBS (previously maintained at the room temperature). The PBS
was then removed, and 400 µL of Accutase cell detachment solution (# A6964
Sigma-Aldrich®, MO) was added to each well. The cells were then incubated under
standard incubation conditions for about 5 -7 minutes.
Following the incubation, 1,000 µL of fluorescent-activated cell sorting
(FACS) buffer (# MB-086-0500 RocklandTM antibody & assays) was added to each
well, and the samples were collected in Eppendorf tubes (1.5 mL). The samples
were then subjected to centrifugation at 1,500 rpm at 21°C for 10 minutes. The
supernatant was discarded via decantation (the vacuum was not used to remove the
supernatant in an effort to prevent cell loss). The pellet was re-suspended with the
cold PBS (1,000 µL), and samples were re-centrifuged at 10,000 rpm for 5 minutes.
The supernatant was discarded, and the pellet was re-suspended with 100
µL Annexin V binding buffer and vortexed. To each prepared sample, 4 µL of
Annexin V and 4 µL of 7-AAD (# 640922, FITC Annexin V Apoptosis Detection
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Kit with 7-AAD, BioLegend®, CA) was added, and gently mixed and allowed to
stand for 30 minutes.
Subsequently, 400 µL of binding buffer was added to each sample, and the
samples were run at the medium speed (with the limit set at 10,000 events) using
the BD LSRFortessa™ X-20 cell analyzer as per the manufacturer’s protocol.254
The data generated represents four sections: percentage of live cells;
percentage of cells positive for Annexin V; percentage of cells positive for 7-AAD;
and percentage of cells positive for both Annexin V and 7-AAD. The cells positive
for Annexin V indicate the percentage of cells undergoing apoptosis. The cells
positive for 7-AAD reflect the percentage of cells undergoing necrosis. And, the
cells that were double positive for both Annexin-V and 7-AAD represent the cells
undergoing both apoptosis and necrosis.
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3.7.

IL-6 measurement by the enzyme-linked immunosorbent assay (ELISA)
3.7.1. The principle of IL-6 ELISA
ELISA is an immunological assay used for the detection and quantification
of peptides, antibodies, cytokines, and hormones in biological samples. The general
principle of ELISA is based on the interaction of antigen present in the biological
sample with the specific antibody immobilized to a solid surface, and then its
interaction with a secondary antibody conjugated with an enzyme. The detection is
carried out by measuring the activity of the enzyme-linked by incubating it with a
substrate, yielding a quantifiable product.255
The present study employed ELISA to measure IL-6 levels secreted by
VSMCs in the culture media. For this purpose, rat IL-6 ELISA kits were purchased
(Rat IL-6 Immunoassay, # R6000B Quantikine® ELISA, R&D Inc., MN). The
package comprised of microplates previously coated with monoclonal antibodies
for rat IL-6. The samples were loaded into the microplates. A secondary antibody
(specific to rat Il-6) was then added making a sandwich of immobilized antibody
specific for rat IL-6, samples (containing IL-6 antigen), and secondary antibody.
The secondary antibody conjugated with horseradish peroxidase (HRP)
produced a colored or fluorescent reaction when a chemical substrate was added.
The fluorescent signals were detected by a Biotek microplate reader (BiotekSynergy H1 Hybrid Reader, VT), thus determining the presence and the quantity of
IL-6 antigen in the samples. A typical ELISA sandwich is depicted in the following
figure:
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Figure 3.4. A typical enzyme-linked immunosorbent assay (ELISA) sandwich.
Adapted

from

https://www.immunology.org/public-information/bitesized-

immunology/experimental-techniques/enzyme-linked-immunosorbent-assay.
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3.7.2. The procedure of IL-6 ELISA
The reagents contained in the rat IL-6 ELISA kit (Rat IL-6 Immunoassay,
# R6000B Quantikine® ELISA, R&D Inc., MN) were prepared as per the
manufacturer's protocol.
First, 50μL of assay diluent was added to each well in the assay plate, and
then 50μL of standards, 50μL of each sample, and 50μL of assay control were
added in their designated wells in the plate. Subsequently, the plate was incubated
at room temperature (25°C) for 2 hours.
After incubation, the plate was washed five times with wash buffer and
10μL of rat IL-6 conjugate was added to each well.
The plate was incubated again for 2 hours at room temperature. After
incubation, the rat IL-6 conjugate was aspirated, and each well was washed five
times with wash buffer. 100μL of substrate solution was added to each well, and
the plate was incubated under darkness for 30 minutes.
At the end of the 30 minutes, the stop solution was added to each well, and
the plate was read by a Biotek microplate reader (Biotek-Synergy H1 Hybrid
Reader, VT) at 450 nm.256
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3.8.

ROS assay
3.8.1. The principle of ROS assay
The

ROS

assay

employs

a

fluorogenic

dye

named

2’,7’–

dichlorofluorescein diacetate (DCFDA).257 It measures the free radicals such as
hydroxy, peroxyl and other ROS within a cell. The assay principle is based on the
process of deacetylation of DCFDA. The dye readily diffuses into cells and gets
deacetylated into a ‘non-fluorescent’ compound by cellular esterase enzymes
present in cells. The so formed non-fluorescent compound later gets oxidized by
ROS present in cells into a ‘highly fluorescent’ compound called 2’,7’–
dichlorofluorescein (DCF) which is detected by fluorescence spectroscopy with
maximum excitation at 485 nm and emission at 535 nm.258
3.8.2. ROS assay procedure
The ROS assay was carried out as per the manufacturer’s protocol (#
ab113851, DCFDA Cellular ROS Detection Assay Kit, Abcam®, MA). Aortic
VSMCs were seeded at 1×104 cells/well in 96-well plates, cultured and made
quiescent by replacing serum media with SFM 24 hours prior to treatment. On the
day of the experiment, cells were first washed with sterile PBS and then stained
with 100 µL of DCFDA (concentration of 25 µM/well) for 45 minutes under
standard incubation conditions.
After incubation, the cells were re-washed with sterile PBS, and 100 µl of
SFM was added to each well, and the treatment was carried out as per the
experimental protocol. Post-treatment, the 96-well plates were read using a Biotek
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microplate reader [(excitation at 485 nm and Emission at 535 nm), Biotek-Synergy
H1 Hybrid Reader, VT].
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3.9.

Western blotting
3.9.1. The principle of Western blotting
Western blotting is also known as immunoblotting. It is a reliable and
sensitive technique routinely employed in research for the detection and
characterization of proteins. It is a qualitative and semi-quantitative method.
Western blotting involves the electrophoretic separation of protein samples based
on their size and molecular weight in a polyacrylamide gel. The proteins are
electrically transferred from a gel to a nitrocellulose membrane. The electrical
transfer of proteins from gel-to-membrane is called ‘blotting.’
Following the transfer, membranes are probed with a specific primary
antibody and a secondary antibody conjugated with an enzyme (horseradish
peroxidase) for the chemiluminescence detection of protein(s).259 The various steps
in Western blotting is shown schematically in Figure 3.5.
3.9.2. Preparation of cell lysate and procedure of Western blotting
Cultured aortic VSMCs were lysed on ice with lysis buffer [sodium chloride
(NaCl) 137 mM; Tris- hydrochloric acid (HCl) 20 mM; glycerol 10% v/v; Triton
X-100 1% v/v; protease inhibitor cocktail―1 tablet per10 mL (PierceTM Protease
Inhibitor, Thermo Scientific, IL)], and centrifuged at 10,000 rpm for 10 minutes at
4°C. The supernatants were collected, and the bicinchoninic acid (BCA) assay
(PierceTM BCA Protein Assay Kit, Thermo Scientific, IL) was carried out for
estimating total protein content.
Subsequently, samples were diluted with a modified laemmli sample buffer
[2.5% SDS, 20% glycerol, 10% beta-mercaptoethanol, 0.004% bromphenol blue,
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0.125 M Tris HCl, and pH 6.8 (Bio-Rad, CA)]. The preheated protein samples
(equivalent to 20 µg proteins off each sample) were loaded in each well in 10%
polyacrylamide gel and were subjected to sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE).
Nitrocellulose membranes were used to transfer the proteins from the gels.
The membranes were blocked with 5% w/v non-fat milk (Blotting-Grade Blocker,
Bio-Rad, CA) solution [in 0.1% Tween in Tris-buffer saline (TBST)] for one hour
at room temperature (25°C).
The membranes were washed three times for five minutes with 0.1% TBST
solution and were incubated with primary antibodies overnight at 4°C. After that,
the membranes were probed with secondary antibodies conjugated with horseradish
peroxidase for one hour at room temperature (25°C). The enhanced
chemiluminescence (ECL) reagents (ECL Femto Max, Thermo Scientific, IL) were
utilized for visualizing the membranes under chemiluminescence.
The bands were quantified with the Image J Software (National Institutes
of Health, MD). The membranes were stripped with the stripping buffer (RestoreTM
Western Blot Stripping Buffer, VWR Life Science, GA), washed, and blocked in a
similar manner as described above, and were incubated with primary antibodies for
the housekeeping protein [glyceraldehyde-3-phosphate dehydrogenase (GAPDH)],
probed with secondary antibodies, and visualized under chemiluminescence and
quantified as stated previously.260,261
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Figure 3.5. A schematic representation of the various steps in Western blotting.
Adapted

from

https://microbeonline.com/western-blot-technique-principle-

procedures-advantages-and-disadvantages/
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The primary and secondary antibodies employed in Western blotting are
mentioned in the following table:
Table 3.1: Primary and secondary antibodies used in Western blotting
#

Antibody

Code #

Manufacturer

1

p44/42 MAPK (ERK1/2)

4695

Cell Signaling Technology®,

(137F5) Rabbit mAb
2

Phospho-p44/42 MAPK

Inc., MA
9101

(ERK1/2) (Thr202/Tyr204)
3

ROCK-1 (C8F7) Rabbit

Inc., MA
4035

mAb
4

ROCK-2 Antibody

Cell Signaling Technology®,

Cell Signaling Technology®,
Inc., MA

8236

Cell Signaling Technology®,
Inc., MA

5

6

PI3-Kinase Flour® 680 p110

sc-8010

Santa Cruz Biotechnology

Antibody (D-4) Mouse

AF 680

Inc., TX

Phospho-AKT (Ser473)

4051

Cell Signaling Technology®,

587F11 Mouse mAb
7

GAPDH (D16H11) XP®

Inc., MA
8884

Rabbit mAb HRP conjugate
8

Anti-Rabbit IgG HRP-linked
Antibody

Cell Signaling Technology®,
Inc., MA

7074

Cell Signaling Technology®,
Inc., MA
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9

Anti-Mouse IgG (Fab
specific)-Peroxidase
Conjugate

A3682

Sigma-Aldrich®, MO
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The concentrations of primary and secondary antibodies used in Western
blotting are mentioned in the following table:
Table 3.2. Concentrations of primary and secondary antibodies used in Western
blotting
#

Antibody

Dilution

Function

1

p44/42 MAPK (ERK1/2)

1:1000 in TBST

Proliferation marker

1: 1000 in TBST

Proliferation marker

Phospho-p44/42 MAPK
2
(ERK1/2)
Vasocontraction
3

ROCK-1

1: 1000 in TBST
marker
Vasocontraction

4

ROCK-2

1: 1000 in TBST
marker

5

PI3-Kinase p110α

1:200 in TBST

Proliferation marker

1: 1000 in 5%
w/v non-fat dry
6

Phospho-AKT

Proliferation marker
milk, 1x TBS, and
0.1% Tween-20
Loading control

7

GAPDH

1: 1000 in TBST
(housekeeping)

Anti-Rabbit IgG HRP8

1: 10000 in TBST
linked Antibody

Secondary antibody
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Anti-Mouse IgG (Fab
9

specific)-Peroxidase

1: 10000 in TBST

Secondary antibody

Conjugate

The compositions of buffers and polyacrylamide gels: separating and
stacking gels used in Western blotting are mentioned in Table 3.3, Table 3.4, and
Table 3.5, respectively.
Table 3.3: Composition of buffers used in Western blotting
Buffers

10X

Running buffer

Tris: 15.20 g

(for gel electrophoresis)

Glycine: 72.02 g
Sodium dodecyl sulfate (SDS): 5.00 g
Make the volume up to 1,000 mL with distilled water.

Transfer buffer

Tris: 15.20 g

(for blotting)

Glycine: 72.02 g
Make the volume up to 1,000 mL with distilled water.

Tris-buffered saline

Tris: 60.57g

(TBS)

Sodium chloride (NaCl): 87.66 g
Make the volume up to 1,000 mL with distilled water.

Phosphate-buffered

Sodium chloride (NaCl): 82.00 g

saline (PBS)

Potassium chloride (KCl): 2.00 g
Disodium hydrogen phosphate (Na2HPO4): 29.00 g
Potassium dihydrogen phosphate (KH2PO4): 2.00 g
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Make the volume up to 1,000 mL with distilled water.

Table 3.4: Composition of 10% resolving (separating) gel used in Western
blotting
Ingredients

2 gels

4 gels

Acrylamide (30%)

3.75 mL

7.50 mL

SDS (10%)

112.50 μL

225.00 μL

Tris-HCl (1.5 M, pH 8.8)

2.85 mL

5.70 mL

Distilled water

4.65 mL

9.3 mL

37.50 μL

75 μL

7.50 μL

15 μL

Ammonium per sulfate
[(APS), 10%]
Tetramethylethylenediamine
(TEMED)

Table 5: Composition of 5% stacking gel used in Western blotting
Ingredients

2 gels

4 gels

Acrylamide (30%)

487.50 μL

975.00 μL

SDS (10%)

37.50 μL

75.00 μL

Tris-HCl (1.5 M, pH 8.8)

937.50 μL

1875.00 μL

Distilled water

2.25 mL

4.50 mL

Ammonium per sulfate

19.00 μL

38.00 μL

[(APS), 10%]
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Tetramethylethylenediamine 4.00 μL

3.10.

8.00 μL

Statistical Analysis
The analysis of variance (ANOVA) was used for comparison between
Wistar rats and SHRs. The unpaired Student t-test was applied to determine whether
differences between the two individual treatment groups were significant. The
difference between the treatment groups was considered statistically significant if
the probability value (P value) was less than 0.05.262
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3.11.

Specific aims 1 and 2, strategies, and experimental design
Specific aim 1: To characterize the effect of oxytocin on proliferation,
inflammation, oxidative stress, and on vasocontraction pathway in primary aortic
VSMCs obtained from normotensive Wistar rats.
Specific aim 2: To determine the interaction between oxytocin and Ang II with
regards to proliferation, inflammation, oxidative stress, and on vasocontraction
pathway in primary aortic VSMCs obtained from normotensive Wistar rats.
Strategies and experimental design for specific aims 1 and 2:
The following four strategies and experimental designs were devised for
specific aims 1 and 2:
Strategy 1a:
To investigate the effect of oxytocin, and its interaction with Ang II on the
proliferation of aortic VSMCs obtained from normotensive Wistar rats, the
following techniques were utilized:
1. Cells were counted directly by employing the Hemocytometer method.
2.

Cell viability was assessed using the MTT assay.

3. Cell growth was determined using the 3H-Thymidine incorporation
assay.
4.

Cell apoptosis and necrosis were detected by Flow Cytometry.

Experimental design for the strategy 1a:
VSMCs were seeded in 6-well plates, 24-well plates, and 96-well plates in
the hemocytometer experiments, 3H-Thymidine incorporation assays, and MTT
assays, respectively. For the hemocytometer method, MTT-assay, and

3

H-
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Thymidine incorporation assay, the treatment groups were identical and are stated
in the following table:
Table 3.6: Treatment groups in Hemocytometer method, MTT, and 3HThymidine incorporation assays
#

Treatment Groups

1

The control group (only SFM and no treatment)

2

Oxytocin 100 nM

3

Ang II 100 nM

4

Oxytocin (100 nM) + Ang II (100 nM)

5

L-371,257 [oxytocin receptor antagonist (OXTA)] 1 μM

6

OXTA 1 μM + Oxytocin (100 nM) + Ang II (100 nM)

7

OXTA 1 μM + Oxytocin (100 nM)

Cells were pre-treated with oxytocin (VWR Life Science, GA) ten minutes
before treatment with Ang II (VWR Life Science, GA). OXTA (Santa Cruz
Biotechnology Inc., TX) was added 30 minutes before the treatment with oxytocin.
In both the hemocytometer method and MTT assay, the treatment was carried out
every 24 hours through 72 hours. In the 3H-Thymidine incorporation assay, the
treatment was carried out at 24 and 48 hours, respectively. The SFM was
replenished (every 24 hours) before the start of treatments.
For the flow cytometer assay, 6-well plates were used to seed cells. There
were three experimental groups: control (only SFM and no treatment), oxytocin (10
nM), and oxytocin (100 nM). The treatment was carried out only for 24 hours.
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Strategy 1b:
To further understand the mechanism of oxytocin, and its interaction with
Ang II on the proliferation of aortic VSMCs in Wistar rats, the two critical signaling
pathways involved in VSMCs proliferation were investigated: ERK1/2 pathway
and PI3K/Akt pathway. Western blotting technique was utilized as a part of strategy
1b.
Experimental design for Strategy 1b:
Cells were seeded in 6-well plates. The experimental design consisted of
the following treatment groups mentioned in Table 3.7:
Table 3.7: Treatment groups for ERK1/2 and PI3K/Akt pathway experiments
#

Treatment Groups

1

The control group (only SFM and no treatment)

2

Oxytocin 100 nM

3

Ang II 100 nM

4

Oxytocin (100 nM) + Ang II (100 nM)

5

L-371,257 [oxytocin receptor antagonist (OXTA)] 1 μM

6

OXTA 1 μM + Oxytocin (100 nM) + Ang II (100 nM)

For investigating the effect of oxytocin, and its interaction with Ang II on
the phosphorylation of ERK1/2, PI3K p110α, and Akt, cells were treated with
oxytocin for ten minutes, and also with Ang II also for ten minutes. In the
combination group, cells were pre-treated with oxytocin for ten minutes before the
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treatment with Ang II. OXTA was added 30 minutes before the treatment with
oxytocin.
Strategy 2:
To investigate the effect of oxytocin, and its interaction with Ang II on
oxidative stress in aortic VSMCs (Wistar rats), ROS levels were measured. A ROS
assay was carried out to determine ROS levels.
Experimental design for strategy 2:
Cells were seeded in 96-well plates. The experimental design for the ROS
assay comprised of the following treatment groups (Table 3.8):
Table 3.8: Treatment groups for the ROS assay
#

Treatment Groups

1

The control group (SFM and no treatment)

2

Oxytocin 100 nM

3

Ang II 100 nM

4

Oxytocin (100 nM) + Ang II (100 nM)

5

L-371,257 [oxytocin receptor antagonist (OXTA)] 1 μM

6

OXTA 1 μM + Oxytocin (100 nM) + Ang II (100 nM)

7

OXTA 1 μM + Oxytocin (100 nM)

8

OXTA 1 μM + Ang II (100 nM)

Cells were treated for ten minutes with oxytocin and Ang II. In the
combination group, cells were pre-treated with oxytocin ten minutes before the
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treatment with Ang II. OXTA was added 30 minutes before the treatment with
oxytocin and Ang II.
Strategy 3:
To investigate the effect of oxytocin, and its interaction with Ang II on
inflammation in aortic VSMCs (Wistar rats), the levels of IL-6, a critical
inflammatory mediator, were measured. An IL-6 ELISA was utilized to measure
IL-6 levels.
Experimental design for strategy 3:
Cells were seeded in 6-well plates. The experimental design for the IL-6
assay included the following treatment groups (Table 3.9):
Table 3.9: Treatment groups for the IL-6 assay
#

Treatment Groups

1

The control group (only SFM and no treatment)

2

Oxytocin (10 nM)

3

Oxytocin (100 nM)

4

Oxytocin (1000 nM)

5

Ang II (100 nM)

6

Oxytocin (10 nM) + Ang II (100 nM)

7

Oxytocin (100 nM) + Ang II (100 nM)

8

Oxytocin (1000 nM) + Ang II (100 nM)

9

L-371,257 [oxytocin receptor antagonist (OXTA)] + Oxytocin
(100 nM) + Ang II (100 nM)
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Cells were treated with different concentrations of oxytocin for ten minutes,
and with Ang II for ten minutes. In the combination group, cells were pre-treated
with oxytocin ten minutes before the treatment with Ang II. OXTA was added 30
minutes before the treatment with oxytocin and Ang II. Post-treatment, IL-6
secreted in the media (supernatant) was collected, and IL-6 ELISA was carried out
as per the manufacturer’s protocol.
Strategy 4:
The effect of oxytocin, and its interaction with Ang II on vasocontraction in
aortic VSMCs in Wistar rats was assessed indirectly by investigating the Rhokinase pathway (ROCK-1 and ROCK-2) a critical pathway implicated in
vasocontraction of VSMCs. The Western blotting method was employed as part of
strategy 4.
Experimental design for strategy 4:
Cells were seeded in 6-well plates. The experimental design to pursue
strategy 4 incorporated the following treatment groups (Table 3.10):
Table 3.10: Treatment groups for Rho kinase pathway experiments
#

Treatment Groups

1

The control group (only SFM and no treatment)

2

Oxytocin 100 nM

3

Ang II 100 nM

4

Oxytocin (100 nM) + Ang II (100 nM)

5

L-371,257 [oxytocin receptor antagonist (OXTA)] 1 μM

6

OXTA 1 μM + Oxytocin (100 nM) + Ang II (100 nM)
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To determine the effect of oxytocin, and its interaction with Ang II on the
phosphorylation of ROCK-1 and ROCK-2, cells were treated with oxytocin for ten
minutes, and with Ang II also for ten minutes. In the combination group, cells were
pre-treated with oxytocin for ten minutes before the treatment with Ang II. OXTA
was added 30 minutes before the treatment with oxytocin.
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3.12.

Specific aim 3, strategy, and experimental design
Specific aim 3: To characterize the effect of oxytocin and its interaction with Ang
II on proliferation, inflammation, oxidative, and vasocontraction pathway in
primary aortic VSMCs obtained from SHRs.
Strategies and experimental design for specific aim 3:
To pursue specific aim 3, the approaches similar to specific aims 1 and 2
were adopted, and identical experimental designs were employed in aortic VSMCs
obtained from hypertensive rats (SHRs).
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Chapter 4: Results
4.1. Normotensive Wistar rats
(Specific aims 1 and 2)
4.1.1. Effects of oxytocin and Ang II on proliferation of aortic VSMCs
isolated from normotensive Wistar rats
4.1.1.1. Cell counting by Hemocytometer method in Wistar VSMCs
Oxytocin (100 nM) significantly reduced the proliferation of aortic VSMCs
compared to the control group in normotensive Wistar rats. Oxytocin-induced
reduction of VSMCs proliferation rate of VSMCs was time-dependent, with a
50.9% ± 8.3% (P < 0.05) reduction in proliferation at 24 hours, 89.2% ± 1.2 % (P
< 0.001) reduction at 48 hours and 94.7% ± 5.3% (P < 0.001) at 72 hours compared
to control (Figures 4.1 and 4.2).
Contrary to oxytocin, Ang II (100 nM) significantly increased the
proliferation of VSMCs by 354% ± 46% (P < 0.001) at 24 hours, 217% ± 13% (P
< 0.001) at 48 hours, and 118% ± 73% (P < 0.001) at 72 hours when compared to
control (Figures 4.1 and 4.2).
Pre-treatment with oxytocin (100 nM) for ten minutes remarkably reduced
the Ang II-induced increase in VSMCs proliferation by 62.9% ± 8.8% (P < 0.01)
at 24 hours, 82.9% ± 21.5% (P < 0.001) at 48 hours and 86.9% ± 5.5% (P < 0.001)
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at 72 hours compared to Ang II alone. These effects of oxytocin were prevented by
pre-treatment with the OXTA– L-371,257 (1µM), (Figures 4.1 and 4.2).

85

Figure 4.1. The effect of oxytocin and different treatment groups on aortic
VSMCs proliferation in Wistar rats as assessed by the Hemocytometer method.
Cells were seeded at 1×106 cells/well in 6-well plates. Cell proliferation was
measured by counting the number of cells per milliliter (mL). The data are
represented as the mean ± SEM from three independent experiments performed in
duplicates using aortic VSMCs from three Wistar rats. Ang II indicates Angiotensin
II; OXTA, Oxytocin receptor antagonist.
* P < 0.05 and *** P < 0.001 : All groups versus Control
P < 0.05,

P < 0.01, and

P < 0.001 : Oxytocin versus (OXTA + Oxytocin);

and Oxytocin versus Ang II
##

P < 0.01 and

###

P < 0.001 : (Oxytocin + Ang II) versus Ang II alone; and

(Oxytocin + Ang II) versus (OXTA + Oxytocin + Ang II)
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Figure 4.2. The effect of oxytocin and different treatment groups on the
proliferation rate of aortic VSMCs in Wistar rats as assessed by the
Hemocytometer method. Cells were seeded at 1×106 cells/well in 6-well plates.
Cell proliferation rate was assessed as percent (%) change of control. The data are
represented as the mean ± SEM from three independent experiments performed
using aortic VSMCs from three Wistar rats. Ang II indicates Angiotensin II; OXTA,
Oxytocin receptor antagonist.
* P < 0.05 and *** P < 0.001 : All groups versus Control
P < 0.05,

P < 0.01, and

P < 0.001 : Oxytocin versus (OXTA + Oxytocin);

and Oxytocin versus Ang II
##

P < 0.01 and

###

P < 0.001 : (Oxytocin + Ang II) versus Ang II alone; and

(Oxytocin + Ang II) versus (OXTA + Oxytocin + Ang II)
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4.1.1.2. Assessment of cell viability with the MTT-assay in Wistar
VSMCs
The effect of oxytocin on cell viability in aortic VSMCs was evaluated with
the MTT assay. Oxytocin (100 nM) induced a significant decrease in cell viability
of VSMCs in a time-dependent manner with 4.4% ± 3% (P < 0.001), 22.6% ± 7%
(P < 0.001), and 21.4% ± 6% (P < 0.001) reduction at 24, 48 and 72 hours,
respectively compared to control (Figures 4.3 and 4.4).
Contrary to oxytocin’s effect, Ang II (100 nM) treatment showed a
significant increase in cell viability of VSMCs with 112% ± 15% (P < 0.001), 119%
± 15% (P < 0.001), and 79.6% ± 10% (P < 0.001) increases in proliferation of
VSMCs at 24, 48, and 72 hours, respectively compared to control (Figures 4.3 and
4.4).
The pre-treatment with oxytocin (100 nM) also significantly reduced Ang
II-induced VSMCs viability with 53.8% ± 4.5% (P < 0.001) decrease at 24 hours,
63.8% ± 7.7% (P < 0.001) decrease at 48 hours and a 51.6% ± 5.8% (P < 0.001)
decrease at 72 hours compared to Ang II alone. Both these effects of oxytocin were
significantly antagonized by the OXTA (Figures 4.3 and 4.4).
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Figure 4.3. The effect of oxytocin and different treatment groups on Wistar aortic
VSMCs viability as assessed by the MTT assay. Cells were seeded at 1×104
cells/well in 96-well plates. Cell viability was determined as the function of an
optical density (OD) measured at 570 nm. The data are shown as the mean ± SEM
of three independent experiments performed using aortic VSMCs isolated from
three Wistar rats. Each experiment was performed with 12 replicates. Ang II
indicates Angiotensin II; OXTA, Oxytocin receptor antagonist.
*** P < 0.001 : All groups versus Control
P < 0.05,

P < 0.01, and

P < 0.001 : Oxytocin versus (OXTA + Oxytocin);

and Oxytocin versus Ang II
###

P < 0.001 : (Oxytocin + Ang II) versus Ang II alone; and (Oxytocin + Ang II)

versus (OXTA + Oxytocin + Ang II)
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Figure 4.4. The effect of oxytocin and different treatment groups on Wistar aortic
VSMCs viability rate as assessed by the MTT assay. Cells were seeded at 1×104
cells/well in 96-well plates. Cell viability was measured as the percent (%) change
of control. The data are the shown as the mean ± SEM of three independent
experiments performed using aortic VSMCs isolated from three Wistar rats. Each
experiment was performed with 12 replicates. Ang II indicates Angiotensin II;
OXTA, Oxytocin receptor antagonist.
*** P < 0.001 : All groups versus Control
P < 0.05,

P < 0.01, and

P < 0.001 : Oxytocin versus (OXTA + Oxytocin);

and Oxytocin versus Ang II
###

P < 0.001 : (Oxytocin + Ang II) versus Ang II alone; and (Oxytocin + Ang II)

versus (OXTA + Oxytocin + Ang II)

90
4.1.1.3.

Assessment of cell growth with 3H-Thymidine incorporation
assay in Wistar VSMCs

The growth assay allowed an indirect measurement of cell division/growth
– as the function of the incorporation of the radioisotope 3H-Thymidine into
deoxyribonucleic acid (DNA) of the rapidly dividing cells. The radioactivity
recovered from the cells was measured in terms of counts per minute (cpm). A
higher count indicated a higher growth rate and vice-versa.
Growth assay results validated that oxytocin (100 nM) significantly
reduced the 3H-Thymidine incorporation in aortic VSMCs from 5,857 ± 3,825 cpm
(control) to 2,171 ± 1,446 cpm [44% ± 12% decrease (P < 0.01), Figure 4.5].
On the other hand, treatment with Ang II (100 nM) significantly increased
3

H-Thymidine incorporation in VSMCs from 5,857 ± 3,825 cpm (control) to 11,194

± 7,874 cpm [70% ± 15% increase (P < 0.01), Figure 4.5].
Ang II-induced growth of VSMCs was significantly decreased by pretreatment with oxytocin [4,092 cpm ± 2,257 cpm (43% ± 15% decrease), P < 0.01]
compared to Ang II alone (11,194 cpm ± 7,874 cpm). Both these effects of oxytocin
were antagonized by OXTA (Figure 4.5).
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Figure 4.5. The effect of oxytocin and various treatment groups on aortic Wistar
VSMCs growth as assessed by the 3H-Thymidine incorporation assay. VSMCs
were seeded at 5×104 cells/well in 24-well plates. Cell growth was measured as the
function of the intake of the radioisotope 3H-Thymidine into the deoxyribonucleic
acid (DNA) of the rapidly dividing cells and counted by the scintillation counter.
The data are represented as the counts per minute (cpm) and are shown as the
mean ± SEM of four independent experiments, each performed with triplicates,
using aortic VSMCs from four Wistar rats. Ang II indicates Angiotensin II; OXTA,
Oxytocin receptor antagonist.
* P < 0.05 and ** P < 0.01 : versus Control
P < 0.01 and

P < 0.001 : Oxytocin versus (OXTA + Oxytocin);

and

Oxytocin versus Ang II
#

P < 0.05 and ## P < 0.01 : (Oxytocin + Ang II) versus (OXTA + Oxytocin + Ang

II);and (Oxytocin + Ang II) versus and Ang II alone
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4.1.1.4. Assessment of cell viability by flow cytometry in Wistar
VSMCs
The outcomes of the flow cytometry experiments revealed that treatment
with oxytocin decreased cell viability, and induced apoptosis and necrosis in aortic
VSMCs isolated from Wistar rats.
The flow experiments utilized two different concentrations of oxytocin: 10
nM and 100 nM. When compared to the control group (95.5% ± 0.7%), the live cell
percentage in aortic VSMCs significantly decreased to 91.7 % ± 0.4% (P < 0.05) in
the 10 nM oxytocin group and further plummeted to 67.5% ± 2.3% (P < 0.01) in
the 100 nM oxytocin group, respectively (Figure 4.6).
Oxytocin significantly induced apoptosis in aortic VSMCs. The treatment
with 100 nM oxytocin significantly increased apoptosis up to 26.1% ± 3% (P <
0.05) compared to apoptosis in the control group (2.6% ± 1.1%). However, there
were no significant differences in the percentage of apoptotic cells between the 10
nM oxytocin group (4.2% ± 1.6%) and the control group [2.7% ± 1.1% (Figure
4.6)].
In addition to inducing apoptosis, the flow results demonstrated that
oxytocin considerably induced necrosis in aortic VSMCs. When compared to
control (0.7% ± 0.1%), the percentage of cells undergoing necrosis significantly
increased to 3.6% ± 1.4% (P < 0.05) and 3.9% ± 0.3% (P < 0.01) in the10 nM
oxytocin group and the 100 nM oxytocin group, respectively. However, there was
no statistically significant difference between the percentage of necrotic cells
between oxytocin 10 nM an oxytocin 100 nM treatment groups (Figure 4.6).
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The percentage of aortic VSMCs double positive for both necrosis and
apoptosis significantly increased from 0.9% ± 0.1% (in control group) to 2.5% ±
0.1% [in 100 nM oxytocin group (P < 0.01)]. Conversely, there were no significant
differences between the 10 nM oxytocin group (0.5% ± 0.1%) and the control group
[0.9% ± 0.1% (Figure 4.6)].
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Figure 4.6. The effect of oxytocin on apoptosis and necrosis in aortic Wistar
VSMCs as assessed by flow cytometry. VSMCs were seeded at 1×106 cells/well in
6-well plates. The data are shown as the percentage of cells positive for apoptosis,
necrosis and apoptosis + necrosis across different treatment groups. The data are
represented as the mean ± SEM from three independent experiments performed
using aortic VSMCs from three Wistar rats. The treatment was carried out for 24
hours with the two different concentrations of oxytocin: 10 nM and 100 nM. Cells
in the control group were not treated with oxytocin (only SFM). Cells were stained
with fluorescent dyes: Annexin V (for apoptosis) and 7-amino actinomycin D [(7AAD) for necrosis] and assessed with the flow cytometer.
* P < 0.05 : Live cells in Oxytocin 10 nM group versus Live cells in Control group
** P < 0.01 : Live cells in Oxytocin 100 nM group versus Live cells in Control
group
P < 0.05 : Apoptotic cells in Oxytocin 100 nM group versus Apoptotic cells in
Control group
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#

P < 0.05 : Necrotic cells in Oxytocin 10 nM group versus Necrotic cells in Control

group
##

P < 0.01 : Necrotic cells in Oxytocin 100 nM group versus Necrotic cells in

Control group
P < 0.01 : (Apoptotic + Necrotic cells) in Oxytocin 100 nM group versus
(Apoptotic + Necrotic cells) in Control group
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4.1.2. Effect of oxytocin and its pre-treatment with Ang II on the
phosphorylation of ERK1/2 in aortic Wistar VSMCs
In aortic Wistar VSMCs, oxytocin (100 nM) significantly decreased the
active phosphorylated form of ERK1/2 (pERK1/2) after ten minutes of treatment
compared to the control group (basal levels). While the treatment with Ang II (100
nM) significantly increased pERK1/2 after ten minutes of treatment compared to
control (Figure 4.7).
The pre-treatment with oxytocin (100 nM) significantly reduced Ang IIinduced activation of pERK1/2, and pre-treatment with OXTA (1 μM) for 30
minutes significantly abrogated these effects of oxytocin (Figure 4.7).
The densitometric analysis of the western blot images showed that oxytocin
significantly decreased pERK1/2 by 57.9% ± 14.2% (P < 0.001) compared to
control, Ang II significantly increased pERK1/2 by 223% ± 11% (P < 0.001)
compared to control, and the oxytocin pre-treatment significantly decreased
pERK1/2 by 76.6% ± 1.4% (P < 0.01) compared to Ang II alone (Figure 4.7).
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Figure 4.7. The effect of oxytocin and different treatment groups on the
phosphorylation of ERK1/2 in aortic Wistar VSMCs. Western blotting was utilized
to measure phospho-ERK1/2 levels, and the data were normalized with total
ERK1/2. The effect of oxytocin and its combination with different treatment groups
on the phosphorylation of ERK1/2 is shown as the percent (%) of control, with
control as 100%. The data are shown as the mean ± SEM of five independent
experiments, performed using aortic VSMCs isolated from five Wistar rats. **
indicates P < 0.01 versus control; *** P < 0.001 versus control;

P < 0.01

Oxytocin versus Ang II; ## P < 0.01 (Oxytocin + Ang II) versus Ang II alone; and
(Oxytocin + Ang II) versus (OXTA + Oxytocin + Ang II). Ang II indicates
Angiotensin II; OXTA, Oxytocin receptor antagonist.
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4.1.3. Effect of oxytocin and its pre-treatment with Ang II on the
phosphorylation of PI3K p110𝒂 and Akt in aortic Wistar VSMCs
In primary aortic VSMCs obtained from Wistar rats, the densitometric
analysis of the western blot images showed that the treatment with oxytocin (100
nM) significantly decreased the active phosphorylated form of PI3K p110alpha
(phospho-PI3K p110a) by 64.8% ± 2.8% (P < 0.01) and the active phosphorylated
form of Akt (phospho-Akt) by 46.2% ± 9.5% (P < 0.05) compared to controls,
respectively (Figures 4.8 and 4.9).
One the other hand, treatment with Ang II (100 nM) significantly increased
the levels of phospho-PI3K p110a by 184% ± 17% (P < 0.05) and phospho-Akt by
44.4% ± 3.5% (P < 0.001) compared to control respectively (Figures 4.8 and 4.9).
Pre-treatment with oxytocin (100 nM) significantly reduced Ang IImediated increased levels of phospho-PI3K p110a by 83.8% ± 8.6% (P < 0.01) and
phospho-Akt by 62.1% ± 10.9% (P < 0.001) compared to Ang II alone,
respectively. These effects of oxytocin were significantly abated by pre-treatment
with OXTA (1 μM) for 30 minutes (Figures 4.8 and 4.9).
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Figure 4.8. The effect of oxytocin and different treatment groups on the
phosphorylation of PI3K p110α in aortic Wistar VSMCs. Western blotting was
utilized to measure the phosphorylation of PI3K p110α, and the data were
normalized with glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The effect
of oxytocin and its combination with different treatment groups on the
phosphorylation of PI3K p110α is shown as the percent (%) of control, with control
as 100 %. The data are shown as the mean ± SEM of three independent
experiments, performed using aortic VSMCs isolated from three Wistar rats. *
indicates P < 0.05 versus control; ** P < 0.01 versus control;

P < 0.01 Oxytocin

versus Ang II; ## P < 0.01 (Oxytocin + Ang II) versus Ang II alone; ### P < 0.001
(Oxytocin + Ang II) versus (OXTA + Oxytocin + Ang II). Ang II indicates
Angiotensin II; OXTA, Oxytocin receptor antagonist.
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Figure 4.9. The effect of oxytocin and different treatment groups on the
phosphorylation of Akt in aortic Wistar VSMCs. Western blotting was utilized to
measure the phosphorylation of Akt, and the data were normalized with
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The effect of oxytocin and
its combination with different treatment groups on the phosphorylation of Akt is
shown as the percent (%) of control, with control as 100%. The data are shown as
the mean ± SEM of four independent experiments, performed using aortic VSMCs
isolated from four Wistar rats. ** indicates P < 0.01 versus control; *** P < 0.001
versus control;

P < 0.001 Oxytocin versus Ang II; ### P < 0.001 (Oxytocin +

Ang II) versus Ang II alone, and (Oxytocin + Ang II) versus (OXTA + Oxytocin +
Ang II). Ang II indicates Angiotensin II; OXTA, Oxytocin receptor antagonist.
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4.1.4. Effect of oxytocin and its pre-treatment with Ang II on the activation
of ROCK -1 and ROCK-2 in aortic Wistar VSMCs
Densitometric analysis of the western blot images showed that in Wistar
rats, oxytocin (100 nM) significantly reduced the activation of ROCK-1 by 60.4%
± 7.6% (P < 0.001) and ROCK-2 by 38.7% ± 13.1% (P < 0.01) compared to
controls, respectively (Figures 4.10 and 4.11).
Ang II (100 nM) significantly enhanced the activation of ROCK-1 by 147%
± 50% (P < 0.05) and ROCK-2 by 83.2% ± 14.6% (P < 0.001) compared to controls,
respectively (Figures 4.10 and 4.11).
Pre-treatment with oxytocin (100 nM) significantly reduced Ang II-induced
activation of ROCK-1 by 85.2% ± 10.6% (P < 0.01) and ROCK-2 by 65.9% ±
13.2% (P < 0.001) compared to Ang II alone, respectively. These effects of
oxytocin were significantly reduced by pre-treatment with OXTA (1µM) (Figures
4.10 and 4.11).
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Figure 4.10. The effect of oxytocin and different treatment groups on the
activation of ROCK- 1 in aortic Wistar VSMCs. Western blotting was utilized to
measure the ROCK-1 levels, and the data were normalized with glyceraldehyde-3phosphate dehydrogenase (GAPDH). The effect of oxytocin and its combination
with different treatment groups on the activation of ROCK- 1 is shown as the
percent (%) of control, with control as 100%. The data are shown as the mean ±
SEM of four independent experiments, performed using aortic VSMCs isolated
from four Wistar rats. * indicates P < 0.05 versus control; *** P < 0.001 versus
control;

P < 0.01 Oxytocin versus Ang II; ## P < 0.01 (Oxytocin + Ang II) versus

Ang II alone, and (Oxytocin + Ang II) versus (OXTA + Oxytocin + Ang II). Ang II
indicates Angiotensin II; OXTA, Oxytocin receptor antagonist; ROCK, Rhoassociated coiled-coil containing protein kinase.
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Figure 4.11. The effect of oxytocin and different treatment groups on the
activation of ROCK-2 in aortic Wistar VSMCs. Western blotting was utilized to
measure the ROCK-2 levels, and the data were normalized with glyceraldehyde-3phosphate dehydrogenase (GAPDH). The effect of oxytocin and its combination
with different treatment groups on the activation of ROCK-2 is shown as the percent
(%) of control, with control as 100%. The data are shown as the mean ± SEM of
five independent experiments, performed using aortic VSMCs isolated from five
Wistar rats. * indicates P < 0.05 versus control; ** P < 0.01 versus control; ***
P < 0.001 versus control;

P < 0.001 Oxytocin versus Ang II;

###

P < 0.001
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(Oxytocin + Ang II) versus Ang II alone;

##

P < 0.01 (Oxytocin + Ang II) versus

(OXTA + Oxytocin + Ang II). Ang II indicates Angiotensin II; OXTA, Oxytocin
receptor antagonist; ROCK, Rho-associated coiled-coil containing protein kinase.

105
4.1.5. Effect of oxytocin and its pre-treatment with Ang II on IL-6 secretion
in aortic Wistar VSMCs
The IL-6 ELISA assay was carried out as per the manufacturer’s protocol.
The concentration of IL-6 secreted by aortic VSMCs in the culture media was
measured in ‘picogram per milliliter’ (pg/mL). In Wistar rats, the outcomes of the
IL-6 assay showed that oxytocin treatment resulted in a significant increase in IL6 secretion compared to the control group. Three different concentrations of
oxytocin were used: 10 nM, 100 nM, 1,000 nM. The treatment with oxytocin at 100
nM and 1,000 nM resulted in significant increases in IL-6 with 1,033 ± 24 pg/mL
(P < 0.01) at 100 nM and 959 ± 52 pg/mL (P < 0.05) at 1,000 nM, respectively
compared to control group [614 ± 104 pg/mL (Figure 4.12)].
However, there was no significant difference between oxytocin 10 nM (695
± 101 pg/mL) and control group (614 ± 104 pg/mL). There was no significant
difference between oxytocin 100 nM (1,033 ± 24 pg/mL) and oxytocin 1,000 nM
[959 ± 52 pg/mL (Figure 4.12)].
Ang II (100 nM) treatment showed a significant increase in IL-6 [1,481 ±
91 pg/mL (P < 0.01)] compared to control group (614 ± 104 pg/mL). Ang II (100
nM) treatment resulted in more IL-6 secretion (1,481 ± 91 pg/mL) compared to
treatment with oxytocin [100 nM (1,033 ± 24 pg/mL), P < 0.01] when compared to
control [614 ± 104 pg/mL (Figure 4.12)].
Interestingly, in contrast to its singular effect, oxytocin’s pre-treatment (100
nM) with Ang II (100 nM) significantly decreased IL-6 secretion (735 ± 77 pg/mL)
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compared to Ang II 100 nM alone [1,481 ± 91 pg/mL (P < 0.01)] and oxytocin 100
nM alone [1,033 ± 24 pg/mL (P < 0.01)], respectively (Figure 4.12).
The effect of oxytocin pre-treatment (100 nM) on Ang II (100 nM) was
significantly abolished by pre-treatment with 1µM OXTA. IL-6 secretion was
significantly higher [1,487 ± 64 pg/mL (P < 0.001] in the OXTA-pre-treatment
group [OXTA (1µM) + Oxytocin (100 nM) + Ang II (100 nM)] than Oxytocin 100
nM + Ang II 100 nM group [735 ± 77 pg/mL (Figure 4.12)].
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Figure 4.12. The effect of oxytocin and different treatment groups on IL-6
secretion in aortic Wistar VSMCs. The concentration of IL-6 secreted by aortic
VSMCs in the culture media was measured in picogram per milliliter (pg/mL). The
data are represented as the mean ± SEM from three independent experiments
performed using aortic VSMCs from three Wistar rats. In each experiment each
treatment group had duplicates. * indicates P < 0.05 versus Control group; ** P
< 0.01 versus Control group;

P < 0.05 Oxytocin 10 nM versus Oxytocin 100 nM

and Oxytocin 1000 nM respectively. # P < 0.05 (Oxytocin 100 nM + Ang II 100 nM)
versus Oxytocin 100 nM alone;
versus Ang II 100 nM alone;

##

###

P < 0.01 (Oxytocin 100 nM + Ang II 100 nM)

P < 0.001 (Oxytocin 100 nM + Ang II 100 nM)

versus (OXTA 1µM + Oxytocin 100 nM + Ang II 100 nM);

P < 0.01 Oxytocin

100 nM versus Ang II 100 nM. Ang II indicates Angiotensin II; OXTA, Oxytocin
receptor antagonist.

108
4.1.6. Effect of oxytocin and its pre-treatment with Ang II on ROS in aortic
Wistar VSMCs
ROS was assessed as the function of fluorescent units. The outcomes of the
ROS assay in aortic Wistar VSMCs demonstrated that the treatment with oxytocin
(100 nM) significantly increased ROS production [8,584 ± 114 (P < 0.001)]
compared to the control group (7,542 ± 128). Ang II (100 nM) significantly
increased ROS production [8,336 ± 204 (P < 0.001)] compared to the control group
(7,542 ± 128). There was no significant difference in the ROS production between
oxytocin [100 nM (8,584 ± 114)] and Ang II [100 nM (8,336 ± 204)] treatment
groups (Figure 4.13).
The pre-treatment of oxytocin (100 nM) with Ang II (100 nM) significantly
increased ROS production [9,346 ± 143 (P < 0.001)] compared to the control group
[7,542 ± 128 (Figure 4.13)].
Interestingly, the pre-treatment of oxytocin (100 nM) followed by Ang II
(100 nM) resulted in significantly higher (P < 0.001) ROS production (9,346 ± 143)
than oxytocin (100 nM) alone (8,584 ± 114) and Ang II (100 nM) alone (8,336 ±
204), respectively, indicating an additive effect (Figure 4.13).
OXTA (1 µM) on its own significantly increased ROS production [8,530 ±
267 (P < 0.001)] compared to the control group (7,542 ± 128). In addition, pretreatment of OXTA (1 µM) with oxytocin (100 nM) resulted in significantly
increased ROS production [9,594 ± 177 (P < 0.001)] when compared with oxytocin
(100 nM) alone (8,584 ± 114). This suggests an additive effect of OXTA on
oxytocin-stimulated ROS production (Figure 4.13).

109
The combination of OXTA (1 µM), oxytocin (100 nM), and Ang II (100
nM) significantly increased ROS production [10,511 ± 179 (P < 0.001)] compared
to control (7,542 ± 128) in aortic Wistar VSMCs (Figure 4.13).
ROS production in the combination group of OXTA (1 µM), oxytocin (100
nM), and Ang II (100 nM) was significantly higher [10,511 ± 179 (P < 0.001)] than
Oxytocin (100 nM) alone (8,584 ± 114), Ang II (100 nM) alone (8,336 ± 204), and
OXTA (1 µM) alone (8,530 ± 267), respectively, thus indicating an additive effect
(Figure 4.13).

110

Figure 4.13. The effect of oxytocin and different treatment groups on ROS
4

production in aortic Wistar VSMCs. VSMCs were seeded at 1×10 cells/well in
96-well plates. The ROS levels were measured as the function of the fluorescent
unit. The data are represented as the mean ± SEM from three independent
experiments performed using aortic VSMCs from three Wistar rats. In each
experiment each treatment group had 12 replicates. *** indicates P < 0.001 versus
Control group;

###

P < 0.01 (Oxytocin + Ang II) versus Oxytocin alone, Ang II

alone, and (OXTA + Oxytocin + Ang II);

P < 0.001 (OXTA + Oxytocin + Ang

II) versus Oxytocin alone, Ang II alone, and OXTA alone;

P < 0.001 Oxytocin

versus (OXTA + Oxytocin). Ang II indicates Angiotensin II; OXTA, Oxytocin
receptor antagonist.

111
4.2.

Spontaneously hypertensive rats [Specific Aim 3]
4.2.1. Effect of oxytocin and its pre-treatment with Ang II on aortic SHR
VSMCs proliferation
4.2.1.1. Cell counting by Hemocytometer method in SHR VSMCs
Similar to its effects on VSMCs proliferation from the normotensive rats,
oxytocin (100 nM) significantly reduced aortic VSMCs proliferation in SHRs
compared to the control group (Figures 4.14 and 4.15).
The hemocytometer cell counting revealed that oxytocin-induced reduction
in SHR VSMCs proliferation rate was time-dependent, with 44.8% ± 3% reduction
(P < 0.001) in proliferation at 24 hours, 84.4% ± 0.9% reduction (P < 0.001)
reduction at 48 hours and 88.2% ± 4.0% reduction (P < 0.001) reduction at 72 hours
compared to control (Figures 4.14 and 4.15).
On the other hand, the treatment with Ang II (100 nM) significantly
increased SHR VSMCs proliferation, with 190% ± 18% (P < 0.001) increase in
proliferation rate at 24 hours, 112% ± 15% (P < 0.001) increase at 48 hours, and
207 % ± 56% (P < 0.001) increase at 72 hours compared to control (Figures 4.14
and 4.15).
It is noteworthy that even in the SHRs, the oxytocin (100 nM) pre-treatment
significantly reduced Ang II-induced VSMCs proliferation in a time-dependent
manner, with 66% ± 24% (P < 0.001) decrease at 24 hours, 93% ± 3% (P < 0.001)
decrease at 48 hours and 97% ± 4 % (P < 0.001) decrease at 72 hours compared to
Ang II alone (Figures 4.14 and 4.15). Pre-treatment with OXTA (1 µM)
significantly diminished these effects of oxytocin (Figures 4.14 and 4.15).
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Figure 4.14. The effect of oxytocin and different treatment groups on aortic
VSMCs proliferation in SHRs as assessed by the Hemocytometer method. SHR
VSMCs were seeded at 1×106 cells/well in 6-well plates. Cell proliferation was
measured by counting the number of cells per milliliter (mL). The data are
represented as the mean ± SEM from three independent experiments performed
using aortic VSMCs from three SHRs. Ang II indicates Angiotensin II; OXTA,
Oxytocin receptor antagonist.
*** P < 0.001 : All groups versus Control
P < 0.01 and

P < 0.001 : Oxytocin versus (OXTA + Oxytocin); and

Oxytocin versus Ang II
###

P < 0.001 : (Oxytocin + Ang II) versus Ang II alone; and (Oxytocin + Ang II)

versus (OXTA + Oxytocin + Ang II)
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Figure 4.15. The effect of oxytocin and different treatment groups on aortic
VSMCs proliferation rate in SHRs assessed by the Hemocytometer method. SHR
VSMCs were seeded at 1×106 cells/well in 6-well plates. Cell proliferation rate was
assessed as the percent (%) change of control. The data are represented as the
mean ± SEM from three independent experiments performed using aortic VSMCs
from three SHRs. Ang II indicates Angiotensin II; OXTA, Oxytocin receptor
antagonist.
*** P < 0.001 : All groups versus Control
P < 0.01 and

P < 0.001 : Oxytocin versus (OXTA + Oxytocin); and

Oxytocin versus Ang II
###

P < 0.001 : (Oxytocin + Ang II) versus Ang II alone; and (Oxytocin + Ang II)

versus (OXTA + Oxytocin + Ang II)

114
4.2.1.2. Assessment of cell viability with MTT-assay in SHR VSMCs
The findings from the MTT assay in aortic SHRs VSMCs were similar to
those in Wistar rats. Oxytocin (100 nM) significantly reduced cell viability of aortic
SHR VSMCs (Figures 4.16 and 4.17).
The MTT assay demonstrated that oxytocin caused a reduction in the cell
viability of SHR VSMCs by 37.5% ± 3.9% (P < 0.001) and 32 % ± 3.8% (P <
0.001) at 48 hours and 72 hours, respectively compared to control. However, at 24
hours oxytocin did not show any significant reduction in VSMCs viability rate
(Figures 4.16 and 4.17).
The treatment with Ang II (100 nM) showed an increase in the VSMCs
viability with 145% ± 20% (P < 0.001), 121% ± 14% (P < 0.001), and 166% ± 13%
(P < 0.001) increase at 24, 48 and 72 hours, respectively compared to control
(Figures 4.16 and 4.17).
The pre-treatment with oxytocin (100 nM) prominently reduced Ang IIinduced VSMC viability by 51.8% ± 8.3% (P < 0.001) at 24 hours, 63.7% ± 5.7%
(P < 0.001) at 48 hours, and 71.9% ± 3.9% (P < 0.001) at 72 hours compared to
Ang II alone, and the pre-treatment with OXTA (1 µM) significantly blocked the
effects of oxytocin (Figures 4.16 and 4.17).
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Figure 4.16. The effect of oxytocin and different treatment groups on aortic SHR
VSMCs viability as assessed by the MTT assay. SHR VSMCs were seeded at 1×104
cells/well in 96-well plates. Cell viability was determined as the function of an
optical density (OD) measured at 570nm. The data are shown as the mean ± SEM
of three independent experiments performed using aortic VSMCs isolated from
three SHRs. Each experiment was performed with 12 replicates. Ang II indicates
Angiotensin II; OXTA, Oxytocin receptor antagonist.
*** P < 0.001 : All groups versus Control
P < 0.001 : Oxytocin versus Ang II; and Oxytocin versus (OXTA + Oxytocin)
###

P < 0.001 : (Oxytocin + Ang II) versus Ang II alone; and (Oxytocin + Ang II)

versus (OXTA + Oxytocin + Ang II)
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Figure 4.17. The effect of oxytocin and different treatment groups on aortic SHR
VSMCs viability rate as assessed by the MTT assay. SHR VSMCs were seeded at
1×104 cells/well in 96-well plates. Cell viability was measured as the percent (%)
change of control. The data are shown as the mean ± SEM of three independent
experiments performed using aortic VSMCs isolated from three SHRs. Each
experiment was performed with 12 replicates. Ang II indicates Angiotensin II;
OXTA, Oxytocin receptor antagonist.
*** P < 0.001 : All groups versus Control
P < 0.001 : Oxytocin versus Ang II; and Oxytocin versus (OXTA + Oxytocin)
###

P < 0.001 : (Oxytocin + Ang II) versus Ang II alone; and (Oxytocin + Ang II)

versus (OXTA + Oxytocin + Ang II)
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4.2.1.3.

Assessment of cell growth with 3H-Thymidine incorporation
assay in SHR VSMCs

The growth assay results corroborated that oxytocin (100 nM) significantly
reduced 3H-Thymidine incorporation in aortic SHR VSMCs from 2,668 ± 1,419
cpm (control) to 1,958 ± 2,473 cpm [36% ± 6% decrease (P < 0.01), Figure 4.18].
In contrast, treatment with Ang II (100 nM) significantly increased the 3HThymidine incorporation into aortic SHR VSMCs from 2,668 ± 1,419 cpm
(control) to 5,245 cpm ± 1,108 cpm [46% ± 71% increase (P < 0.001), Figure 4.18].
Pre-treatment with oxytocin (100 nM) followed by Ang II (100 nM)
significantly decreased Ang II-induced growth of SHR VSMCs [1,385 cpm ± 1,170
cpm (73% ± 25% decrease), P < 0.001] compared to Ang II alone (5,245 ± 1,108
cpm), and these effects were antagonized by OXTA [1 µM (Figure 4.18)].
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Figure 4.18. The effect of oxytocin and various treatments groups on aortic SHR
VSMCs growth as assessed by the 3H-Thymidine incorporation assay. SHR
VSMCs were seeded at 5×104 cells/well in 24-well plates. Cell growth was
measured as the function of the uptake of the radioisotope 3H-Thymidine into the
deoxyribonucleic acid (DNA) of the rapidly dividing cells and counted by the
scintillation counter. The data are represented as the count per minute (cpm) and
are shown as the mean ± SEM of four independent experiments, each performed
with triplicates, using aortic VSMCs isolated from four SHRs. Ang II indicates
Angiotensin II; OXTA, Oxytocin receptor antagonist.
** P < 0.01 and *** P < 0.001 : versus Control
P < 0.05 and

P < 0.001 : Oxytocin versus (OXTA + Oxytocin); and

Oxytocin versus Ang II
###

P < 0.01 : (Oxytocin + Ang II) versus (OXTA + Oxytocin + Ang II); and

(Oxytocin + Ang II) versus Ang II alone
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4.2.1.4. Assessment of cell viability by flow cytometry in SHR VSMCs
In aortic SHR VSMCs, the flow cytometry results showed oxytocin
treatment decreased the cell viability and induced apoptosis in a concentrationdependent manner, also caused necrosis (Figure 4.19).
The flow experiments utilized two different concentrations of oxytocin: 10
nM and 100 nM. When compared to the control group (93.4% ± 1.10%), the live
cell percentage in aortic VSMCs significantly decreased to 80.9% ±0.7% (P < 0.01)
in 10 nM oxytocin group and further declined to 65% ± 0.9% (P < 0.01) in 100 nM
oxytocin group, respectively (Figure 4.19).
Oxytocin significantly induced apoptosis in aortic SHR VSMCs. The
treatment with 10 nM and 100 nM oxytocin significantly increased apoptosis up to
13.9% ± 0.4% (P < 0.001) and 23.9% ± 0.1% (P < 0.001), respectively compared
to apoptosis in the control group [2.6% ± 1.1% (Figure 4.19)].
In addition to inducing apoptosis, oxytocin considerably induced necrosis
in aortic VSMCs. The percentage of aortic VSMCs undergoing necrosis
significantly increased from 2.2% ± 0% (in control group) to 8.6% ± 1.3% (P <
0.05) in 100 nM oxytocin group. However, there was no significant difference
between 10 nM oxytocin group (2.6% ± 0.3%) and the control group [2.2% ± 0%
(Figure 4.19)].
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Figure 4.19. The effect of oxytocin on apoptosis and necrosis in aortic SHR
VSMCs as assessed by flow cytometry. SHR VSMCs were seeded at 1×106
cells/well in 6-well plates. The data are shown as the percentage of cells positive
for apoptosis, necrosis and apoptosis + necrosis across different treatment groups.
The data are represented as the mean ± SEM from three independent experiments
performed using aortic VSMCs from three SHRs. The treatment was carried out for
24 hours with the two different concentrations of oxytocin: 10 nM and 100 nM. The
cells in the control group were not treated with oxytocin (only SFM). The cells were
stained with fluorescent dyes: Annexin V (for apoptosis) and 7-amino actinomycin
D [(7-AAD) for necrosis] and assessed with flow cytometer.
** P < 0.01 : Live cells in Oxytocin 10 nM group versus Live cells in Control group
** P < 0.01 Live cells in Oxytocin 100 nM group versus Live cells in Control group
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P < 0.001 Apoptotic cells in Oxytocin 10 nM group versus Apoptotic cells in
Control group
P < 0.001 Apoptotic cells in Oxytocin 100 nM group versus Apoptotic cells in
Control group
#

P < 0.05 Necrotic cells in Oxytocin 100 nM group versus Necrotic cells in Control

group.
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4.2.2. Effect of oxytocin and its pre-treatment with Ang II on the
phosphorylation of ERK1/2 in aortic SHR VSMCs
In aortic VSMCs isolated and cultured from SHRs, the densitometric
analysis of the western blot images showed that treatment with oxytocin (100 nM)
significantly decreased the active phosphorylated form of ERK1/2 (pERK1/2) by
35.4% ± 4% (P < 0.001) compared to control (Figure 4.20).
Contrary to oxytocin’s effect on pERK1/2 in SHR VSMCs, treatment with
Ang II (100 nM) significantly increased phosphorylation of ERK1/2 by 157% ±
21% (P < 0.001) compared to control (Figure 4.20).
Interestingly, the oxytocin (100 nM) pre-treatment significantly reduced
Ang II-induced pERK1/2 levels by 93.3% ± 1.4% (P < 0.001) compared to Ang II
alone. The effects of oxytocin were significantly antagonized by the pre-treatment
with 1 µM OXTA (Figure 4.20).
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Figure 4.20. The effect of oxytocin and different treatment groups on the
phosphorylation of ERK1/2 in aortic SHR VSMCs. Western blotting was utilized
to measure phospho-ERK1/2 levels, and the data were normalized with total
ERK1/2. The effect of oxytocin and its combination with different treatment groups
on the phosphorylation of ERK1/2 is shown as the percent (%) of control, with
control as 100%. The data are represented as the mean ± SEM of five independent
experiments, performed using aortic VSMCs isolated from five SHRs. *** indicates
P < 0.001 versus control;

P < 0.001 Oxytocin versus Ang II;

###

P < 0.001

(Oxytocin + Ang II) versus Ang II alone, and (Oxytocin + Ang II) versus (OXTA +
Oxytocin + Ang II). Ang II indicates Angiotensin II; OXTA, Oxytocin receptor
antagonist.
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4.2.3. Effect of oxytocin and its pre-treatment with Ang II on the
phosphorylation of PI3K p110α and Akt in aortic SHRs VSMCs
In aortic VSMCs cultured from SHRs, the densitometric analysis of western
blot images showed that treatment with oxytocin (100 nM) significantly decreased
the phosphorylated forms of PI3K p110a by 31% ± 5.1% (P < 0.01) and Akt by
45.5% ± 8.6% (P < 0.01) compared to control, respectively (Figures 4.21 and 4.22).
On the other hand, treatment with Ang II (100 nM) increased
phosphorylated forms of PI3K p110a by 79.8% ± 10.3% (P < 0.001) and Akt by
70.2% ± 20.4% (P < 0.05) compared to control, respectively (Figures 4.21 and
4.22).
It is noteworthy that the oxytocin (100 nM) pre-treatment significantly
reduced Ang II-induced higher levels of phospho-PI3K p110a by 61.3% ± 4.8% (P
< 0.01) and phospho-Akt by 60.4% ± 2.6% (P < 0.001) compared to Ang II alone,
respectively. And these effects of oxytocin were antagonized by pre-treatment with
1 µM OXTA (Figures 4.21 and 4.22).
Western blots depicting effect of oxytocin and various treatments on the
phosphorylation of PI3K p110a and Akt in SHR VSMCs are shown in Figures
4.21 and 4.22, respectively.
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Figure 4.21. The effect of oxytocin and different treatment groups on the
phosphorylation of PI3K p110α in aortic SHR VSMCs. Western blotting was
utilized to measure the phosphorylation of PI3K p110α, and the data were
normalized with glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The effect
of oxytocin and its combination with different treatment groups on the
phosphorylation of PI3K p110α is shown as the percent (%) of control, with control
as 100%. The data are shown as the mean ± SEM of three independent experiments,
performed using aortic VSMCs isolated from three SHRs. ** indicates P < 0.01
versus control; *** P < 0.001 versus control;

P < 0.001 Oxytocin versus Ang

II; ### P < 0.001 (Oxytocin + Ang II) versus Ang II alone, and (Oxytocin + Ang II)
versus (OXTA + Oxytocin + Ang II). Ang II indicates Angiotensin II; OXTA,
Oxytocin receptor antagonist.
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Figure 4.22. The effect of oxytocin and different treatment groups on the
phosphorylation of Akt in aortic SHR VSMCs. Western blotting was utilized to
measure the phosphorylation of Akt, and the data were normalized with
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The effect of oxytocin and
its combination with different treatment groups on the phosphorylation of Akt is
shown as the percent (%) of control, with control as 100%. The data are shown as
the mean ± SEM of four independent experiments, performed using aortic VSMCs
isolated from four SHRs. * indicates P < 0.05 versus control; ** P < 0.01 versus
control; *** P < 0.001 versus control;

P < 0.01 Oxytocin versus Ang II; ## P <

0.01 (Oxytocin + Ang II) versus Ang II alone, and (Oxytocin + Ang II) versus
(OXTA + Oxytocin + Ang II). Ang II indicates Angiotensin II; OXTA, Oxytocin
receptor antagonist.
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4.2.4. Effect of oxytocin and its pre-treatment with Ang II on the activation
of ROCK -1 and ROCK-2 in aortic SHR VSMCs
In aortic SHR VSMCs, the densitometric analysis of western blot images
showed treatment with oxytocin (100 nM) significantly reduced the activation of
ROCK-1 by 58.9% ± 5.4% (P < 0.001) and ROCK-2 by 41.5% ± 12.8% (P < 0.01)
compared to control, respectively (Figures 4.23 and 4.24).
Treatment with Ang II (100 nM) prominently increased the activation of
ROCK-1 by 102% ± 43% (P < 0.05) and ROCK-2 by 81.2% ± 14.8% (P < 0.001)
compared to control, respectively (Figures 4.23 and 4.24).
Pre-treatment with oxytocin (100 nM) significantly reduced Ang II-induced
activation of ROCK-1 by 79% ± 6.9% (P < 0.01) and ROCK-2 by 69.5% ± 13.2%
(P < 0.001) compared to Ang II alone, respectively. These effects of oxytocin were
significantly blocked by pre-treatment with 1µM OXTA (Figures 4.23 and 4.24).
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Figure 4.23. The effect of oxytocin and different treatment groups on the
activation of ROCK-1 in aortic SHR VSMCs. Western blotting was utilized to
measure the ROCK-1 levels, and the data were normalized with glyceraldehyde-3phosphate dehydrogenase (GAPDH). The effect of oxytocin and its combination
with different treatment groups on the activation of ROCK-1 is shown as the percent
(%) of control, with control as 100%. The data are shown as the mean ± SEM of
four independent experiments, performed using aortic VSMCs isolated from four
SHRs. * indicates P < 0.05 versus control; *** P < 0.001 versus control;

P<

0.01 Oxytocin versus Ang II; ## P < 0.01 Oxytocin + Ang II versus Ang II alone; #
P < 0.05 Oxytocin + Ang II versus OXTA + Oxytocin + Ang II. Ang II indicates
Angiotensin II; OXTA, Oxytocin receptor antagonist; ROCK, Rho-associated
coiled-coil-containing protein kinase.
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Figure 4.24. The effect of oxytocin and different treatment groups on the
activation of ROCK-2 in aortic SHR VSMCs. Western blotting was utilized to
measure the ROCK-2 levels, and the data were normalized with glyceraldehyde-3phosphate dehydrogenase (GAPDH). The effect of oxytocin and its combination
with different treatment groups on the activation of ROCK-2 as the percent (%) of
control, with control as 100%. The data are shown as the mean ± SEM of five
independent experiments, performed using aortic VSMCs isolated from five SHRs.
** indicates P < 0.01 versus control; *** P < 0.001 versus control;
Oxytocin versus Ang II;

###

P < 0.01

P < 0.01 Oxytocin + Ang II versus Ang II alone, and

Oxytocin + Ang II versus OXTA + Oxytocin + Ang II. Ang II indicates Angiotensin
II; OXTA, Oxytocin receptor antagonist; ROCK, Rho-associated coiled-coil
containing protein kinase.
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4.2.5. Effect of oxytocin and its pre-treatment with Ang II on IL-6 secretion
in aortic SHR VSMCs
As per the manufacturer’s protocol, the IL-6ELISA assay was carried out
and the concentration of IL-6 secreted by the aortic VSMCs in the culture media
was measured as ‘picogram per milliliter’ (pg/mL). In spontaneously hypertensive
rats (SHRs), the findings of the IL-6 assay demonstrated that oxytocin significantly
increased IL-6 secretion in culture media compared to the control group (Figure
4.25).
The assay employed three different concentrations of oxytocin: 10 nM, 100
nM, 1,000 nM. When compared with control group (848 ± 9 pg/mL), oxytocin
significantly increased IL-6 secretion in a concentration-dependent manner: 985 ±
25 pg/mL (P < 0.01) at 10 nM; 1,289 ± 8 pg/mL (P < 0.001) at 100 nM; and 1,468
± 19 pg/mL (P < 0.01) at 1,000 nM, respectively (Figure 4.25).
The treatment with Ang II (100 nM) showed a significant increase in IL-6
secretion [1,620 ± 66 pg/mL (P < 0.001)] compared to the control group [(848 ± 9
pg/mL), Figure 4.25].
When oxytocin (100 nM) and Ang II (100 nM) groups were compared to
the control group, Ang II (100 nM) showed significantly more IL-6 [1,620 ± 66
pg/mL (P < 0.01)] than oxytocin [100 nM (1,289 ± 8 pg/mL)] compared to the
control group [(848 ± 9 pg/mL), Figure 4.25].
Although oxytocin on its own significantly increased IL-6 secretion,
interestingly, oxytocin’s pre-treatment (100 nM) with Ang II (100 nM)
significantly decreased IL-6 secretion [891 ± 59 pg/mL (P < 0.001)] compared to
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Ang II 100 nM alone (1,620 ± 66 pg/mL) and oxytocin 100 nM alone [1,289 ± 8
pg/mL (P < 0.001)], respectively (Figure 4.25).
The effect of oxytocin’s pre-treatment (100 nM) on Ang II (100 nM) was
significantly inhibited by pre-treatment with 1µM OXTA. IL-6 secretion was
significantly higher [1,476 ± 58 pg/mL (P < 0.01)] in the OXTA-pre-treatment
group [OXTA (1µM) + Oxytocin (100 nM) + Ang II (100 nM)] than Oxytocin 100
nM + Ang II 100 nM group [(891 ± 59 pg/mL), Figure 4.25].
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Figure 4.25. The effect of oxytocin and different treatment groups on IL-6
secretion in aortic SHR VSMCs. The concentration of IL-6 secreted by aortic SHR
VSMCs in culture media was measured in picogram per mL (pg/mL). The data are
represented as the mean ± SEM from three independent experiments performed
using aortic VSMCs from three SHRs. In each experiment each treatment group
had duplicates. ** indicates P < 0.01 versus Control group; *** P < 0.001 versus
Control group;

P < 0.001 Oxytocin 10 nM versus Oxytocin 100 nM and

Oxytocin 1000 nM respectively, and Oxytocin 100 nM versus Oxytocin 1000 nM. ##
P < 0.01 Oxytocin 100 nM + Ang II 100 nM versus Oxytocin 100 nM alone and
OXTA 1µM + Oxytocin 100 nM + Ang II 100 nM; ### P < 0.001 Oxytocin 100 nM
+ Ang II 100 nM versus Ang II 100 nM alone;

P < 0.01 Oxytocin 100 nM versus

Ang II 100 nM. Ang II indicates Angiotensin II; OXTA, Oxytocin receptor
antagonist.
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4.2.6. Effect of oxytocin and its pre-treatment with Ang II on ROS production
in aortic SHR VSMCs
The outcomes of the ROS assay in aortic SHR VSMCs revealed that
oxytocin significantly increased ROS production and its pre-treatment with Ang II
also considerably increased ROS production (Figure 4.26).
Measured as the function of fluorescent units, the ROS assay findings
showed that treatment with oxytocin (100 nM) significantly increased ROS
production [6,657 ± 202 (P < 0.001)] compared to the control group (5,411 ± 259)
in aortic SHR VSMCs. The treatment with Ang II (100 nM) significantly increased
ROS production [6,286 ± 208 (P < 0.001)] compared to the control group (5,411 ±
259) (Figure 4.26).
There was no significant difference in ROS production between oxytocin
[100 nM (6,657 ± 202)] and Ang II [100 nM (6,286 ± 208)] treatment groups
(Figure 4.26).
The pre-treatment of oxytocin (100 nM) followed by Ang II (100 nM)
significantly increased ROS production [7,481 ± 162 (P < 0.001)] compared to the
control group [5,411 ± 259 (Figure 4.26)].
Additionally, pre-treatment with Oxytocin (100 nM) followed by Ang II
(100 nM) significantly increased the ROS production (7,481 ± 162) compared to
oxytocin (100 nM) alone [6,657 ± 202 (P < 0.01)] and Ang II (100 nM) alone
[6,286 ± 208 (P < 0.001)], respectively, indicating an additive effect (Figure 4.26).
Interestingly, OXTA (1 µM) on its own significantly increased the ROS
production [6,703 ± 173 (P < 0.001)] compared to the control group (5,411 ± 259).
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In addition, pre-treatment with OXTA (1 µM) followed by Oxytocin (100 nM) also
significantly increased ROS production [6,978 ± 223 (P < 0.001)] compared to
control group [5,411 ± 259 (Figure 4.26)].
There was no significant difference between Oxytocin (100 nM) group
(6,657 ± 202) and OXTA (1 µM) + Oxytocin (100 nM) group [6,978 ± 223 (Figure
4.26)].
The combination of OXTA (1 µM), Oxytocin (100 nM), and Ang II
significantly increased ROS production [7,705 ± 211 (P < 0.001)] compared to
control (5,411 ± 259) in aortic SHR VSMCs (Figure 4.26).
The combination of OXTA, Oxytocin, and Ang II (100 nM) significantly
increased ROS production [7,705 ± 211 (P < 0.001)] compared to Oxytocin (100
nM) alone (6,657 ± 202), Ang II (100 nM) alone (6,286 ± 208) and OXTA (1 µM)
alone (6,703 ± 173), respectively, indicating an additive effect (Figure 4.26).
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Figure 4.26. The effect of oxytocin and different treatment groups on ROS
production in aortic SHR VSMCs. SHR VSMCs were seeded at 1×104 cells/well
in 96-well plates. The ROS levels were measured as the function of the fluorescent
unit. The data are represented as the mean ± SEM from three independent
experiments performed using aortic VSMCs from three SHRs. In each experiment
each treatment group had 12 replicates. ** indicates P < 0.01 Ang II versus
Control; *** P < 0.001 versus Control group; ## P < 0.01 Oxytocin + Ang II versus
Oxytocin alone; ### Oxytocin + Ang II versus Ang II alone;

P < 0.001 OXTA +

Oxytocin + Ang II versus Oxytocin alone, Ang II alone, and OXTA alone. Ang II
indicates Angiotensin II; OXTA, Oxytocin receptor antagonist.
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4.3.

Comparison of the effects of oxytocin and its pre-treatment with Ang II on
aortic Wistar VSMCs versus SHR VSMCs
The effects of oxytocin on aortic Wistar VSMCs and SHR VSMCs alone
and after pre-treatment with Ang II were analyzed and compared, and are explained
under the following sub-headings:
4.3.1. Comparison between Wistar VSMCs and SHR VSMCs regarding the
effect of oxytocin and its pre-treatment with Ang II on aortic VSMCs
proliferation
In control group, the proliferation of Wistar VSMCs was significantly
higher at 24 hours [6.37 × 106 cells/mL ± 9.20 × 105 cells/mL (P < 0.05)] and 48
hours [1.50 × 107 cells/mL ± 1.47 × 106 cells/mL (P < 0.05)] compared to SHR
VSMCs (4.24 × 106 cells/mL ± 1.51 × 105 cells/mL at 24 hours and 1.10 × 107
cells/mL ± 7.04 × 105 at 48 hours). However, at 72 hours there was no significant
difference in proliferation between Wistar VSMCs (2.30 × 107 cells/mL ± 5.53 ×
106 cells/mL) and SHR VSMCs [1.59 × 107 cells/mL 2.72 × 106 cells/mL (Figure
4.27)].
Oxytocin significantly decreased proliferation in Wistar VSMCs: 3.12 × 106
cells/mL ± 4.14 × 105 cells/mL at 24 hours; 1.64 × 106 cells/mL ± 3.07 × 105
cells/mL at 48 hours; and 1.23 × 106 cells/mL ± 4.45 × 105 cells/mL at 72 hours
post-treatment compared to their respective control. Similar to the results in Wistar
VSMCs, oxytocin remarkably decreased proliferation in SHR VSMCs: 2.34 × 106
cells/mL ± 1.98 × 105 cells/mL at 24 hours; 1.72 × 106 cells/mL ± 1.04 × 105
cells/mL at 48 hours; and 1.71 × 106 cells/mL ± 4.29 × 105 cells/mL at 72 hours
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post-treatment compared to their respective control. It is noteworthy that there was
no significant difference in the pattern and magnitude of oxytocin-induced
inhibition of proliferation in Wistar VSMCs and SHR VSMCs (Figure 4.27).
Ang II showed significantly more proliferation in Wistar VSMCs [2.88 ×
107 cells/mL ± 1.74 × 106 cells/mL (P < 0.001) at 24 hours; 4.73 × 107 cells/mL ±
3.45 × 106 cells/mL (P < 0.01) at 48 hours; and 5.03 × 107 cells/mL ± 1.82 × 106
cells/mL (P < 0.05) at 72 hours post-treatment] than SHR VSMCs (1.22 × 107
cells/mL ± 2.98 × 105 cells/mL at 24 hours; 2.33 × 107 cells/mL ± 1.03 × 106
cells/mL at 48 hours; and 4.88 × 107 cells/mL ± 9.99 × 105 cells/mL at 72 hours
post-treatment) compared to their respective controls (Figure 4.27).
Oxytocin pre-treatment with Ang II significantly reduced Ang II-mediated
proliferation of VSMCs isolated from both Wistar rats (1.07 × 107 cells/mL ± 2.99
× 106 cells/mL at 24 hours; 8.06 × 106 cells/mL ± 3.13 × 106 cells/mL at 48 hours;
and 6.55 × 106 cells/mL ± 2.23 × 106 cells/mL at 72 hours post-treatment) and SHRs
(4.14 × 106 cells/mL ± 8.47 × 105 cells/mL at 24 hours; 1.60 × 106 cells/mL ± 2.80
× 105 cells/mL at 48 hours; and 1.37 × 106 cells/mL ± 2.32 × 105 cells/mL at 72
hours post-treatment) compared to their respective Ang II (alone) groups. However,
this effect was significantly higher in SHRs than Wistar Rats at 24 hours (P < 0.05),
48 hours (P < 0.05), and 72 hours (P < 0.05) post-treatment (Figure 4.27).
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Figure 4.27. The comparison of the effects of oxytocin, Ang II, and the pretreatment of oxytocin with Ang II on proliferation of aortic VSMCs between
Wistar VSMCs and SHR VSMCs as assessed by the Hemocytometer method.
VSMCs isolated from both Wistar rats and SHRs were seeded at 1×106 cells/well
in 6-well plates. Cell proliferation was measured by counting the number of cells
per milliliter (mL). The data are represented as the mean ± SEM from three
independent experiments performed using aortic VSMCs from three Wistar rats and
three SHRs, respectively. * indicates P < 0.05 versus Control Wistar rats versus
Control SHRs;

P < 0.05 (Oxytocin + Ang II) Wistar rats versus (Oxytocin + Ang

II) SHRs; ## P < 0.01 Ang II Wistar rats vs Ang II SHRs; ### P < 0.001 Ang II Wistar
rats vs Ang II SHRs. Ang II indicates Angiotensin II; OXTA, Oxytocin receptor
antagonist.
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4.3.2. Comparison between Wistar VSMCs and SHR VSMCs regarding the
effect of oxytocin and its pre-treatment with Ang II on aortic VSMCs
viability
In MTT assay, the cell viability was determined as the function of the
optical density (OD) measured at 570 nm. On comparing the cell viability of aortic
VSMCs isolated from both Wistar rats and SHRs, significantly higher cell viability
was observed in the control group SHR VSMCs [0.4 OD ± 0.1 (P < 0.05)] OD at
24 hours than Wistar VSMCs (0.3 OD ± 0.0 OD). However, at 48 hours and 72
hours there was no significant difference in the cell viability between Wistar
VSMCs (0.5 OD ± 0.0 OD at 48 hours and 0.7 OD ± 0.0 OD and 72 hours) and
SHR VSMCs [0.5 OD ± 0.0 OD at 48 hours and 0.8 OD ± 0.0 OD at 72 hours
(Figure 4.28).
Oxytocin significantly decreased the cell viability of aortic VSMCs isolated
from both Wistar rats and SHRs compared to the control groups, respectively. At
24 hours post-treatment, Oxytocin significantly decreased more cell viability of
Wistar VSMCs [0.2 OD ± 0.0 OD (P < 0.05)] than SHR VSMCs (0.4 OD ± 0.1
OD). However, at 48 hours and 72 hours there was no significant difference in the
oxytocin-induced decrement in viability between the Wistar VSMCs (0.3 OD ±
0.0 OD at 48 hours and 0.6 OD ± 0.1 OD at 72 hours) and SHR VSMCs (0.3 OD ±
0.0 OD at 48 hours and 0.5 OD ± 0.0 OD at 72 hours). Oxytocin showed a similar
pattern and magnitude of inhibition in cell viability in both Wistar VSMCs and
SHR VSMCs at 48 hours and 72 hours post-treatment (Figure 4.28).
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Ang II significantly increased the cell viability of aortic VSMCs isolated
from both Wistar rats (0.5 OD ± 0.1 OD at 24 hours, 1.0 OD ± 0.1 OD at 48 hours,
and 1.3 OD ± 0.1 OD at 72 hours) and SHRs (0.7 OD ± 0.0 OD at 24 hours, 1.1
OD ± 0.1 OD at 48 hours, and 2.0 OD ± 0.1 OD at 72 hours) compared to the
respective control groups. However, at 72 hours post-treatment, Ang II showed a
more significant increase in cell viability in SHR VSMCs [2.0 OD ± 0.1 OD (P <
0.001)] than Wistar VSMCs [1.3 OD ± 0.1 OD (Figure 4.28)].
The pre-treatment of oxytocin with Ang II significantly decreased Ang IIinduced cell viability in both Wistar VSMCs (0.2 OD ± 0.0 OD at 24 hours, 0.3
OD ± 0.0 OD at 48 hours, and 0.6 OD ± 0.1 OD at 72 hours) and SHR VSMCs (0.4
OD ± 0.1 OD at 24 hours, 0.3 OD ± 0.0 OD at 48 hours, and 0.6 OD ± 0.0 OD at
72 hours) compared to the respective Ang II (alone) groups (Figure 4.28).
At 24 hours post-treatment, the oxytocin-pretreatment showed more
significant decrease viability in Wistar VSMCs [0.2 OD ± 0.0 OD (P < 0.01)] than
SHR VSMCs (0.4 OD ± 0.1 OD). Although, at 48 and 72 hours, respectively, there
was no significant difference in the cell viability between Wistar VSMCs and SHR
VSMCs in the oxytocin-pre-treatment with Ang II group (Figure 4.28).
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Figure 4.28. The comparison of the effects of oxytocin, Ang II, and the pretreatment of oxytocin with Ang II on viability of aortic Wistar VSMCs and SHR
VSMCs as assessed by the MTT assay. VSMCs isolated from both Wistar rats and
SHRs were seeded at 1×104 cells/well in 96-well plates. Cell viability was
measured as the function of an optical density (OD) at 570 nm. The data are shown
as the mean ± SEM from three independent experiments performed using aortic
VSMCs from three Wistar rats and three SHRs, respectively. Each experiment was
performed with 12 replicates. * indicates P < 0.05 Control Wistar rats versus
Control SHRs; § P < 0.05 Oxytocin Wistar rats versus Oxytocin SHRs;
(Oxytocin + Ang II) Wistar rats versus (Oxytocin + Ang II) SHRs;

###

P < 0.01
P < 0.001

Ang II Wistar rats versus Ang II SHRs. Ang II indicates Angiotensin II; OXTA,
Oxytocin receptor antagonist.
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4.3.3. Comparison of the effect of oxytocin on apoptosis and necrosis between
Wistar VSMCs and SHR VSMCs
In aortic VSMCs isolated from both Wistar rats and SHRs, the flow
cytometry results showed that oxytocin significantly reduced live cells percentage,
prominently induced apoptosis (in a concentration-dependent manner) and induced
necrosis.
The flow experiments employed two different concentrations of oxytocin:
10 nM and 100 nM. In the control group, there was no significant difference
between: live cells in Wistar VSMCs (95.5 ± 0.7%) and SHR VSMCs (93.4% ±
1.1% in SHRs); and apoptotic cells in Wistar VSMCs (2.7% ± 1.1%) and SHR
VSMCs (2.4% ± 0.3%). However, the SHR VSMCs control group showed a
significantly higher percentage of necrotic cells [1.5% ± 0.0% (P < 0.01)] compared
to the Wistar VSMCs control group [0.7% ± 0.1% (Figure 4.29)].
The treatment with oxytocin 10 nM resulted in a more significant reduction
in live cells percentage in SHR VSMCs [80.9% ± 0.7% (P < 0.01)] than Wistar
VSMCs (91.6% ± 0.4%) compared to their respective controls. In addition,
oxytocin 10 nM induced significantly more apoptosis in SHR VSMCs [13.9% ±
0.4% (P < 0.05)] than Wistar VSMCs (4.2% ± 1.6%) compared to their respective
controls (Figure 4.29).
Treatment with oxytocin 100 nM showed a similar pattern and magnitude
in reduction of the percentage of live cells and induction of apoptosis in between
Wistar VSMCs (67.5% ± 2.3% live cells and 26.1% ± 3.0% apoptotic cells) and
SHR VSMCs (65.0% ± 0.9% live cells and 23.9% ± 0.1% apoptotic cells) compared
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to their respective controls. Interestingly, oxytocin 100 nM resulted in a
significantly higher percentage of cells undergoing necrosis [8.6% ± 1.3% (P <
0.05)] in SHR VSMCs than Wistar VSMCs [3.9% ± 0.3% (Figure 4.29)].
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Figure 4.29. The comparison of the effects of oxytocin on the live cells, apoptosis,
and necrosis between Wistar VSMCs and SHR VSMCs as assessed by flow
cytometry. Aortic VSMCs isolated from both Wistar rats and SHRs were seeded at
1×106 cells/well in 6-well plates. The data are shown as the percentage of cells and
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are represented as the mean ± SEM from three independent experiments performed
using aortic VSMCs from three Wistar rats and three SHRs, respectively. The
treatment was carried out 24 hours with two different concentrations of oxytocin:
10nM and 100nM. The cells were stained with fluorescent dyes: Annexin V (for
apoptosis) and 7-amino actinomycin D [(7-ADD) for necrosis]. ** indicates P <
0.01 Live Cells in Oxytocin 10 nM group in Wistar rats versus Live Cells in
Oxytocin 100 nM in group SHRs;

P < 0.05 Apoptotic cells in Oxytocin 10 nM

group in Wistar rats versus Apoptotic cells in Oxytocin 10 nM group in SHRs; # P
< 0.05 Necrotic cells in Oxytocin 100 nM group in Wistar rats vs Necrotic cells in
Oxytocin 100 nM group in SHRs;

##

P < 0.01 Necrotic cells in Control group in

Wistar rats vs Necrotic cells in Control group in SHRs.
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4.3.4. Comparison of the effect of oxytocin and its pre-treatment with Ang II
on the phosphorylation of ERK1/2, PI3K p110𝑎, and AKT in aortic
Wistar VSMCs and SHR VSMCs
Western blotting was utilized to study the effect of oxytocin, Ang II, and its
pre-treatment with Ang II on the phosphorylation of ERK1/2, PI3K p110α, and
Akt. The densitometric analysis of western blot images demonstrated that oxytocin
and its pre-treatment with Ang II significantly decreased the phosphorylation of
ERK1/2, PI3K p110 α, and Akt in aortic Wistar VSMCs and SHR VSMCs.
On the phosphorylation of ERK1/2
There was no significant difference between Wistar VSMCs and SHR
VSMCs regarding oxytocin-mediated decrease in the levels of the phosphorylated
forms of (active form) ERK1/2: oxytocin decreased the phosphorylation of ERK1/2
by 57.9% ± 14.2% in Wistar VSMCs and by 35.4% ± 4% in SHR VSMCs compared
to respective controls (Figure 4.30 b).
Although, Ang II-induced phosphorylation of ERK1/2 was significantly
higher in Wistar VSMCs (P < 0.05) than SHR VSMCs. In Wistar VSMCs, Ang II
increased the phosphorylation of ERK1/2 by 223% ± 11% compared to control,
whereas, in SHR VSMCs, Ang II increased the phosphorylation of ERK1/2 by
157% ± 21% compared to control (Figure 4.30 a).
The pre-treatment of oxytocin with Ang II caused more significant decrease
in the phosphorylation of ERK1/2 in SHR VSMCs [93.3% ± 1.4% decrease (P <
0.001) than in Wistar VSMCs (76.6% ± 1.4% decrease) compared to their
respective Ang II (alone) groups (Figure 4.30 c).
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On the phosphorylation of PI3K p110a
There was a significant difference between oxytocin-mediated reduction in
the phosphorylated form of (active form) of PI3K p110a between Wistar VSMCs
and SHR VSMCs. Oxytocin showed a more substantial decrease of phospho-PI3K
p110a in Wistar VSMCs (P < 0.01) than SHR VSMCs. In Wistar VSMCs, oxytocin
reduced phospho-PI3K p110a by 64.8% ± 2.8% compared to control. On the other
hand, in SHR VSMCs, oxytocin reduced phospho-PI3K p110a by 31% ± 5.1%
compared to control (Figure 4.30 e).
Ang II-induced phosphorylation of PI3K p110a was significantly higher in
Wistar VSMCs (P < 0.01) than SHR VSMCs. In Wistar VSMCs, Ang II increased
phospho-PI3K p110a by 184% ± 17% compared to control, whereas, in SHR
VSMCs, Ang II increased phospho-PI3K p110a by 79.8% ± 10.3% compared to
control (Figure 4.30 d).
The oxytocin’s pre-treatment with Ang II showed significantly more
decrease in phospho-PI3K p110a levels in Wistar VSMCs (P < 0.05) than SHR
VSMCs. The oxytocin’s pre-treatment decreased the phosphorylation of PI3K
p110a by 83.8% ± 8.6% in Wistar VSMCs and by 61.3% ± 4.8% in SHR VSMCs,
respectively, compared to their respective Ang II (alone) groups (Figure 4.30 f).
On the phosphorylation of Akt
There was no significant difference in oxytocin-mediated decrease in the
phosphorylation of Akt between Wistar VSMCs (46.2% ± 9.5% decrease) and SHR
VSMCs (45.5% ± 8.6% decrease) compared to the respective control groups
(Figure 4.30 h).
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Similarly, Ang II-induced increase in the phosphorylation of Akt was not
markedly different between Wistar VSMCs (44.4% ± 3.5%) rats and SHR VSMCs
(70.2% ± 20.4% increase) compared to their respective control groups (Figure 4.30
g).
The pre-treatment of oxytocin with Ang II also didn’t show any significant
difference in inhibiting phospho-Akt between Wistar VSMCs (62.1% ± 10.9%
decrease) and SHR VSMCs (60.4% ± 2.6% decrease) compared to the respective
Ang II (alone) groups (Figure 4.30 i).
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Figure 4.30. The comparison of the effects of oxytocin, Ang II, and pre-treatment
of oxytocin with Ang II on the phosphorylation of ERK1/2 (figure a, b, and c),
PI3K p110⍺ (figure d, e, and f), and Akt (figure g, h, and i) in aortic Wistar and
SHR VSMCs. The data are shown as the normalized relative intensity of the bands
and are represented as percent (%) of control, with control as 100%. The data are
shown as the mean ± SEM of five (five Wistar rats and five SHRs each), three (three
Wistar rats and three SHRs each), and four (four Wistar rats and four SHRs each)
independent experiments conducted for ERK1/2, PI3K p110⍺, and Akt,
respectively. * indicates P < 0.05; ** P < 0.01; *** P < 0.001. Ang II indicates
Angiotensin II; OXTA, oxytocin receptor antagonist; ERK, extracellular signalregulated kinase; PI3K, phosphatidylinositol-3-kinase.
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4.3.5. Comparison of the effect of oxytocin and its pre-treatment with Ang II
on vasocontraction pathway: ROCK-1 and ROCK-2 in aortic VSMCs
isolated from Wistar rats and SHRs
Western blotting was employed to investigate the effect of oxytocin, Ang
II, and its pre-treatment with Ang II on the activation of ROCK-1 and ROCK-2.
The densitometric analysis of western blot images demonstrated that oxytocin
significantly decreased the activation of ROCK-1 and ROCK-2 in both aortic
Wistar VSMCs and SHR VSMCs.
On ROCK-1
There was no significant difference between oxytocin-mediated reduced
activation of ROCK-1 between Wistar VSMCs and SHR VSMCs, respectively
(Figure 4.31).
Oxytocin reduced the ROCK-1 activation by 60.4% ± 7.6% in Wistar
VSMCs and by 58.9% ± 5.4% in SHR VSMCs compared to their respective control
groups (Figure 4.31 b).
Similarly, Ang II-induced activation of ROCK-1 was not markedly different
between Wistar VSMCs (147 % ± 50 % increase) and SHR VSMCs (102% ± 43%
increase) compared to their respective control groups (Figure 4.31 a).
The pre-treatment of oxytocin with Ang II also didn’t show any significant
difference in reducing the activation of ROCK-1 between Wistar VSMCs (85.2%
± 10.6% decrease) and SHR VSMCs (79% ± 6.9% decrease) compared to the
respective Ang II (alone) groups (Figure 4.31 c).
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On ROCK-2
Similar to ROCK-1, the impact of oxytocin in reducing the activation of
ROCK-2 was not markedly different between Wistar VSMCs and SHR VSMCs
(Figure 4.31).
Oxytocin-mediated reduced activation of ROCK-2 in Wistar VSMCs
(38.7% ± 13.1% decrease) was not statistically different from that in SHR VSMCs
[(41.5% ± 12.8% decrease (Figure 4.31 e)]. Ang II-induced increased activation of
ROCK-1 in Wistar VSMCs (83.2% ± 14.6% increase) was not prominently
different from SHR VSMCs (81.2% ± 14.8% increase) compared to their respective
control groups (Figure 4.31 d).
The pre-treatment of oxytocin with Ang II also didn’t show any substantial
difference in reducing the activation of ROCK-1 between Wistar VSMCs (65.8%
± 13.2% decrease) and SHR VSMCs (69.5% ± 13.2% decrease) compared to their
Ang II (alone) groups respectively (Figure 4.31 f).

152

Figure 4.31. The comparison of the effects of oxytocin, Ang II, and the
pretreatment of oxytocin with Ang II on the phosphorylation of Rho kinases –
ROCK-1 (figure a, b, and c) and ROCK-2 (figure d, e, and f) in aortic Wistar and
SHR VSMCs. The data are shown as the normalized relative intensity of the bands
and are represented as percent (%) of control, with control as 100%. The data are
shown as the mean ± SEM of four (four Wistar rats and four SHRs each) and five
(five Wistar rats and five SHRs each) independent experiments conducted for
ROCK-1 and ROCK-2, respectively. Ang II indicates Angiotensin II; OXTA,
oxytocin receptor antagonist; ROCK, rho-associated coiled-coil containing protein
kinase.
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4.3.6. Comparison of the effect of oxytocin and its pre-treatment with Ang II
on IL-6 in aortic Wistar VSMCs and SHR VSMCs
The ELISA based IL-6 assay involved the measurement of the
concentration of IL-6 released in the culture media. The findings of IL-6 assay
established that oxytocin significantly increased IL-6 secretion from aortic VSMCs,
but its pre-treatment with Ang II significantly decreased IL-6 in both Wistar
VSMCs and SHR VSMCs.
There was a significant difference in IL-6 secretion levels in the control
group between Wistar VSMCs and SHR VSMCs. The control group in SHR
VSMCs showed more IL-6 [848 ± 9 pg/mL (P < 0.05)] than Wistar VSMCs [614 ±
104 pg/mL (Figures 4.32 and 4.33)].
The assay employed three different concentrations of oxytocin: 10 nM, 100
nM, 1000 nM. In response to different concentrations of oxytocin, aortic SHRs
VSMCs showed significantly more IL-6 secretion [985 ± 25 pg/mL (P < 0.05) at
10 nM (Figure 4.32); 1,289 ± 8 pg/mL (P < 0.001) at 100 nM (Figures 4.32 and
4.33); and 1,468 ± 19 pg/mL (P < 0.001) at 1,000 nM (Figure 4.32)] than Wistar
VSMCs (695 ± 101 pg/mL at 10 nM; 1033 ± 24 pg/mL at 100 nM; and 959 ± 52
pg/mL at 1,000 nM) compared to their respective controls.
There was no significant difference between Wistar VSMCs and SHR
VSMCs with regards to Ang II-induced secretion of IL-6 (1,481 ± 91 pg/mL in
Wistar VSMCs and 1,620 ± 66 pg/mL in SHR VSMCs) compared to their
respective control groups (Figures 4.32 and 4.33).

154
Although oxytocin on its own significantly increased IL-6 in both Wistar
VSMCs

and SHR VSMCs, interestingly, oxytocin’s pre-treatment (100 nM)

followed by Ang II (100 nM) significantly decreased IL-6 secretion in both Wistar
VSMCs (735 ± 77 pg/mL) and SHR VSMCs (891 ± 59 pg/mL) compared to their
respective Ang II 100 nM (alone) groups (Figures 4.32 and 4.33).
However, there was no significant difference between the Wistar VSMCs
and SHR VSMCs concerning the effect of oxytocin’s pre-treatment on Ang IIinduced IL-6 secretion (Figures 4.32 and 4.33). The pattern and magnitude of the
impact of oxytocin pre-treatment on Ang II-mediated IL-6 secretions were similar
in both Wistar VSMCs and SHR VSMCs.
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Figure 4.32. The comparison of the effect of oxytocin (10 nM, 100 nM, and
1,000nM), Ang II (100 nM), pre-treatment of oxytocin with Ang II on IL-6
secretion in aortic Wistar VSMCs and SHRs VSMCs. The concentration of IL-6
secretion by the aortic VSMCs in the culture media was measured in picogram per
mL (pg/mL). The data are represented as the mean ± SEM from three independent
experiments performed using aortic VSMCs from three Wistar rats and three SHRs,
respectively. In each experiment each treatment group had duplicates. * indicates
P < 0.05 Control Wistar rats versus Control SHRs;
Wistar rats versus Oxytocin 10 nM SHRs;

P < 0.05 Oxytocin 10 nM

P < 0.001 Oxytocin 100 nM Wistar

rats versus Oxytocin 100 nM SHRs; ### P < 0.001 Oxytocin 1000 nM Wistar rats
versus Oxytocin 1000 nM SHRs. Ang II indicates Angiotensin II.
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Figure 4.33. The comparison of the effect of oxytocin (100 nM), Ang II (100 nM),
pre-treatment of oxytocin (100 nM) with Ang II (100 nM) on IL-6 secretion in
aortic Wistar VSMCs and SHRs VSMCs. The concentration of IL-6 secreted by
the aortic VSMCs in the culture media was measured in picogram per mL (pg/mL).
The data are represented as the mean ± SEM from three independent experiments
performed using aortic VSMCs from three Wistar rats and three SHRs,
respectively. In each experiment each treatment group had duplicates. * indicates
P < 0.05 Control group Wistar rats versus Control group SHRs;

###

P < 0.001

Oxytocin 100 nM in Wistar rats versus Oxytocin 100 nM in SHRs. Ang II indicates
Angiotensin II.
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4.3.7. Comparison of the effect of oxytocin and its pre-treatment with Ang II
on ROS production in aortic Wistar VSMCs and SHR VSMCs
The ROS assay findings demonstrated that oxytocin significantly increased
the ROS production in aortic VSMCs isolated from both Wistar rats and SHRs.
In addition, the pre-treatment of oxytocin followed by Ang II significantly
increased ROS production in both Wistar VSMCs and SHR VSMCs. However,
there was a significant difference in the impact of oxytocin and its pre-treatment
with Ang II on ROS production between Wistar VSMCs and SHR VSMCs.
The control group Wistar VSMCs showed more ROS levels [7,542 ± 128
(P < 0.001)] compared to the control group SHR VSMCs [5,411± 259 (Figure
4.44)].
The treatment with oxytocin (100 nM) resulted in a significantly more ROS
production in Wistar VSMCs [8,584 ± 114 (P < 0.001)] than SHR VSMCs (6,657
± 202) compared to their respective controls (Figure 4.44).
Ang II (100 nM)-induced ROS production was significantly higher in
Wistar VSMCs [8,336 ± 204 P < 0.001)] than SHR VSMCs [6,286 ± 208 (Figure
4.44)].
The pre-treatment of oxytocin (100 nM) followed by Ang II (100 nM) also
showed significantly higher ROS production [9,346 ± 143 P < 0.001)] in Wistar
VSMCs than SHR VSMCs (7,481 ± 162) compared to their respective Ang II
(alone) and Oxytocin groups (alone), respectively (Figure 4.44).
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Figure 4.44. The comparison of the effect of oxytocin, Ang II, pre-treatment of
oxytocin with Ang II on ROS production between aortic Wistar and SHR VSMCs.
VSMCs were seeded at 1×104 cells/well in 96-well plates. The ROS levels were
measured as the function of the fluorescent unit. The data are represented as the
mean ± SEM from three independent experiments performed using aortic VSMCs
from three Wistar rats and three SHRs, respectively. In each experiment each
treatment group had 12 replicates. *** indicates P < 0.001 Control group in Wistar
rats versus Control group in SHRs;

P < 0.001 Oxytocin 100 nM in Wistar rats

versus Oxytocin 100 nM in SHRs; ### P < 0.001 Ang II 100 nM in Wistar rats versus
Ang II 100 nM in SHRs;

P < 0.001 Oxytocin 100 nM + Ang II 100 nM in Wistar

rats versus Oxytocin 100 nM + Ang II 100 nM in SHRs. Ang II indicates
Angiotensin II.
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Chapter 5: Discussion
CVD is the leading cause of hospitalization in the United States and accounts for
mortality more than other any other disease, including cancer and communicable
diseases.263 Each year about 17 million deaths occur due to CVD, which is two times higher
than deaths caused by cancer, and in all probability, this number is going to increase to
about 23.3 million by 2030.264
Despite advancement in diagnosis and improvement in efforts aimed at prevention,
control, and treatment, CVD remains a primary cause of premature death and disability
across the globe.265 Consequentially, CVD healthcare management has imposed an
enormous financial burden on patients.266
The current standard CVD management includes therapies aimed at controlling
patients’ lipid-profiles (statins), blood glucose levels (metformin), and prescription of antihypertensive (ACE inhibitors) and anti-platelet medications (aspirin).267 However, lesser
favorable patient outcomes, as well as the rapidly rising rate of mortality due to CVD, paint
a different picture. It reflects a growing need to expand CVD research so that new
therapeutic options can be devised to effectively treat CVD. The present study was a step
towards exploring the potential of oxytocin in CVS.
Over decade oxytocin, which is often referred to as a female reproductive
hormone,1,9,268,269 has garnered the attention of the scientific community as a hormone with
cardioprotective effects.23,24 Much of the research so far has focused on oxytocin-mediated
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protective effects in cardiomyocytes, vascular endothelial cells, and cardiogenesis.
247,30,32,40

Besides identifying the presence of the oxytocin receptors in VSMCs,25 not much

research has been done concerning the potential effect of oxytocin on VSMCs.
VSMCs play a crucial role in cardiovascular physiology and are often at the center
of the events in the pathophysiology of CVD including hypertension.270 They undergo
increased cell proliferation in response to hypertension-induced stress on the vasculature,
leading to hypertrophy and an aberrant increase in vascular contraction.271,80 These changes
are mediated by complex signaling pathways mainly the ERK1/2 pathway,99 the PI3K/Akt
pathway,105 and ROCK pathway.144 In addition, increased oxidative stress and prolonged
inflammation add to and exacerbate injury to VSMCs, and manifest the long-term
pathological changes in vasculature.272,273
Interestingly, the interaction of oxytocin with other vital peptides playing crucial
roles in CVD such as Ang II has not been well-researched. Ang II is the primary effector
hormone and the central component of the RAAS. It causes vasoconstriction and maintains
blood pressure in normal physiological conditions.50
Ang II is also involved in CVD such as atherosclerosis, congestive heart failure,
diabetes, hypertension, inflammation, and myocardial infarction.51 It mainly binds to
AT1R in the CVS and executes its actions via activation of the ERK1/2 pathways
(increasing phospho-ERK1/2),274,275 PI3K/Akt pathway (phosphorylating PI3K p110α and
increasing phospho-Akt)276,277 and ROCK pathway (activation of ROCK-1 and ROCK2).278,279 These signaling pathways and kinases are involved in Ang II-induced
hypercontraction of VSMCs, hypertrophy, hyperplasia, endothelial dysfunction, leading to
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vascular

diseases

and

their

progression.53,54

In

addition,

in

cardiovascular

pathophysiological conditions Ang II precipitates inflammation and oxidative stress.280,59
We hypothesized that oxytocin provides vascular protection in VSMCs via
modulation of these pathways, inflammation, and reduction of oxidative stress, and
antagonization of the Ang II effects on these pathways, inflammation and oxidative stress.
We investigated oxytocin’s effect on cell proliferation, inflammation, oxidative stress and
on vasocontraction pathway in primary aortic VSMCs, isolated from the adult
normotensive Wistar rats and SHRs.
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5.1.

Oxytocin reduced the proliferation in aortic VSMCs
The findings of the present study demonstrated that oxytocin significantly
decreased cell proliferation of normotensive (Wistar) and hypertensive (SHR)
VSMCs. This is in contrast with the proliferative effect of oxytocin on vascular
endothelial cells derived from: immortalized human dermal microvasculature,
breast-tumors, human umbilical vein; and cardiomyocytes.40,41
It is noteworthy that the kind of effect oxytocin shows on cell proliferation
depends on the type of cells involved. While previous studies have shown oxytocin
exerting a proliferative influence on, for instance, trophoblast and astrocytes, others
have shown oxytocin mediating anti-proliferative effects on cell lines obtained
from breast cancer, ovarian cancer, and prostate cancer.281–283
Even within the cell lines derived from a similar source but from different
stages of differentiation, oxytocin has shown a differential effect on proliferation.
For example, in osteosarcoma cell lines (SaOS-2, TE-85, and UMR-106) obtained
from different stages of differentiation, oxytocin showed dual action on
proliferation. Oxytocin increased cell proliferation in SaoS-2 cells and decreased
cell proliferation in both TE-85 cells and UMR-106 cells.284
Although only one type of oxytocin receptor has been found across species,3
these dual effects of oxytocin on proliferation suggest the probability of another
subtype of oxytocin receptor.
In addition to showing anti-proliferative effects of oxytocin on aortic
VSMCs, the outcomes of the present study have revealed that oxytocin significantly
reduced Ang II-induced cell proliferation of aortic VSMCs isolated from

163
normotensive Wistar rats. Importantly, this effect was consistent in hypertensive
SHRs VSMCs. Further, the oxytocin receptor antagonist significantly attenuated
both these effects, suggesting that oxytocin mediated these effects via its receptors.
It is essential to understand the impact of oxytocin-induced inhibition of
Ang II-mediated proliferation of SHR VSMCs in the broader context of CVD
pathophysiology.
In hypertension induced by hyperactivation of Ang II signaling, VSMCs
undergo extensive remodeling including hypertrophy and fibrosis. Moreover,
cardiomyocytes in the left ventricle of the heart undergo hyper-proliferation leading
to cardiac hypertrophy and ultimately, over time, compromise the function of heart
and blood vessels.285 These events lay the foundation for a cascade of numerous
other intra-vascular and intra-cardiac pathophysiological events worsening
CVD.286
Evidence that oxytocin’s anti-proliferative action on VSMCs and oxytocininduced decrease in Ang II-mediated proliferation of SHR VSMCs generated from
this study underline the potential oxytocin might have in vascular protection in
CVD such as hypertension, and this merits further investigation.
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5.2.

Oxytocin deactivated the proliferation signal transduction pathways in aortic
VSMCs
For greater understanding about how oxytocin reduces cell proliferation in
aortic VSMCs, this study explored the two key downstream cell signaling pathways
involved in the proliferation of VSMCs: the ERK1/2 MAPK pathway and the
PI3K/Akt pathway.
This study results revealed that oxytocin significantly reduced the
phosphorylation of ERK1/2 in normotensive and hypertensive VSMCs. This is in
contrast with reports from previous studies, which reported that oxytocin treatment
increased phosphorylation of ERK1/2 in cardiomyocytes and vascular endothelial
cells.40,102
The differential effects of oxytocin on the phosphorylation of ERK1/2 have
been proposed to be based on the type of cells involved, location of oxytocin
receptors, activation of the different G-proteins, and interaction with a phosphatase.
For example, oxytocin demonstrated dual effects on phosphorylation of ERK1/2 in
human embryonic kidney cells. These effects were based on the site of oxytocin
receptors. Oxytocin decreased the phosphorylation of ERK1/2 when oxytocin
receptors were present outside the caveolin-1-enriched microdomains and resulted
in reduced cell proliferation. And, oxytocin increased the phosphorylation of
ERK1/2 when oxytocin receptors were present inside the caveolin-1-enriched
microdomains and henceforth, increased cell proliferation.103
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It is worth stating that caveolin-1 is vital in the trafficking of Gαs
(stimulatory) protein, inhibition of Gαs/adenylyl cyclase pathway,104 and is also
thought to be involved in the regulation of cell proliferation and cell survival.287
In another study, oxytocin caused the dephosphorylation of eukaryotic
elongation factor 2 (eEF2) and contributed to an increase in protein translation and
synthesis in myometrial cells via PKC.288 The eEF2 kinase is responsible for the
phosphorylation of eEF2. The phosphorylated form of eEF2 is inactive and causes
downregulation of protein translation, whereas, the dephosphorylated form is the
active form and leads to an increase in protein translation and synthesis. The eEF2
kinase is regulated by a phosphatase known as protein phosphatase 2 A (PP2A).289
In addition to oxytocin inducing dephosphorylation of eEF-2 through
PKC,288 it could very well be that oxytocin might increase the phosphatase (PP2A)
leading to reduced activity of eEF2 kinase and thus inducing dephosphorylation of
eEF2. Furthermore, oxytocin reduced Ang II-induced phosphorylation of ERK1/2,
and these effects were significantly abolished by pre-treatment with an oxytocin
receptor antagonist. Interestingly, these effects of oxytocin were consistent in aortic
VSMCs isolated from hypertensive rats.
The significance of the study results demonstrating oxytocin-induced
inhibition of phosphorylation of ERK1/2 and oxytocin-mediated inhibition of Ang
II-induced ERK 1/2 phosphorylation in SHR VSMCs can be understood by
assessing the implication of the ERK1/2 signaling pathway in CVD
pathophysiology.290
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An upregulation of agonist (Ang II)-stimulated ERK1/2 signaling for
prolonged duration has been shown to induce pathological hypertrophy in VSMCs
and decompensated cardiac hypertrophy in the heart.291 Thus, the ERK 1/2
signaling pathway plays a crucial role in the precipitation of CVD, for example,
hypertension, myocardial infarction, and stroke.99,
The

present

study

provided

evidence,

that

by

decreasing

the

phosphorylation of ERK1/2, oxytocin deactivated Ang II-stimulated ERK1/2
signaling in SHR VSMCs, and thus supports a protective role of oxytocin in
pathophysiological conditions, for instance, hypertension. However, in vivo studies
are required to further shed more light on oxytocin’s protective effect on
hypertension.
The PI3K/Akt signaling pathway has been shown to alter vascular function
by increasing the myogenic tone of resistant arteries.107 It also results in an aberrant
increase in the activity of L-VGCC leading to increased intracellular calcium,
increased cell volume in cardiomyocytes, and hyper-proliferation of VSMCs.120,110
Thus, the PI3K/Akt pathway leads to various cardiovascular pathophysiological
conditions including hypertension, pathological cardiac hypertrophy, and cardiac
arrhythmia .119

Ang II has been known to participate in and worsen these

pathophysiological events via hyper-activation of the PI3K/Akt signaling. 276,53
The findings of this study showed that oxytocin remarkably reduced the
phosphorylation of PI3K p110α and Akt in aortic VSMCs isolated from
normotensive and hypertensive rats. These findings are consistent with a previous

167
study, wherein oxytocin reduced the phosphorylation of PI3K p110α and Akt, albeit
in gut cells.292
Similar to the effect of oxytocin on Ang II-induced induced phosphorylation
of ERK1/2, oxytocin prominently diminished Ang II-induced phosphorylation of
PI3K p110α and Akt, whereas, the oxytocin receptor antagonist prevented these
effects of oxytocin. These findings were also consistent in aortic SHR VSMCs,
which further suggests that oxytocin induced-deactivation of PI3K/Akt signaling
pathway in SHR VSMCs might provide vascular protective effects in hypertension
in vivo.
There is a possibility that in aortic VSMCs, oxytocin via its receptors, which
belong to GPCRs superfamily,3 might be recruiting Gαi (inhibitory) protein, and
thus inhibiting downstream cell signaling by reducing the levels of phosphoERK1/2, phospho-PI3K p110α, and phospho-Akt, leading to the deactivation of the
ERK1/2 pathway and the PI3K/Akt pathway.
Alternatively, it could very well be that oxytocin might regulate the
phosphatase and thereby reduce the phosphorylation of ERK/12, PI3K p110α, and
Akt.
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5.3.

Oxytocin deactivated the ROCK pathway in aortic VSMCs
The present study explored the effect of oxytocin on the ROCK pathway.
The agonist-mediated phosphorylation of Rho kinases leads to the activation of
both ROCK-1 and ROCK-2, along with concurrent calcium mobilization, causing
the organization and remodeling of the actin cytoskeleton, extracellular matrix, and
contraction of VSMCs.146 The ROCK signaling pathway has been implicated in
the pathogenesis of various CVD such as hypertension, pulmonary hypertension,
angina pectoris, stroke, and heart failure.

140–144

It is also established that Ang II

activates ROCK signaling in these pathophysiological conditions.135,53
Together with the reduction in cell proliferation and deactivation of the
proliferation signal transduction pathways by oxytocin, the present research
demonstrated for the first time that oxytocin significantly reduced Rho kinasemediated vasocontraction in aortic VSMCs. The study results highlight that
oxytocin reduced the activation of both ROCK-1 and ROCK-2 in aortic VSMCs
isolated not only from normotensive rats but also from hypertensive rats. These
findings suggest that oxytocin could provide vascular protective effects in
pathophysiological conditions associated with hyper-signaling of ROCK pathways
such as hypertension and stroke.
However, to state definitively about oxytocin’s anti-vasocontraction effect
on VSMCs, direct measurement of oxytocin’s impact on vasocontraction would be
needed. The study was limited in this regard as this study did not directly assess
oxytocin’s effect on vasocontraction. Instead, it investigated the impact of oxytocin
on the vasocontraction pathway (ROCK pathway). Future studies could be carried

169
out by employing an ex vivo model such as the organ bath to directly measure
vasocontraction.
The study outcomes further revealed that oxytocin reduced Ang II-mediated
activation of both ROCK-1 and ROCK-2 in normotensive as well as in hypertensive
VSMCs, and these effects were blocked by an oxytocin receptor antagonist,
indicating that oxytocin causes these effects via its receptors. Based on the study
results, the fact that oxytocin antagonized Ang II-stimulated ROCK pathway in
aortic VSMCs suggests the potential cardioprotective effects oxytocin might have
in conditions where Ang II-mediated hyper-signaling of ROCK causes
vasoconstriction of blood vessels and disrupts the hemodynamics, culminating in
the development and worsening of CVD such as hypertension, angina pectoris, and
stroke.
This study was the first attempt to investigate the impact of oxytocin and its
pre-treatment with Ang II on the ROCK pathway. However, future in vivo studies
would be needed to further explore oxytocin’s effect on the contraction of blood
vessels in normal and pathophysiological conditions, for example, hypertension.
All three pathways: the ERK1/2 pathway, the PI3K/Akt pathway, and the
ROCK1/ROCK2 pathway are crucial in precipitating deleterious events such as
hypertrophy and hyper-contractility in VSMCs, which further lead to
cardiovascular complications manifested in CVD such as hypertension and
arrhythmia.99,119,144
Our results indicate that oxytocin may prevent these changes in the
dynamics of the vasculature by reducing the phosphorylation of ERK1/2, PI3K, and
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Akt and by decreasing the activation of ROCK-1 and ROCK-2 in normotensive as
well as hypertensive conditions (Figure 5).

Figure 5. Inhibition of the ERK1/2 pathway, the PI3K/Akt pathway, and the Rhokinase pathway by oxytocin in aortic VSMCs. Oxytocin mediates anti-proliferative
effects by inhibiting phosphorylation of ERK1/2, PI3K, and Akt. Oxytocin
deactivates Rho-kinase pathway involved in vasocontraction of VSMCs by
inhibiting the phosphorylation of ROCK-1 and ROCK-2. It may be possible that
either via the recruitment of Gαi proteins or by stimulating phosphatases oxytocin
decreases phosphorylation of ERK1/2, PI3K, Akt, ROCK-1, and ROCK-2. ERK
indicates extracellular signal-regulated kinase; PI3K, phosphoinositide-3-kinase;
ROCK, rho-associated coiled-coil containing protein kinase; Ang II, angiotensin
II; AT-1, angiotensin type-1; Gαi, G alpha inhibitory protein. Dotted red arrows
indicate inhibition; black arrows, activation.
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5.4.

Oxytocin increased IL-6 in aortic VSMCs
One of the objectives of the current study was to investigate the effects of
oxytocin on inflammation responses using aortic VSMCs. Hence, IL-6, a biomarker
of inflammation, was measured.
In contrast to previous studies carried out on vascular endothelial cells,34
the outcomes of the present study, conducted on aortic VSMCs, revealed that
oxytocin significantly increased IL-6, but remarkably reduced Ang II-stimulated
IL-6 levels.
It is essential to understand the role of IL-6 while interpreting these results.
IL-6 has been known for its pleiotropic effects.172 It is involved in various
physiological events including inflammation (production of CRP) and
immunological responses (activation and differentiation of T-cells and Bcells).174,175,178,180,181
Several studies have shown that an increase in IL-6 levels by any
treatment(s) or peptide(s) under investigation can be detrimental, especially in
conditions, for example rheumatoid arthritis and heart disease, wherein IL-6
mediated immunological and pathophysiological events contribute in worsening of
the symptoms.293,294
However, the effects of IL-6 can be both harmful and protective.192 It is the
duration of the pathogenic stimuli or pathophysiological conditions that determines
which one of the two effects IL-6 will manifest.
cardioprotective

effects

on

cardiomyocytes

pathophysiological condition(s).192

For example, IL-6 elicits

when

exposed

to

acute
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Conversely, IL-6 signaling can prove detrimental if the exposure to
pathophysiological condition(s) is chronic. In such a scenario, IL-6 may result in
pathological changes, for instance, reduced cardiac contractility, pathological
cardiac hypertrophy, and ultimately leading to decreased cardiac function.197,198
In this context, based on this study findings, oxytocin-induced IL-6
secretion in VSMCs could be vascular protective, as oxytocin-induced IL-6
secretion might boost the immunological defense required to counter the
pathogenic stimulus for a shorter period. The fact that oxytocin’s effect on IL-6 was
consistent in VSMCs isolated from hypertensive rats suggests oxytocin could
similarly bolster immune defense against an acute exposure to a pathogen in
diseased condition. However, further in vivo studies are required to explore the
beneficial effect of oxytocin-induced IL-6 secretion against an acute exposure to
pathogenic stimuli.
Another aspect of the present study was to determine the impact of oxytocin
on Ang II-stimulated IL-6 secretion. The study results demonstrated that oxytocin
reduced Ang II-stimulated IL-6 secretion not only in aortic VSMCs from
normotensive rats but also in aortic VSMCs from hypertensive rats, indicating that
oxytocin could show protective effects against Ang II-induced inflammation
(increase in IL-6), which more likely happens in a chronic basis under
cardiovascular disease conditions such as atherosclerosis and rheumatoid arthritis.
Based on the study findings that the singular treatment of oxytocin increased
IL-6 secretion, it can be suggested that oxytocin might provide beneficial effects in
conditions where a short-term inflammatory response is required to arrest the host
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damage, for example, in cardiomyocytes where short-term IL-6 signaling provided
cardioprotective effects.192 Furthermore, oxytocin's antagonistic action against Ang
II-induced IL-6 secretion could provide protection against chronic inflammation
such as in coronary heart disease and atherosclerosis. 293,294
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5.5.

Oxytocin increased ROS in aortic VSMCs
The current study was carried out to determine the effect of oxytocin on
oxidative stress. Oxidative stress is often at the center of many pathophysiological
conditions in the CVS.295 It is caused by an imbalance between oxidants and antoxidants.296 The oxidants are ROS such as hydrogen peroxide (H2O2) and
superoxide (O2-). On the other hand, antioxidants include superoxide dismutase
(SOD), catalase (CAT), glutathione peroxidase (GPx), and glutathione reductase
(GRx).297
In cardiovascular cells such as VSMCs, endothelial cells, and
cardiomyocytes, ROS is primarily produced by NADPH oxidase.217 Others include
mitochondrial transport chain and uncoupling of eNOS.225,227 The vasoconstrictor
peptides such as Ang II and ET -1 increase oxidative stress via increased production
of ROS, contributing to the pathogenesis of CVD including hypertension.219,221
The results of the ROS measurement in the present study showed that
oxytocin increased ROS production in aortic VSMCs. These results are in contrast
with the effect of oxytocin on ROS production in vascular endothelial cells as
reported in previous studies.34 Also, oxytocin’s pre-treatment with Ang II further
increased ROS production, suggesting an additive effect. These effects of oxytocin
were consistent in SHR VSMCs. The basal levels of ROS were higher in Wistar
VSMCs, and consequently, oxytocin-induced ROS production was higher in Wistar
VSMCs than SHR VSMCs.
These results suggest that oxytocin increases oxidative stress and further
potentiate Ang II-induced oxidative stress in cultured aortic VSMCs. However, it
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is essential to mention that the current study employed the in vitro experimental
models, the effect of oxytocin was measured on isolated aortic VSMCs, of which
the findings showed oxytocin increased ROS production. It cannot be assumed that
oxytocin would show similar effects in vivo, where VSMCs are not separate and
co-exist with endothelial cells.
It is worth noting endothelial cells, VSMCs, and their interaction plays a
crucial role in maintaining vascular homeostasis. However, events such as
increased ROS production causing oxidative stress and reduced availability of NO
can lead to endothelial dysfunction. This can adversely impact the functions of
VSMCs. VSMCs in such conditions are prone to excessive proliferation and hypercontraction owing to lack of vasorelaxants (NO) and can lead to the development
of CVD, for example, atherosclerosis.298
As stated earlier, oxytocin has been shown to induce protective effects in
vascular endothelial cells via reduction of ROS production. It might be that in vivo,
where both endothelial cells and VSMCs co-exist, oxytocin-mediated opposite
effects on ROS production in VSMCs and endothelial cells might negate each other.
This might not disrupt the overall redox equilibrium and may not adversely impact
oxidative stress in blood vessels. This could be useful in conditions associated with
increased oxidative stress such as hypertension, atherosclerosis, and rheumatoid
arthritis.
However, the present study did not investigate the interaction between
endothelial cells and VSMCs with regards to oxytocin’s effect on ROS production,
and this could be a subject of future investigation where oxytocin’s effect on ROS
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production in VSMCs and endothelial cells can be determined simultaneously by
employing co-cultures of VSMCs and endothelial cells and in vivo studies.
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5.6.

Summary of the dissertation research
In the last decade and a half, the status of oxytocin as a contractor of the
pregnant uterus, and an initiator of milk-ejection reflex have transcended to a
hormone eliciting protective effects in the CVS, in general, and on cardiovascular
cells including cardiomyocytes and vascular endothelial cells, in particular.
However, oxytocin's impact on VSMCs, which form an integral layer of blood
vessels and play a crucial role in physiological and pathophysiological conditions
associated with CVS, have not been well-established. This study was carried out to
investigate oxytocin's effect on proliferation, oxidative stress, inflammation, and on
vasocontraction pathway in aortic VSMCs isolated from both normotensive and
hypertensive rats.
In addition, this study also examined the interaction of oxytocin with Ang
II, a vital hormone of the RAAS in the CVS. Ang II-induced proliferation, oxidative
stress, inflammation, and vasocontraction of VSMCs have been associated with the
development and worsening of various vascular diseases, including hypertension
and atherosclerosis. This study investigated the effect of oxytocin's pre-treatment
on Ang II-induced proliferation, oxidative stress, inflammation, and Ang IIstimulated vasocontraction pathway in VSMCs in aortic VSMCs isolated from both
normotensive and hypertensive rats.
The present study employed primary aortic VSMCs isolated from
normotensive Wistar rats and hypertensive SHRs. For investigating the effect of
oxytocin, and its interaction with Ang II, on the proliferation of VSMCs, this study
utilized various methods: Hemocytometer method for cell counting; MTT assay for
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cell viability assessment; 3H-Thymidine incorporation assay for cell growth
measurement; and flow cytometry to determine apoptosis and necrosis.
To gain a better understanding of the impact of oxytocin on VSMCs
proliferation, the two key proliferation signal transduction pathways were
investigated: the ERK1/2 pathway and the PI3K/Akt pathway. Western blot
technique was utilized to study the effect of oxytocin on these two pathways. For
studying the impact of oxytocin, and its interaction with Ang II, on the
vasocontraction pathway in VSMCs, the ROCK pathway was investigated. The
western blot technique was utilized to study oxytocin's effect on the ROCK
pathway.
To investigate the effect of oxytocin, and its interaction with Ang II, on
inflammation and oxidative stress, the ELISA-based IL-6 assay, and the fluorescent
spectroscopy-based ROS assay were carried out, respectively.
The outcomes of proliferation studies indicated that oxytocin reduces
VSMCs proliferation by inhibiting the phosphorylation of ERK1/2, PI3K p110α,
and Akt. Besides, oxytocin also reduced Ang II-induced proliferation by reducing
Ang II-mediated phosphorylation of ERK1/2, PI3K p110α, and Akt not only in
VSMCs isolated from normotensive rats but also in hypertensive rats. This may
have clinical relevance in conditions associated with higher levels of Ang II and
Ang II-mediated hyper-signaling of proliferation pathways in the CVS, such as in
hypertension and atherosclerosis. Nonetheless, further in vivo studies are required
to demonstrate the protective effects of oxytocin against deleterious effects of Ang
II in these pathophysiological conditions.
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The study findings further revealed that oxytocin and its pre-treatment with
Ang II led to dysregulation of the ROCK pathway via inhibition of the activation
of ROCK1 and ROCK2. These findings suggest a possible cardioprotective role of
oxytocin in conditions where there is an excessive vasocontraction of blood vessels
linked with Ang II-mediated hyper-signaling of ROCK pathway, for example,
hypertension. However, this study was limited in its scope with regards to
oxytocin's effect on vasocontraction as the study did not directly measure
vasocontraction of VSMCs and rather investigated the vasocontraction pathway,
and this could be further investigated in the future.
Furthermore, the results of an ELISA-based IL-6 assay indicated that
oxytocin's treatment increased IL-6 secretion in aortic VSMCs. This may be
beneficial in conditions where a short-term increase in IL-6 release bolsters
immunological response against a pathogenic stimulus for a shorter duration. Also,
our findings demonstrated that oxytocin reduced the Ang II-mediated IL-6
secretion in aortic VSMCs isolated from both Wistar rats and SHRs. This could be
favorable in conditions associated with Ang II-induced prolonged inflammation
such as rheumatoid arthritis. However, further studies investigating oxytocin's
effect on inflammation and its interaction with Ang II on the inflammatory
response, especially in vascular conditions associated with aggravated
inflammation such as atherosclerosis, are required.
The ROS assay findings showed that oxytocin increased ROS production
and its pre-treatment with Ang II further increased ROS production in aortic
VSMCs isolated from both Wistar rats and SHRs. This suggests that oxytocin might
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increase oxidative stress in cultured VSMCs. However, it cannot be assumed that
in vivo, oxytocin would exhibit similar effects. In vivo, VSMCs co-exist with
vascular endothelial cells, wherein oxytocin has been previously shown to reduce
ROS production. It could very well be that the opposite effects of oxytocin on ROS
production in VSMCs and endothelial cells cancel out each other and might not
disturb the overall redox equilibrium. Henceforth, oxytocin might not contribute to
a change in oxidative stress in blood vessels, which could be significant in
pathophysiological conditions associated with increased oxidative stress in CVS.
Nevertheless, further studies would be required where oxytocin's effect on ROS can
be assessed simultaneously in both VSMCs and endothelial cells, such as in vitro
studies employing co-culturing of VSMCs and endothelial cells and in vivo
studies.
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5.7.

Conclusion
VSMCs undergo various pathophysiological changes in hypertension and
other CVD, which render them as a potential target for newer approaches for their
therapeutic management. The present in vitro study investigated the effects of
oxytocin on cell proliferation, inflammation, oxidative stress, and also on the
pathways involved in cell proliferation and vasocontraction in primary aortic
VSMCs, isolated from normotensive (Wistar rats) and hypertensive rats (SHRs).
This study demonstrated that oxytocin inhibits proliferation and increases
inflammation (IL-6) and oxidative stress (ROS) in aortic VSMCs obtained from
Wistar rats and SHRs. Based on the study outcomes, it can be suggested that the
anti-proliferative effect of oxytocin is mediated by inhibition of ERK1/2 and
PI3K/Akt phosphorylation. Also, oxytocin deactivated Rho-kinase signaling
pathway, a critical pathway involved in the contraction of VSMCs, by inhibiting
the phosphorylation of ROCK-1 and ROCK-2.
The increased proliferation in VSMCs and hypercontraction mediated by
peptides such as Ang II, worsen hypertension and precipitate other CVD and their
progression. Oxytocin not only decreased VSMCs proliferation but also reduced
Ang II-induced VSMCs proliferation and Ang II-stimulated vasocontraction
pathways.
Overall, this study indicates that oxytocin might have therapeutic potential
in the management of CVD including hypertension. However, future in vivo studies
are required to examine the cardiovascular protective effect of oxytocin in
hypertension.
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5.8.

Future recommendation
The present study utilized all the existing techniques available to assess the
effect of oxytocin and its pretreatment with Ang II on cell proliferation in VSMCs.
However, the study was limited in its scope with regards to the direct measurement
of vasocontraction in aortic VSMCs.
The current study indirectly assessed vasocontraction by investigating the
vasocontraction pathway — ROCK pathway. In the future, this aspect can be
addressed. The effect of oxytocin on vasocontraction can be studied by determining
the intracellular calcium levels in aortic VSMCs. This can be achieved by
employing techniques such as fluorescent-based calcium measurement assay and
more directly employing organ bath studies using vascular smooth muscle tissue.
Furthermore, to understand the mechanism of how oxytocin decreases the
phosphorylation of the ERK1/2, PI3K p110α, and Akt, Gαi inhibitors may be
employed. Since oxytocin receptors are GPCRs and have been previously shown
to recruit different G-proteins in different cells and in different physiological
conditions, it is a likely that oxytocin recruits Gαi and thus inhibits ERK1/2 and
PI3K/Akt-mediated downstream signaling pathways involved in the proliferation
of VSMCs.
Another such possibility could be that oxytocin stimulates phosphatases and
consequently inhibits the phosphorylation of ERK1/2, PI3K p110α, and Akt. This
can be explored in future research endeavors.
Also, the present study employed in vitro experimental models. All the
study experiments were performed on primary aortic VSMCs isolated from Wistar
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rats and SHRs. This study has generated sufficient scientific evidence to warrant
the use of in vivo experimental models in the future. And, based on the results of a
future in vivo study, the next step would be to conduct a pilot clinical trial as
oxytocin is a peptide that has been approved by the food and drug administration
(FDA), and has been subjected to various clinical trials.
As demonstrated by the study outcomes, this research highlighted the
significant vascular protective effects of oxytocin and its antagonistic actions on
Ang II effects in VSMCs isolated from both normotensive and hypertensive rats.
These findings suggest that oxytocin may have therapeutic implication in
conditions where hyper-activation of Ang II leads to hyper-signaling of Ang IImediated signaling pathways resulting in the development and progression of
various CVD, including hypertension. However, future in vivo studies and clinical
studies would be required to explore the protective effect of oxytocin in CVD.
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